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ABSTRACT 
The aim of this work was to investigate the role of Mesenchymal stem cells 
(MSC) in the modulation of immune responses, focusing on suppression and 
induction of immune tolerance.  To date, MSC therapy has proved beneficial for the 
treatment of inflammatory and autoimmune diseases, such as acute Graft versus Host 
Disease (aGvHD) and Crohn’s disease.  However, the exact mechanisms of 
therapeutic benefit remain unclear.  The key goals of this study were to identify the 
role of MSC derived soluble and contact dependent factors and how these influence 
innate and adaptive immune responses; to develop a novel humanised mouse model 
of aGvHD; and to investigate the effect of MSC therapy for the prevention or 
treatment of aGvHD. 
This study demonstrated that human MSC induced functional CD4
+
 CD25
+
 
FoxP3
+
 T regulatory cells from a purified population of human CD4
+
 T cells in vitro. 
Induction was dependent on both soluble factors and direct cell contact.  MSC 
derived TGFβ1 and prostaglandin E2 were involved in this induction.  Murine MSC 
suppressed dendritic cell (DC) maturation, antigen presentation and cytokine 
production, inducing DC with tolerogenic attributes in vitro.  MSC modulation of 
DC function was also dependent on direct cell contact.  Blocking studies revealed 
that the Notch signalling pathway was essential for this process.   
A humanised mouse model of aGvHD based on delivery of human peripheral 
blood mononuclear cells (PBMC) to NOD-scid IL-2rγnull (NSG) mice was developed 
to allow robust exploration of the role of MSC in cell therapy.  MSC therapy resulted 
in the dramatic reduction of liver and gut pathology and significant increased 
survival of NSG mice with aGvHD.  Protection was dependent on the timing of 
MSC therapy with conventional MSC proving effective only after delayed 
xi 
 
administration.  In contrast, IFNγ stimulated MSC were more potent and were 
effective when delivered concurrent with PBMC.  The beneficial effect of MSC was 
not due to the induction of donor PBMC apoptosis, anergy or T regulatory cells in 
this model; but likely due to the inhibition of donor CD4
+
 T cell proliferation and the 
significant reduction in systemic human TNFα. 
These findings contribute to a broader understanding of immune regulation 
by MSC and provide a rational basis for ongoing and future clinical studies 
involving allogeneic human MSC as a cell therapy. 
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1.  INTRODUCTION  
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1.1  MESENCHYMAL STEM CELLS 
 Friedenstein was first to describe a rare fibroblast-like, non-hematopoietic 
cell population in the bone marrow that formed plastic adherent colonies in vitro and  
differentiated into osteocytes, adipocytes and chondrocytes (Friedenstein, 1966; 
Friedenstein, 1974).  Based on this capacity to differentiate, Caplan coined the term 
“Mesenchymal Stem Cells” (MSC), to describe this population as potential agents 
for regenerative medicine (Caplan, 1991).    Caplan and Prockop extended the 
concept of regenerative MSC by showing that MSC home to sites of injury and 
secrete large amounts of “trophic factors” that repair through recruitment and 
activation of other reparative cells or cytoprotective mechanisms (Caplan, 2006; 
Prockop, 2009).  These findings positioned MSC as key modulators of localised 
tissue inflammation.   
In the last decade, data from in vitro and in vivo models of inflammatory 
disease have indicated that MSC possess modulatory abilities that target the innate 
and adaptive immune systems (Ryan, 2005; Barry, 2005; Uccelli, 2008; Griffin, 
2010).  These findings suggested a role for MSC in the induction of immune 
tolerance and as potent therapeutic interventions.  To this effect, there has been 
interest in the use of MSC as a cell therapy for inflammatory mediated diseases.  The 
fact that MSC can directly suppress cells of the innate and adaptive immune systems, 
(Section 1.7.1 & 1.7.2), has led to the hypothesis that MSC induce immunological 
tolerance, through the secretion of cytokines and the induction of regulatory cells 
(Ryan, 2005; Caplan, 2006; English, 2008; Uccelli, 2008).  This hypothesis of 
immunological tolerance induction by MSC will be explored in this thesis, at both an 
innate and adaptive immune level, using both human and murine derived MSC.  
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1.2 THE HISTORY OF IMMUNOLOGICAL TOLERANCE 
It is reasonable to assume that the adaptive immune system of mammals has 
evolved for protection against an ever-changing population of microbial pathogens.  
The innate immune system senses danger and initiates a rapid immune response 
without evoking immunological memory (Hoffmann, 1999; Janeway, 1989).  The 
adaptive immune system in contrast generates specific receptors capable of detecting 
a wide diversity of pathogens with fine specificity and with a capacity for long-lived 
immune memory (Burnet, 1957; Hozumi, 1976).  Potentially harmful self-reactive 
lymphocytes are controlled by a mechanism known as “self tolerance” (Billingham, 
1953), one of the key forms of immune regulation.   
The idea of specific immunological tolerance was first proposed in the 
1940’s.  Pioneering work carried out by Owen et al. described the phenomenon of 
red-cell chimerism (Owen, 1945).  Dizygotic twin cattle share a prolonged exchange 
of blood for the duration of gestation.  After birth, these twin cattle were found to 
share a stable mixture of each sibling’s blood type throughout their lifetime.  In order 
for this to occur, the exchange of red cell precursors and not just red blood cells 
alone must have taken place during their gestation stage, as the red cells were found 
to be native to each cow.  The implication of this was that the recipient calf was 
tolerant to non-self or allogeneic red cell precursors from the sibling (Owen, 1945).  
Anderson and Billingham extended this idea of immune tolerance in dizygotic twin 
cattle by examining the transplantation of skin grafts between twin cattle.  They 
found that dizygotic twin cattle could accept skin grafts from one another, but third 
party skin grafts were rejected (Anderson, 1951; Billingham, 1952).  These findings 
showed that some level of immune tolerance between twin animals allowed 
successful transplantation.   
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Collectively, these findings led to the Nobel Prize winning experiment in 
tissue transplantation by Billingham, Brent and Medawar in 1953 (Billingham, 
1953).  They performed a series of experiments, using murine transplantation models 
where lymphoid cells taken from CBA mice (Black) were injected into an adult 
strain of mice at that time called strain A (White) (Fig 1.1).  In this situation, the 
CBA cells were identified as foreign and were destroyed.  Likewise, if the strain A 
mouse received CBA cells again, these too were destroyed.  This led to the 
hypothesis that if it were possible to recreate the same circumstances as dizygotic 
twin cattle, (i.e. exposure in utero of CBA mice to strain A antigen) then tolerance 
would prevent rejection.  To explore this, CBA cells were injected into neonatal 
strain A mice and surprisingly, these CBA cells were accepted resulting in the 
development of chimeric mice.  Interestingly, adult strain A mice were found to 
accept any later skin tissue grafts from a CBA mouse, as if the graft were autologous 
(Billingham, 1953).     
The induction of tolerance in this case was due to an alteration or acquired 
feature in the host and not an adaptation of the graft.  Once tolerance was 
established, tolerance was systemic through the whole mouse.  However, Billingham 
et al. found that tolerance could be destroyed through a mechanism known as 
adoptive transfer.  In this situation, if a strain A mouse that had previously accepted 
a CBA skin graft, received strain A lymphoid cells from a mouse that had not been 
tolerised, these injected strain A cells would break the tolerant state and result in 
graft rejection.  These findings indicated that a major aspect of tolerance was due to 
a central, rather than a peripheral, “editing” mechanism.     
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Fig 1.1  Billingham’s discovery of tolerance in a tissue transplantation model.  
(A)  Adult strain A mice received a skin graft from a CBA strain donor mouse.  This 
CBA skin graft was rejected by the strain A mouse.  (B)  Neonatal strain A mice 
received CBA lymphoid cells, resulting in the development of a chimeric mouse.  
Interestingly, when this chimeric strain A mice received a CBA skin graft, these 
mice did not reject the graft. 
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1.3 CENTRAL TOLERANCE 
Central tolerance is now understood in great detail.  The central “editing” of 
the repertoire of lymphocytes occurs in the primary lymphoid organs: the bone 
marrow and thymus.  Progenitor B cells undergo somatic diversification in the bone 
marrow, while progenitor T cells undergo the same mechanism in the thymus.  
Somatic diversification allows for the rearrangement of B cell receptor (BCR) or T 
cell receptor (TCR) genes, containing variable (V), diversity (D) and joining (J) gene 
segments for the generation of a diverse repertoire of lymphocytes each expressing a 
different specificity for a particular antigen receptor, a process known as V(D)J 
recombination (Cooper, 1965).  This random rearrangement of V(D)J genes involves 
the recombination activating genes, RAG-1 and RAG-2 and (as the resulting 
sequence  is not directly germ line encoded) inevitably this can lead to the generation 
of lymphocytes with high affinity for self antigen (Yu, 1999).  In this case, a 
mechanism is required whereby self-reactive lymphocytes are deleted, while non-self 
reactive lymphocytes are permitted to leave the primary lymphoid organs and 
expand.  This mechanism is central tolerance.  However, these mechanisms are not 
perfect, as some self-reactive lymphocytes can escape central tolerance and enter the 
periphery.  Therefore, in order to prevent the development of autoimmunity, a 
secondary mechanism exists in the periphery known as peripheral tolerance (Van 
Noort, 1993; Lohmann, 1996).  This system of checkpoints and fail-safes are 
important for the maintenance of tolerance and keeping the risk of developing 
autoimmune disease at a minimum.  
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1.3.1 B CELL DEVELOPMENT AND CENTRAL TOLERANCE 
The development of B cells from hematopoietic stem cells takes place in the 
bone marrow (Hardy, 2001).  Pre and pro-B cells expressing rearranged B cell 
receptors (BCR) with low affinity to self, progress into development through 
positive selection.  This results in the switching off of the RAG genes and the 
migration of immature B cells to the spleen and periphery (Buhl, 2000).  Pro-B cells 
that are reactive to self-antigens are not permitted to progress into development and 
subsequently do not switch off the RAG genes.  These autoreactive B cells are 
primed for programmed cell death primarily through apoptosis (Yu, 1999).  Until 
1993, it was thought that all self-reactive B cells were deleted in the bone marrow 
through apoptosis.  However, Tiegs, Gay and Radic found that not all autoreactive B 
cells undergo apoptosis automatically.  They identified a mechanism where 
autoreactive B cells can eliminate a self-reactive BCR and express a novel, non self-
reactive, BCR through secondary V(D)J recombination.  This process was coined 
receptor editing (Tiegs, 1993; Gay, 1993; Radic, 1993).  The strength of the BCR 
signal when it encountered antigen determined whether antigen specific B cells were 
eliminated, edited or developed (Ehlich, 1994; Yu, 1999; Hardy, 2001).  Although 
this mechanism of central tolerance in the bone marrow is successful, some self-
reactive B cells do leave the bone marrow and enter the periphery.  Along with the 
induction of apoptosis and receptor editing, two more factors limit autoreactive B 
cell responses in the periphery.  First, B cell responses typically require T cell help 
(Parker, 1993) and so tolerance of the T cell compartment will limit autoreactive B 
cell expansion and secondly, the induction of peripheral tolerance (see below) can 
also eliminate these B cells to maintain immunological tolerance.        
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1.3.2 T CELL DEVELOPMENT AND CENTRAL TOLERANCE 
 T cells develop from hematopoietic progenitors in the bone marrow but then 
migrate to the thymus as CD4
-
 CD8
-
, double negative thymocytes, where they 
mature.  Thymocytes from the bone marrow enter the thymus through high 
endothelial venules and migrate to the subcapsular region.  Here these cells undergo 
V(D)J recombination, creating a repertoire of T cells expressing TCR with different 
antigen specificities (Miller, 1961; Cooper, 1965; Cantor, 1976).  These developing 
T cells then migrate to the cortex, where they undergo a process of positive selection.  
Here these cells express both CD4 and CD8 markers and are known as double 
positive thymocytes (Cantor, 1976).  T cells that receive a signal through MHC class 
I and a survival signal, retain CD8 expression, while losing CD4 expression (Cantor, 
1976).  While T cells that receive a signal through MHC II and a survival signal, 
retain CD4 expression and lose CD8 expression (Cantor, 1976).  T cells that do not 
recognise self-MHC are eliminated by apoptosis, with surviving T cells migrating to 
the medulla, whereas those T cells weakly recognising self-MHC survive (positive 
selection).  In the medulla, T cells that strongly recognise self-antigen presented on 
self-MHC by thymic antigen presenting cells, are eliminated by apoptosis-thus only 
non-reacting T cells are allowed to survive (negative selection) (Scollay, 1980; 
Egerton, 1990).  The remaining T cells are naïve T cells, capable of recognising self-
MHC and non-self antigen.  These cells are permitted to leave the thymus and enter 
the periphery where they can encounter antigen specific for their TCR (Goldrath, 
1999).  However, similar to B cell development, some autoreactive T cells can 
escape central tolerance and enter in the periphery.  In this case, any autoreactive T 
cells should be eliminated through the induction of peripheral tolerance.     
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 An obvious problem with bone marrow/thymus selection mechanisms is that 
tissue specific proteins (e.g. pancreatic proteins) are unlikely to be expressed in the 
bone marrow/thymus.  Over the last decade, it has come to light that many tissue 
specific proteins are in fact expressed by some stromal cells present in the medulla 
region of the thymus (Anderson, 2005; Kuroda, 2005).  This situation allows for the 
negative selection of T cells that recognise self-antigens that are normally expressed 
by tissues outside the thymic medulla, and helped to explain an inexplicable 
autoimmune condition.  In 1946, a severe autoimmune disease called autoimmune 
polyendocrinopathy candidiasis ectodermal dystrophy (APECED) was described in 
patients, presenting with chronic mucocutaneous candidiasis, hypoparathyroidism 
and type 1 diabetes (Leonard, 1946; Betterle, 1998).  Although APECED manifested 
itself in 1946, it was not until 1997 that the underlying genetic defect that caused 
APECED was discovered (Nagamine, 1997; Gibson, 1998).  Mutations in an 
autoimmune regulator gene, AIRE, were responsible for the development of 
APECED.  AIRE gene expression is restricted to primary lymphoid organs, 
particularly the thymus (Gibson, 1998; Heino, 1999).  In the thymus, AIRE is 
expressed by medullary epithelial cells, important cells in the negative selection of 
autoreactive T cells, (Kishimoto, 1997; Anderson, 2005).  AIRE expression allows 
medullary epithelial cells to express peripheral tissue antigens, allowing for the 
deletion of autoreactive T cells specific for peripheral self-antigens before leaving 
the thymus (Klein, 2000).  Mutations in the AIRE gene do not disrupt thymocyte 
development, as AIRE knockout mice have normal levels of thymocytes.  However, 
these mice develop autoimmune disease (Kuroda, 2005).  This suggested that 
mutations in AIRE affected thymic epithelial cells and their expression of peripheral 
tissue antigens.  This mutation permits the development of naïve self-reactive 
10 
 
thymocytes, which are permitted to leave the thymus and enter the periphery (Klein, 
2000).   
 
1.4 PERIPHERAL TOLERANCE 
A supplementary mechanism, peripheral tolerance, controls self-reactive T 
and B lymphocytes that may have escaped central tolerance and are circulating in the 
periphery.  There are numerous ways in which the immune system deals with self 
reactive lymphocytes in the periphery; these are by induction of 1) deletion, 2) 
anergy, 3) ignorance and 4) suppression/regulation.  Dendritic cells (DC), which are 
important innate cells involved in the induction of adaptive peripheral tolerance are 
located in the skin, airways, lymphoid tissues, other organs and blood (Steinman, 
1974; Schuler, 1985; Holt, 1990).  This distribution of DC strategically places these 
cells for optimal detection of both foreign but also self-tissue specific antigen for 
presentation to antigen specific CD4
+
 T cells.  The presentation of antigen (foreign 
or self) by DC to effector T cells shapes the type of immune response that will occur 
(Mosmann, 1986; Steinman, 2000). 
The induction of self-tolerance in the periphery is achieved in numerous 
ways.    Deletion involves the induction of apoptosis in self-reactive T and B 
lymphocytes (O’Shea, 2001; Abbas, 2003).  The most common pathway for the 
deletion of self-reactive lymphocytes is activation-induced cell death (AICD) by the 
Fas/Fas ligand pathway (CD95/CD95L) (Fife, 2008), which results in the control of 
autoimmune disease development.  Mice defective in Fas receptor genes (lpr mouse) 
or the Fas ligand (gld mouse) exhibit autoimmune lymphoproliferative and lupus like 
autoimmune syndrome (Roths, 1984).  It has also been hypothesised that the 
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expression Fas ligand in immune privileged sites, such as the brain or the anterior 
chamber of the eye, can lead to apoptosis of Fas expressing activated T cells and 
inflammatory cells infiltrating these immune privileges sites (Griffith, 1995; Saas, 
1997).   
Anergy is defined as a state of lymphocyte unresponsiveness to specific 
antigen and is associated with a marked decreased in Interleukin (IL)-2 production 
and other effector functions (Schwartz, 1997).  Anergic T cells persist in the 
periphery in an altered and unresponsive state, due to the absence of costimulation 
between antigen presenting cells such as DC and effector T cells (Steinman, 2000; 
Jonuleit, 2001).  Costimulation typically involves (CD80 or CD86 but can also 
involve IL-1, IL-12, Tumour necrosis factor alpha (TNFα), and CD40).  Typically, 
antigen presented to naive antigen specific T cells supports significant lymphocyte 
proliferation when supported by costimulation (Lanier, 1990).  However, in the 
absence of costimulation, the induction of a classical form of anergy can occur 
(Glennie, 2005; Zappia, 2005).  These anergic T cell are refractory to activation, 
even when their specific antigens are subsequently presented via APC expressing 
costimulatory molecules (Jenkins, 1987; Glennie, 2005; Zappia, 2005).  
Interestingly, this unresponsive state of classical anergy can be reversed through the 
addition of exogenous IL-2 and this has been used as a defining characteristic to 
measure anergy induction ex vivo (Glennie, 2005).  The induction of anergic T 
and/or B cells provides a method of prolonged self-tolerance via a peripheral means.  
The induction of suppressor or regulatory cells assists in the maintenance of 
peripheral tolerance through the active suppression of effector T cell populations.  
These regulatory cells, such as T regulatory (T reg) cells and suppressive DC 
contribute to the suppression of autoimmunity by preventing the activation of self-
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reactive lymphocytes. This can occur directly through cell-cell contact-mediated 
suppression of self reactive conventional CD4
+
 T cells by regulatory T cells, 
(infectious tolerance) (Jonuleit 2002; Kendal, 2011) or by killing effector cells or 
through the creation of an immunosuppressive environment via the release of 
regulatory cytokines (bystander suppression).  The best-characterised T reg cell 
subsets coexpress CD4, the α-chain of the IL-2 receptor  CD25 and the transcription 
factor forkhead box protein 3, FoxP3 (Jonuleit, 2003; Yamazaki, 2006).  T reg cells 
can be further divided into natural T reg, which develop in the thymus and enter the 
periphery; and inducible T reg that are induced in the periphery from naïve T cells 
and aid in the maintenance of tolerance (Mills, 2004).  Activated T reg can suppress 
effector T cell proliferation via an antigen non-specific mechanism, which is 
dependent on direct cell contact but independent of immunosuppressive cytokines 
(Thornton, 2000).  However, both types of T reg can achieve suppression through the 
production of soluble factors, IL-10 and transforming growth factor beta (TGFβ) 
(Levings, 2002).   
In bystander tolerance, T reg cells are activated through the recognition of 
specific antigen and secrete cytokines, such as IL-10 and TGFβ.  This release of 
proinflammatory cytokines results in the suppression of effector T cells present in 
the local environment, irrespective of their antigen specificity (Jonuleit, 2002; 
Masteller, 2005).  In the case of infectious tolerance, the presence of T reg cells 
stimulates the outgrowth of further T reg cell populations displaying a broader array 
of antigen specificities distinctly different from that of the original T reg population 
(Qin, 1993; Cobbold, 2009).  The adoptive transfer of these T reg cells can prevent 
or treat type I diabetes in vivo even after the removal of the original T reg population 
(Tarbell, 2007).  
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Subpopulations of DC in the periphery can induce T reg from naïve CD4
+
 T 
cells (Jonuleit, 2000; Yamazaki, 2003).  These DC populations typically exhibit an 
immature phenotype with tolerogenic functions, including low levels of MHC 
molecule expression, decreased IL-12p70 and increased IL-10 production (Mahnke, 
2002; Morelli, 2007).  Tolerogenic DC can present antigen to antigen-specific T 
cells, but fail to deliver adequate costimulation for effector T cell proliferation 
(Morelli, 2007).  A key factor involved in the induction of tolerogenic DC is IL-10, 
as the presence of this cytokine can reduce MHC II expression and IL-12 production 
(Bellinghausen, 2001; Mahnke, 2002).  Tolerogenic DC expand CD4
+
 CD25
+
 T reg 
cells from CD4
+
 CD25
-
 precursors (Kretschmer, 2005).  This results in the expansion 
of antigen-specific T reg, which contributes to the prevention of autoimmunity 
(Maldonado, 2010; Morelli, 2007).   
 
1.5 THE B7 FAMILY OF MOLECULES INVOLVED IN IMMUNE TOLERANCE 
Anergy occurs when CD4
+ 
T cells are stimulated in the absence of 
costimulation (Jonuleit, 2001) and the B7 family of surface molecules are important 
in this process (Collins, 2005).  CD28, cytotoxic T lymphocyte antigen-4 (CTLA-4) 
and B7 family can provide both stimulatory and inhibitory signals involved in the 
activation of lymphocytes (Banchereau, 1998; Suzuki, 1999; McAdam, 2000; 
Nishimura, 1996; Salomon, 2001).  For complete T and B cell activation, antigen 
recognition through TCR ligation requires an additional signal through B7 ligands.  
The CD28 receptor is expressed on naïve T cells and engagement of CD28 receptor 
with B7.1 (CD80) or B7.2 (CD86) on APC results in a potent costimulatory signal to 
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activate T cells (Banchereau, 1998).  Signalling through CD28 induces the 
production of IL-2, upregulation of CD25 and the survival gene Bcl-XL.  
CTLA-4 (CD152) is similar in structure to CD28 and binds to the B7 ligands, 
CD80/86.  However, CTLA-4 is not expressed on naïve T cells, but rather 
upregulated on T cells following their activation.  CTLA-4 is a crucial negative 
regulatory of T cell activation and is important in the reduction of T cell responses 
and restoration of homeostasis after inflammation (Suzuki, 1999).  This sliding 
threshold between CD28 and CTLA-4 is important for the regulation of immune 
activation and the prevention of autoimmunity (Allison, 1998).   
To date, there have been several other proteins identified as new members of 
the CD28, CTLA-4 and B7 families.  The inducible costimulatory (ICOS) (CD278) 
receptor which shares similarities to both CD28 and CTLA-4 (Carreno, 2002).  
ICOS is expressed on activated T cells, while its B7-like ligand LICOS (B7-H2), is 
expressed on APC (McAdam, 2000).  While CD28 engagement induces IL-2 
production, costimulation through ICOS enhances the production of IL-10 by T cells 
(McAdam, 2000).   
The programmed death-1 marker (PD-1) is a member of the CD28 family and 
is a negative regulator of T and B cell activation.  PD-1 receptor is expressed on 
activated T cells, while its ligands PDL-1 (B7.H1) and PDL-2 (B7.DC) are 
expressed on activated APC (Nishimura, 1996).  Engagement of PD-1 by its ligands 
results in decreased interferon gamma (IFNγ), IL-10, IL-4 and IL-2 secretion and the 
reduction in adaptive immune responses (Freeman, 2000).  The interplay between 
these receptors and ligands of the B7 family dictates the type of immune response 
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that will occur, costimulation or coinhibitory (Collins, 2005).  This identifies these 
pathways as key players in the maintenance of immune tolerance.      
1.5.1 THE B7 FAMILY OF MOLECULES AND THE INDUCTION OF REGULATORY 
CELLS 
Coinhibitory signals are important for the inhibition of T cell activation 
against self-antigens and induction of peripheral tolerance.  Darrasse-Jeze et al. 
discussed a relationship between the numbers of T reg cells in the periphery with the 
number of DC present in lymphoid organs (Darrasse-Jeze, 2009).  This study 
highlighted a feedback loop between DC and T reg cells, where altering the number 
of DC directly correlated to the number of T reg (Darrasse-Jeze, 2009).  The 
induction of T reg cells by DC is not unidirectional, as CD4
+
CD25
+
FoxP3
+
 T reg 
communicate with DC influencing their maturation state, inducing a more 
suppressive or tolerogenic DC expressing low levels of costimulatory molecules and 
suppressed IL-12 and TNFα production (Larmonier, 2007).  The production of IL-10 
and TGFβ by T reg is involved in the induction of tolerogenic DC (Cederbom, 2000; 
Larmonier, 2007).     
CD4
+
 CD25
+
 T reg cells depend on mediators, such as IL-10 and TGFβ for 
their differentiation from effector T cells (Yamazaki, 2003).  The balance between 
effector and regulatory CD4
+
T cells involves the ICOS pathway.  ICOS expressed by 
CD4
+
T cells in target organs enhances IL-10 production, supporting T reg induction 
(Herman, 2004).  Patients with deficient ICOS expression have CD4
+
 T cells that are 
insensitive to tolerogenic signals from immature DC and have decreased levels of 
IL-10 (Tuettenberg, 2009).   
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The cross talk between DC and T reg cells involves the engagement of B7 on 
DC and CTLA-4 on T reg.  CTLA-4 expressing T reg down regulated the expression 
of CD80 and CD86 on DC inducing a more suppressive DC phenotype (Wing, 
2008).  CTLA-4
-/-
 T reg cells were less suppressive than CTLA-4
+
 T reg cells in 
coculture with DC in vitro (Tang, 2004).  CTLA-4 upregulated indoleamine 2, 3-
dioxygenase (IDO) production from both human and murine DC, which in turn 
promoted the induction of TGFβ producing T reg (Sharma, 2007; Grohmann, 2002).  
In the true sense of a feedback loop, this induction of IDO activated T reg cells 
increased the expression of PDL-1 on DC, which in turn increased the production of 
IL-10 by DC promoting a more tolerogenic environment (Munn, 2007).    
CD4
+
CD25
+
FoxP3
+
 T reg cells and the PD-1: PDL pathway are important for 
the termination of immune responses and the regulation of autoimmunity.  The 
stimulation of naïve CD4
+
 T cells with PDL-1-Ig in the presence of anti-CD3 and 
TGFβ induced the generation of CD4+ FoxP3+ T reg (Francisco, 2009).  PDL-1-/- DC 
were also less effective in the generation of CD4
+
CD25
+
FoxP3
+
 T reg from naïve 
CD4
+
 T cells (Francisco, 2009).  These data emphasised the importance of the PD-1 
pathway in T reg cell induction.  Interestingly, CD4
+
CD25
+
FoxP3
+
 T reg express 
both PD-1 and PDL-1.  DC express PDL-1 and upon encounter with naïve CD4
+
 T 
cells, the expression of PD-1 is enhanced, leading to the induction of T reg cells.  As 
T reg also express PDL-1, the encounter of naïve CD4
+
 T cells (PD-1) and 
CD4
+
CD25
+
FoxP3
+
 T reg  (PDL-1) could result in the differentiation of naïve T cells 
into additional T reg  (Francisco, 2010).  The expression of PD-1 on DC could 
negatively regulate (hinder) DC function against bacterial infections (Yao, 2009).  
This suggested that PDL-1 expression by T reg cells could indirectly suppress T cell 
responses through the engagement of PD-1 on DC, modulating DC function and 
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immune responses.  Ligation of the PD-1 pathway has proved important in 
diminishing effector T cell activation, while enhancing T reg cell induction.   
Collectively, the above findings have highlighted the CTLA-4 and B7 family 
as key molecules for the regulation of adaptive immune tolerance, primarily through 
the induction of T reg cells and tolerogenic DC.  These findings render these 
pathways as interesting targets for immunotherapeutic interventions for the treatment 
of T cell mediated diseases, especially in transplantation.  The above data suggests 
that MSC induction of regulatory cells, DC or T cells, could involve signalling 
through the CTLA-4 and B7 family pathways.    
 
1.6 OTHER IMMUNE MOLECULES INVOLVED IN IMMUNE REGULATION 
1.6.1  SIALIC-ACID BINDING IMMUNOGLOBULIN-LIKE LECTINS 
 Siglecs are a family of type-1 sialic-acid binding, immunoglobulin-like, 
lectins that are involved in immune cell: cell interactions and regulate the function of 
cells in both the innate and adaptive immune systems through glycan recognition 
(Crocker, 2007).  Siglecs are one of the best-characterised type-1 lectins to date.  
Siglecs play a role in modulating cellular functions through cell: cell interactions 
(Crocker, 2005).  CD33-related Siglecs are mainly expressed by mature cells of the 
innate immune system, such as monocytes, DC or NK.  At present it is known that 
humans express nine CD33-related Siglecs (CD33, Siglecs 5-11 and Siglec-14), 
while mice express only five (CD33, Siglec E, F, G, H) (McMillan, 2008).  Each 
Siglec has specificity for one sialyated ligand/glycan, suggesting that each Siglec 
mediates a distinct function.  However, more than one Siglec can be present on a cell 
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at any one time.  CD33 related Siglecs have been shown to modulate leukocyte 
behaviour, including the inhibition of cellular proliferation, induction of apoptosis 
and the induction of pro-inflammatory cytokines (Vitale, 1999; Balaian, 2003; 
Lajaunias, 2005).   
 The maturation of DC results in changes in glycan expression, through a 
process known as glycosylation (Bax, 2007).  This change in glycan expression on 
maturing DC can affect their recognition by Siglecs and galectins.  CD33-related 
Siglecs relay an inhibitory signal, which inhibits activatory pathways (Falco, 1999).  
This suggests that signalling through Siglecs could play a role in maintaining 
immune tolerance.  Siglec expression by MSC has not been shown to date.  
However, as CD33-related Siglecs are inhibitory, the possibility of MSC expressing 
Siglecs and these molecules interacting with DC is highly plausible.  It was also 
feasible that MSC were acting as a type of aberrant APC (Rameshwar, 2008) and 
therefore MSC expression of Siglecs could be involved in such an adaptive response.  
Therefore, study of Siglec expression by MSC would inform the understanding of 
immune modulation by this proposed cell therapy.  
 1.6.2 NOTCH SIGNALLING PATHWAY 
 During development, cell: cell interactions are critical in deciding cell fates.  
Notch signalling is a well-conserved pathway involved in cell fate decisions during 
development, stem cell maintenance, cell proliferation, differentiation and apoptosis 
(Radtke, 2004; Fiuza, 2007).  Notch signalling is evolutionarily conserved from 
Drosphilia to mammals (Artavanis-Tsakonas, 1999).  There are four Notch genes 
(Notch 1, 2, 3 & 4) and five genes encoding Notch ligands (Jagged 1, 2 and Delta-
like ligand 1, 3 & 4) in both human and mouse.  Notch signalling is activated upon 
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direct cell: cell interaction between Notch receptors and membrane bound ligands, 
Jagged or Delta-like (Baron, 2002).  During signalling, Notch receptors are presented 
to Notch ligands as a heterodimer.  Upon receptor/ligand binding, the proteolytic 
cleavage of the receptor dimer occurs through γ-secretase activity, releasing the 
intracellular domain of the Notch receptor (NICD), which translocates to the 
nucleus.  This cleavage of the receptor dimer is inhibited in vitro by γ-secretase 
inhibitors (GSI).  Once, in the nucleus, NICD associates with transcription factors 
(CSL) and recruits coactivators to activate Notch target genes, such as Hes and Hey 
family genes (Vujovic, 2007). 
 Interactions between Notch receptors and ligands are crucial in the crosstalk 
between cells of the immune system and their surrounding microenvironment 
(Radtke, 2004).  Both Notch receptors and ligands are expressed on DC and the 
presence of bacterial products, such as lipopolysaccharide (LPS) can up regulate the 
expression of Notch ligands on DC (Amsen, 2004).  It has been demonstrated that 
the activation of both Notch 1 and Notch 2 receptors through ligand binding disrupts 
the differentiation of mature DC or macrophages, leading to the accumulation of 
immature myeloid DC (Cheng, 2003).  Cheng et al. have shown that the Notch 
ligand Jagged-1, on bone marrow-derived stromal cells, stimulated the accumulation 
of DC precursors, while preventing their transition to terminally differentiated DC.  
The ligand Delta-like ligand-1 was found to promote the generation of fully 
differentiated DC (Cheng, 2007).   
 Various ligands demonstrate differential capacity for Notch receptor binding, 
which in turn regulate different T cell activation.  Bone marrow derived DC, instruct 
T cell differentiation via Notch (Amsen, 2004; Morelli, 2007).  Both Jagged-1 and 
Delta-like ligand-4 are involved in the differentiation of naïve CD4
+ 
T cells into 
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effector cells.  Amsen et al. found that signalling through Delta-like ligand-4 or 
Jagged-1 promotes Th1 or Th2 responses respectively (Amsen, 2004).  Delta-like 
ligand-1 and Jagged-1 induced partial or complete inhibition of T cell activation, 
respectively (Rutz, 2005).  Notch signalling is involved in the induction of 
immunological tolerance.  Hoyne at al demonstrated that murine DC over-
expressing human Jagged-1 induced CD4
+
CD25
+
FoxP3
+
 T reg that were capable of 
inhibiting both primary and secondary immune responses (Hoyne, 2000).  Both 
murine and human naïve CD4
+
 T cells have been differentiated into FoxP3 
expressing T reg following stimulation in the presence of TGFβ1 (Fu, 2004; Rao, 
2005).   This induction of a FoxP3 expressing T reg population was dependent on 
Notch signalling (Fu, 2004; Rao, 2005; Samon, 2008).  These findings showed that 
Notch signalling was required for TGF-β1 induced FoxP3+ T reg cells (Samon, 
2008). Collectively, these data, suggest that the crosstalk between innate and 
immune cells involves the Notch signalling pathway.  This puts emphasises on the 
Notch signalling pathway and its involvement on MSC modulation of immune 
responses, especially through the induction of regulatory cells.    
 
1.7 MSC AND IMMUNE REGULATION 
 MSC constitute 0.01-0.001% of bone marrow cells (Friedenstein, 1966).  
However, they have been found at low levels in virtually all organs and tissues, 
including liver, adipose tissue and synovium and within the pericyte population in 
the vasculature wall (da Silva Meirelles, 2006; Crisan, 2008).  At present, no specific 
marker or combination of markers has been identified which specifically defines 
MSC.  The International Society of Cellular Therapy (ISCT) proposed minimal 
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criteria to define multipotent MSC (Dominici, 2006).  MSC should be adherent to 
plastic, express CD73, CD90 and CD105, but not CD11b or CD14, CD10 or CD79α, 
CD34, CD45 or HLA-DR.  Finally MSC must be capable of differentiation into 
osteocytes, adipocytes and chondrocytes in vitro (Dominici, 2006).  One of the major 
attractions of MSC lies in the fact that MSC possess a unique mechanism, which 
allows them to escape allogeneic deletion (Le Blanc, 2004).  However, the exact 
mechanisms involved in MSC modulation of immunity in vivo are still unclear.  
Understanding the interactions between MSC and allogeneic immune cells in vivo 
will be critical for the use of MSC as a therapeutic agent.  
1.7.1 MSC AND INNATE IMMUNITY 
MSC interact with both innate and adaptive immune cells which requires 
both contact dependent and soluble factors (Fig 1.2 & Table 1.1).  MSC affect DC 
differentiation and subsequent maturation.  MSC produce several cytokines, such as 
macrophage colony stimulating factor (M-CSF), which are involved in DC 
differentiation from precursors (Djouad, 2007, Chen, 2006; Nauta, 2006).  More 
importantly, MSC interrupt three key features of DC transition from an immature to 
a mature phenotype.  Firstly, in the presence of MSC, the LPS driven upregulation of 
costimulatory molecules, MHC class II, CD40, CD80 and CD86 on DC is prevented 
(English, 2008; Jung, 2007).  Secondly, MSC interfere with the ability of DC to 
present antigen (English, 2008).  Finally, in the presence of MSC, the migratory 
capacity of DC towards CCL19 is affected, due to the down regulation of CCR7 and 
the upregulation of E-cadherin on DC, reducing the migration of DC to lymph node 
derived chemotactic signals (English, 2008).  MSC modulation of DC function 
involves both cell: cell contact and soluble factor dependent mechanisms (Table 1.1).  
MSC secretion of IL-6 induces a semi-mature DC and partly inhibits the 
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differentiation of bone marrow progenitors into DC (Djouad, 2007).  By blocking 
PGE2 synthesis by MSC using indomethacin, DC differentiation and function is 
restored, suggesting PGE2 involvement in MSC modulation of DC differentiation 
(Chen, 2007).  Recently, the Notch signalling pathway, as a possible candidate for 
MSC mediated cell contact dependent mechanism has been hypothesised (Cheng, 
2007, Zhang, 2009).  The Notch ligand, Jagged-1, primarily expressed on bone 
marrow derived stromal cells, stimulates the accumulation of DC precursors, 
preventing their transition to a terminally differentiated DC (Cheng, 2007).  
Recently, Aldinucci et al. demonstrated that MSC required cell contact with human 
monocyte derived DC for the inhibition of DC function.  DC cocultured with MSC 
are unable to form active immune synapses, retaining endocytic activity and 
podosome-like structure, typical of immature DC (Aldinucci, 2010).  To date, the 
exact cell contact signal involved in this induction remains unclear.  Collectively, 
these findings suggest that the Notch signalling pathway could play an important 
role in MSC modulation of DC function.  
1.7.2  MSC AND ADAPTIVE IMMUNITY 
The immunosuppressive activity of MSC extends to adaptive immunity, 
either indirectly through the modulation of cells of innate immunity as described 
above or directly through the modulation of B or T cells.  MSC actively inhibit the 
function of B and T cell function through both soluble factors and cell contact factors 
(Schena, 2010; English, 2009).  B cells contribute to the adaptive immune response 
through the production of antibody.  The effect of MSC on B cell proliferation and 
differentiation remains contradictory and controversial.  Data to date imply that MSC 
inhibit B cell proliferation by blocking the cell cycle at the G0/G1 phase in both 
human and murine studies (Corcione, 2006; Glennie, 2005).  However, studies of 
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systemic lupus erythematosus contradict this; Traggiai et al. suggested that human 
MSC promote the differentiation and proliferation of B cell from patients with 
systemic lupus erythematosus (SLE) (Traggiai, 2008).  In a more recent study, MSC 
inhibited the differentiation and proliferation of plasma cells to B cells in murine 
model of SLE.  This inhibition was IFNγ dependent and involved PD-1/PDL 
pathway (Schena, 2010).   
In vitro studies show that MSC abrogate T cell proliferation in response to 
alloantigens and mitogens (English, 2007).  MSC inhibition of T cell proliferation is 
not MHC-restricted, as it occurs in the presence of autologous and allogenic MSC 
(Ryan, 2007; Ramasamy, 2007; English, 2008; Le Blanc, 2008) and in some cases 
this inhibition appears to be reversed by the addition of exogenous IL-2 (Di Nicola, 
2002).  Various immunosuppressive soluble factors have been implicated in MSC 
mediated T cell suppression, including IL-10, TGFβ1, PGE2, HGF and nitric oxide 
(Di Nicola, 2002; Aggarwal, 2005; Sato, 2007; English, 2009).  MSC do not 
constitutively express IDO, however, upon IFNγ stimulation the expression of IDO 
is induced (Meisel, 2004; Ryan, 2007).  This observation suggests that MSC require 
proinflammatory cytokines for their activation and demonstrates an important 
function for soluble factors present in the local microenvironment of inflammation.   
Not only do MSC suppress T cell proliferation, but they are involved in the 
induction of tolerance in the periphery through the generation of T regulatory cells in 
vitro and in vivo (Casiraghi, 2008; English, 2009; Kavanagh, 2010).  Cell contact, 
PGE2 and TGFβ1 play non-redundant roles in MSC induction of 
CD4
+
CD25
high
FoxP3
+
 T reg cell in vitro (English, 2009).  Importantly, 
CD4
+
CD25
high
FoxP3
+
 T reg cells generated in the presence of MSC are fully 
functional T reg, capable of suppressing alloreactivity when repurified (English, 
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2009).  IL-10 and an unidentified contact signal, induce secretion of HLA-G by 
human MSC to induce a T reg population (Selmani, 2008).  Kavanagh et al. found 
that MSC induced CD4
+ 
FoxP3
+
 T reg in vivo capable of mediated both local and 
systemic inflammation through the decrease of IL-4 and increase of IL-10 in a 
murine model of asthma (Kavanagh, 2010).  Ge et al. also demonstrated the 
importance of MSC induction of CD4
+
CD25
+
FoxP3
+
 T reg.  Here, MSC induction of 
regulatory T cells was associated with IDO expression by MSC, to prevent kidney 
allograft rejection (Ge, 2010).   
 
 
 
Fig 1.2 MSC modulation of immunity.  MSC regulate critical aspects of innate and 
adaptive immune cells by suppressing their development or effector function through 
the release of soluble factors and contact dependent signals  
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Table 1.1 Soluble factors involved in MSC-mediated immune regulation 
 
 
  
Soluble Factor Reference 
Transforming Growth Factor beta 1 
(TGFβ1) 
Kynurenine 
Prostaglandin E2 (PGE2)       
 
Hepatocyte Growth Factor (HGF) 
Interferon gamma (IFNγ) 
Interleukin 1 beta (IL-1 β) 
Tumour Necrosis Factor alpha 
(TNFα) 
Indoleamine 2,3-dioxygenase (IDO) 
Interleukin-6 (IL-6) 
Interleukin-10 (IL-10) 
Nitric Oxide (NO) 
Heme oxygenase-1 (HO-1) 
HLA-G5 
DiNicola, 2002, Tse, 2003, Ryan, 2007, 
English, 2007, English, 2009 
DiNicola, 2002, Ryan, 2007, English, 2007 
Aggarwal, 2005, Ryan, 2007, English, 2007, 
English, 2009 
DiNicola, 2002 
Polchert, 2008, Krampera, 2005 
Groh, 2005 
English, 2007, Beyth, 2005 
 
Krampera, 2005, Meisel, 2004, Ryan, 2007 
Djouad, 2007 
Jiang, 2005 
Sato, 2007 
Cabannes, 2007 
Selmani, 2008 
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1.8  TRANSPLANTATION AND TRANSFUSION; PROTYPIC CELL THERAPIES 
 The major histocompatibility complex (MHC) or human leukocyte antigen 
system (HLA) in humans contains  important polymorphic genes encoding proteins 
that present antigen to self-restricted T cells (Snell, 1948).  The precise patterns of 
co-dominantly expressed MHC genes (the haplotype) are important in supporting the 
discrimination of self and non-self and the regulation of immune tolerance.  The 
MHC haplotype is almost unique to each individual and therefore, allogeneic T cells 
(not tolerised through positive and negative selection against that haplotype) are 
powerfully activated by mismatched MHC molecules (Snell, 1948).  For that reason, 
allogeneic T cells recognise any non-self MHC as foreign and may reject it. 
 In the case of transplantation, cells that express MHC molecules different to 
that of the recipient, are subject to recognition.  This results in the rejection of the 
tissues displaying these foreign MHC antigens.  This was a key finding discovered 
through a body of work carried out by Gorer, Snell, Daussett and others spanning the 
1900s to the 1950s which built on the earlier studies of ABO blood groups and 
transfusion compatibility by Landsteiner (Landsteiner, 1900; Gorer, 1948; Snell, 
1948; Daussett, 1958).  Gorer found that human sera contained natural antibodies 
that could distinguish between red blood cells between three inbred strains of mice 
(Gorer, 1936).  Following the immunisation of rabbits with inbred mouse sera, he 
identified three different blood group antigens, one of which was similar to that 
found in human blood.  He called this mouse antigen, antigen II (Gorer, 1936).  
Gorer then went on to collaborate with Snell, who had discovered tumour 
transplantation resistance genes, which he called histocompatibility genes or H 
genes.  They found that an H-2 locus encoded the strong or “major” 
histocompatibility antigens, which induced rapid transplant rejection when compared 
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to weaker or “minor” histocompatibility antigens (miHA) encoded at another locus 
(Gorer, 1948; Snell, 1948; Snell, 1951).   
These findings focused interest on MHC genes and their role in human 
transplantation.  In 1958, Daussett discovered the first human HLA antigen by 
screening patients that had received multiple blood transfusions.  Daussett found that 
certain sera caused the clumping of leukocytes.  He then found anti-sera that could 
detect an alloantigen present on human leukocytes, which he named MAC.  This 
human antigen has been renamed HLA-A2 (Daussett, 1958).  Ingeniously, at this 
time, Daussett hypothesised that this human antigen and any further antigens to be 
discovered would play very important roles in transplantation; in particularly bone 
marrow transplantation between MHC mismatched donors.  The discovery of HLA 
genes by Gorer, Snell and Daussett (1936-1958), and the concept of immunological 
tolerance and tissue transplantation by Billingham, Medawar and Brent (1953), have 
contributed hugely to the area of transplantation between mismatched donors, both 
organ and bone marrow.  This was revolutionised by the discovery of powerful 
immunosuppressants such as cyclosporine A and tacrolimus, which have permitted 
solid organ transplant even in the scenario of significant tissue mismatch (Messina, 
2008).   
1.8.1 ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION 
Allogeneic haematopoietic stem cell transplantation (HSCT) is an important 
therapy, which has become widely used for the treatment of haematological 
malignancies and inherited blood disorders (Reddy, 2003).  The number of 
allogeneic HSCT carried out is increasing, with more than 25,000 procedures 
performed (globally) annually (Ferrara, 2009).  Patients receiving an allogeneic 
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HSCT (recipient/host) first undergo a conditioning regime that can include 
chemotherapy and/or radiation and/or T cell depleting antibodies (Shlomichik, 
2007).  This conditioning regime eradicates the recipient’s own T and B cells leaving 
the recipient highly immunocompromised and ready for the engraftment of donor 
bone marrow.  Donor T and B cells present in the graft reconstitute adaptive immune 
capacity in the recipient (Trenado, 2003).  Donor T cells have an additional 
beneficial effect against any remaining leukaemic or tumour cells within the host, a 
phenomenon known as graft versus leukaemia (GvL) or graft versus tumour (GvT) 
(Horowitz, 1990; Trenado, 2003).  However, donor T cells can also cause pathology 
involving the damage of host tissues called graft versus host disease (GvHD), which 
is primarily due to varying degrees of donor/host mismatch at both MHC and miHA 
(Korngold, 1978).  In effect, GvHD represents a mirror image of transplant rejection, 
in that it is the donor allogeneic T cells that recognise the recipient host cells bearing 
recipient MHC antigen as “foreign”. 
1.8.2  THE IMMUNE RESPONSE IN GRAFT VERSUS HOST DISEASE 
GvHD is a major complication following allogeneic HSCT, characterised by 
the induction of an intense cytokine storm particularly TNFα, leading to the 
activation of CD4
+
 effector T cells which drive allogeneic reactivity.   GvHD 
accounts for 15-30% of deaths that occur following allogeneic HSCT (Ferrara, 
2009).  In order for GvHD to occur, the donor graft must contain immune competent 
T cells, be transplanted into an immunodeficient recipient unable to mount a 
successful immune response against the graft and the recipient must express tissue 
antigens that are not present in the donor transplant: conditions now termed 
Billingham’s triad (Billingham, 1966). 
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  The development of GvHD occurs in three phases in humans.  In phase I the 
preconditioning regimen prior to transplantation causes tissue/organ damage, 
especially of the gastrointestinal (GI) tract.  Bacterial exposure (e.g. LPS) causes the 
release of inflammatory cytokines and chemokines from monocytes, especially 
TNFα and IL-1.  In phase II these inflammatory cytokines activate endothelium to 
promote tissue inflammation, activate host APC (upregulation of MHC II and 
costimulation) and mobilise allogeneic effector cells to damaged organs.  Here host 
APC expressing MHC II initiate the activation of the donor allogeneic CD4
+
 T cells 
present in the graft, enhancing the secretion of inflammatory cytokines, which leads 
to further donor immune cell activation (Reddy, 2003).  Finally in phase III, 
allogeneic donor CD8
+
 CTL and NK cells destroy host cells directly; CD4
+
 T cell 
drive tissue pathology and prime phagocytes to secrete further TNFα and IL-1 in a 
positive activation cycle, leading to the amplification of damage in multiple organs 
of the host (Reddy, 2003) (Fig 1.2).   
There are two presentations of GvHD, acute (aGvHD) and chronic (cGvHD).  
By definition, aGvHD occurs within the first 100 days post transplantation, while 
cGvHD occurs after 100 days.  However, this classification is unsatisfactory as there 
are presentations of GvHD that include symptoms of both acute and chronic (Martin, 
1990; Sullivan, 1991).  The frequency of GvHD development is directly linked to the 
degree of mismatch between the recipient and donor HLA antigens (Loiseau, 2007).  
Even when high levels of similarity are achieved between the recipient and donor 
bone marrow HLA haplotypes, 40% of patients develop systemic aGvHD, due to 
differences at minor HLA loci (Ferrara, 2009).   
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1.8.3 CLINICAL FEATURES OF AGVHD 
Clinically, the target organs in aGvHD are the skin, GI tract and liver (Table 
1.2).  The skin is the most frequently affected organ, with 81% of patients affected, 
while aGvHD of the GI tract and liver can be seen in about 50% patients (Martin, 
1990).  Due to epithelial cell necrosis, the skin develops a maculopapular rash, which 
is visible on the palms of hands and soles of the feet in most patients (Ferrara, 2009).  
In severe cases, the skin can blister and ulcerate causing extensive pain and 
discomfort.  Epithelial cell necrosis can also cause damage to the GI tract, which 
results in severe abdominal pain, presenting as diarrhoea (Martin, 1990).  An 
increase in bloody diarrhoea can lead to anorexia, nausea and vomiting and result in 
extreme weight loss in patients (Ponec, 1999).  Damage to the liver caused by 
aGvHD is difficult to distinguish from other causes of liver damage following 
HSCT, (e.g. drug toxicity) (Ferrara, 2009).  However, liver damage in aGvHD 
typically presents as hyperbilirubinaemia and jaundice (Ferrara, 2009; Tolar, 2011).   
The severity of aGvHD is characterised by the number of target organs 
involved and the extent of damage made to each organ.  There are four grades of 
GvHD development; grade I (mild), grade II (moderate), grade III (severe) and grade 
IV (very severe).  The more severe the GvHD development, the poorer patient 
prognosis can be (Ferrara, 2009).  Patients presenting with grade III aGvHD have a 
25% long-term survival rate, whereas grade IV patients have only a 5% long-term 
survival rate (Cahn, 2005); suggesting that reductions in the level of GvHD 
pathology might result in improved rates of survival.  
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Table 1.2 Symptoms of acute GvHD (Martin, 1990; Ferrara, 2009) 
Affected Tissue Symptoms 
Skin (81% patients) Macropapular skin rash (palms/soles) 
GI Tract (54% patients) Diarrhoea (bloody), nausea, weight loss 
(anorexia), abdominal pain 
Liver (50% patients) Hyperbilirubinaemia, Jaundice 
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Fig 1.2 Development of Acute GvHD.  Phase I; Preconditioning regime causes 
damage to the epithelial mucosa of the gastrointestinal tract, skin and liver, causing 
loss of barrier integrity and exposure of monocytes to LPS, gut bacteria and other 
damage related innate immune activators.  This causes the release of inflammatory 
cytokines, TNFα and IL-1β, which in turn activate endothelium, host antigen 
presenting cells (APC) and monocytes.  Phase II; Activated APC interact with donor 
T cells and stimulate their proliferation and differentiation.  The release of IFNγ and 
IL-2 from donor T cells activates cytotoxic T lymphocytes (CTL) and natural killer 
(NK) cells.  Phase III; The activation of effector cells and the release of 
inflammatory cytokines cause apoptosis and damage to target organs.  
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1.9 THERAPEUTIC PREVENTION OF AGVHD 
1.9.1 FIRST LINE TREATMENT FOR AGVHD 
 Despite recent advances in the reduction of GvHD through altering the 
intensity of the preconditioning phase prior to transplantation (Levine, 2003), 
effective treatments for GvHD prevention are still lacking.  Currently, the standard 
first line therapies for aGvHD are glucocorticosteroids such as methylprednisolone, 
in combination with immunosuppressive drugs, such as cyclosporine A or tacrolimus 
(Messina, 2008).  Steroid therapies have improved the outcome and increased 
survival of patients with aGvHD (van Lint, 1998; van Lint, 2006; MacMillian, 
2002).  Steroids induce lysis of lymphocytes during interphase and promote anti-
inflammatory responses, while immunosuppressive drugs keep patients in an 
immunocompromised state, dampening the activation of immune responses (Deeg, 
2007).  Different types and doses of steroids are used to treat patients with aGvHD 
and the grade and severity of aGvHD determines the response to steroid therapy (van 
Lint, 2006; MacMillian, 2002).  A typical steroid regime for aGvHD therapy consists 
of methylprednisolone administered at 2 mg/kg per day for 7 to 14 days, followed by 
a gradual reduction in dose depending on patient response rates (Messina, 2008; Van 
Lint, 1998).      
 The major limitations to steroid therapy are the increased risk of infection, 
hyperglycaemia, osteoporosis and growth defects which may be life threatening 
(Deeg, 2007).  However, it is important to note that steroid therapies have proved 
beneficial for very many patients to date (Van Lint, 2006; McDonald, 2006).  
Depending on the patient and the severity of aGvHD, the systemic exposure to 
steroid therapy can be tapered and the duration of therapy reduced (McDonald, 2006; 
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Cragg, 2000).  Conversely, there are patients who do not successfully respond to 
steroid therapy (Deeg, 2007).  In these cases, a second line of therapy is required.  
1.9.2 SECOND LINE TREATMENT FOR AGVHD 
In steroid refractory aGvHD, determining when to initiate secondary therapy 
is patient specific and depends on initial response to primary therapy.  Typically, if 
the manifestations of aGvHD worsen in any organ over 3 days of primary treatment, 
if there are no clinical changes after 7 days, or if there is incomplete response after 
14 days, then a secondary therapy is considered (Deeg, 2007).  Polyclonal and 
monoclonal antibodies are the most widely used secondary therapies (Doney, 1985, 
Carpenter, 2002).  The partial depletion or elimination of specific T cells from bone 
marrow prior to transplantation gives varied results (Chalandon, 2006; Ho, 2004).    
Anti-thymocyte globulin (ATG) has been in use for more than 3 decades (Doney, 
1985).  Administration of ATG reduces the frequency of GvHD in related-donor 
HSCT recipients without increasing relapse (Kroger, 2002).  However, there are high 
levels of variability between recipients and the development of side effects, such as 
hypotension, thrombocytopenia and even anaphylactic reactions can occur in 80-90 
% of patients, with long-term survival on ATG ranging from 5-32 % (MacMillian, 
2002; Graziani, 2002).  This has made the use of ATG in a clinical setting 
problematic.   
Visilizumab is a humanised anti-CD3 antibody that selectively induces the 
apoptosis of activated T cells (Cole, 1999).  In clinical trials, treatment with 
visilizumab improved aGvHD with the initial dose proving important for the overall 
outcome (Carpenter, 2002).  However, complications with visilizumab therapy 
include the reactivation of latent Epstein Barr Virus (EBV) in patients with aGvHD 
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leading to post transplant lymphoproliferative disease (Carpenter, 2002).  
Alemtuzumab is a monoclonal antibody that binds to CD52, expressed by 
lymphocytes, monocytes and dendritic cells inducing apoptosis (Perez-Simon, 2002).  
In 2005, a phase clinical II trial found that the administration of alemtuzumab 
lowered the incidence of both acute and chronic GvHD (Perez-Simon, 2005).  
However, other studies reported complications with infection, such as 
cytomegalovirus and increased relapse rates, leading to subsequent graft failure 
(Perez-Simon, 2002; Delgado, 2006).  An alternative strategy for the treatment of 
GvHD is the blockade of TNFα.  Elevated levels of TNFα are indicative of more 
severe GvHD development (Holler, 1990; Kitko, 2008).  Clinical trials to date have 
used two drugs: etanercept, which binds trimeric and membrane bound TNF, or 
infliximab, a monoclonal antibody that binds monomeric, trimeric soluble and 
transmembrane TNFα (Ehlers, 2005).  A phase II clinical trial found that etanercept 
in combination with systemic steroid therapy supported complete resolution of 
aGvHD symptoms in 70% of patients, with 80% complete responses in GI tract and 
skin aGvHD (Levine, 2008).  However, the well reported side effects of these drugs 
have proved problematic in the treatment of some patients (MacMillian, 2002; 
Graziani, 2002; Carpenter, 2002; Levine, 2008).  Incomplete efficacy and adverse 
effects associated with the use of monoclonal and polyclonal antibodies, suggests the 
need for a more effective beneficial therapy for aGvHD.  Therefore, current studies 
have focused on the idea of cell therapy for the treatment of inflammatory mediated 
diseases, including aGvHD.   
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1.10  CELL THERAPY FOR AGVHD 
1.10.1 T REGULATORY CELLS AS A CELL THERAPY FOR AGVHD 
 GvHD is caused by the presence of donor T cells in the allograft; 
theoretically, the deletion of donor T lymphocytes prior to transplantation could 
solve this problem.  However, a beneficial role for donor T cells in recipient 
haematopoietic reconstitution and the clearance of remaining leukaemic cells (GvL), 
have highlighted the importance of donor T cells for successfully transplantation 
(Horowitz, 1990).  The most potent self-tolerance mechanism of adaptive immunity 
is carried out through the direct or indirect induction of T reg (Tang, 2008).  It has 
been hypothesised that T reg induced tolerance could be used therapeutically in the 
induction of transplantation tolerance.  Donor and recipient DC that have been 
rendered tolerogenic in vitro have been used to inhibit direct and indirect pathways 
of allorecognition, preventing graft rejection (Wakkach, 2003).  Bone marrow 
derived DC can induce alloantigen specific CD4
+
CD25
+
FoxP3
+
T reg in vitro that are 
capable of suppressing GvHD and autoimmunity (Wakkach, 2003; Tarbell, 2004; 
Yamazaki, 2006).  Mouse studies have shown that bone marrow derived recipient 
DC generated in vitro with granulocyte macrophage colony stimulating factor (GM-
CSF), IL-10, TGFβ1 and pulsed with LPS displayed tolerogenic properties that 
prevented the development of lethal GvHD following allogeneic bone marrow 
transplantation (Sato, 2003).  A single dose of host derived tolerogenic DC 
downregulated donor T cell activation, while increasing the incidence of donor 
derived natural T reg cells.  This therapy also retained GvL effects, which is 
important when considering tolerogenic DC as a possible therapeutic agent in GvHD 
(Sato, 2003).  These findings emphasised a role for tolerogenic DC in the prevention 
of GvHD, primarily through the indirect induction of T reg cells.  
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Knowing that DC are capable of regulating T cell responses, especially 
through the induction of  CD4
+
CD25
+
Foxp3
+
 T reg has led to an examination of the 
effect of ex vivo expanded T reg cells as a direct tolerogenic therapy for GvHD.  
Early mouse models of GvHD in 2002 and 2003, found that when mice were 
irradiated and reconstituted with allogeneic donor bone marrow and T cells, the 
development of lethal aGvHD was seen, while the depletion of CD25
+
 T cells 
accelerated GvHD development.  However, if fresh donor type CD4
+
CD25
+
 T reg 
were administered at high ratios with effector T cells, the development of GvHD was 
significantly delayed (Cohen, 2002; Hoffmann, 2002; Taylor, 2002; Edinger, 2003).  
These findings suggested that CD4
+
CD25
+
 T reg might provide a cell therapy for the 
prevention of GvHD.  As the numbers of T reg required for a beneficial effect in vivo 
were relatively high, this finding imposed a limitation for their use in a clinical 
setting.  Therefore, the potential for ex vivo expanded T reg cells to inhibit GvHD 
was explored.  Ex vivo expanded CD4
+
CD25
+
 T reg significantly inhibited GvHD 
development when expanded using host-type APC, rather than third-party APC 
(Trenado, 2002).  It was also found that these ex vivo T reg cells survived longer in 
vivo (Trenado, 2002).  More recently, Cao et al. showed that human 
CD4
+
CD25
+
Foxp3
+
 T reg enriched from peripheral blood could be successfully 
expanded ex vivo to clinically relevant quantities in 2-3 weeks and that these cells 
maintained the expression of T reg cell markers, such as CD25, FoxP3, CD62L and 
CTLA-4 and displayed in vitro suppressive qualities (Cao, 2009).  Following the 
induction of otherwise lethal xenogeneic GvHD, ex vivo expanded T reg cells 
significantly reduced GvHD symptoms and improved the survival of NOD-scid mice 
following co-transfer with human peripheral blood lymphocytes (Cao, 2009).   
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A correlation between CD4
+
CD25
+
 T reg cells and the occurrence and 
severity of both acute and chronic GvHD in 56 patients following allogeneic HSCT 
has also been examined (Li, 2010).  Interestingly, these data found a significant 
reduction in the frequency of CD4
+
CD25
+ 
T reg in peripheral blood of patients with 
either grades II-IV aGvHD or extensive cGvHD when compared to healthy donors.  
Furthermore, the reduction of T reg correlated with the severity of GvHD, with 
fewer T reg indicative of more severe GvHD.  This was accompanied by a reduction 
in serum TGFβ (produced by T reg) and a significant increase in TNFα, a mediator 
of GvHD development (Li, 2010).  
1.10.2 MESENCHYMAL STEM CELLS AS A CELL THERAPY FOR AGVHD 
 Currently, there are many potential applications for MSC in allogeneic stem 
cell transplantation, including the enhancement of HSC engraftment, the prevention 
and/or treatment of GvHD, Crohn’s disease, Multiple sclerosis and Critical limb 
ischemia (Table 1.3).  Initial studies using MSC as a cell therapy for the treatment of 
haematological malignancies have been promising.  Lazarus et al. were the first to 
report that hMSC were applicable for clinical therapy and that autologous MSC, 
after myeloablative condition in cancer patients, could accelerate haematopoietic 
recovery (Lazarus, 1995).  However, firm conclusions could not be made due to the 
haphazard nature of the study.  Nevertheless, these studies gave circumstantial 
evidence that MSC could be expanded and administered to patients under good 
manufacturing practice (GMP).  In 2002, Bartholomew et al. showed that bone 
marrow derived baboon MSC could prolong the survival of autologous, donor or 
third party skin graft in primates (Bartholomew, 2002).  Since then, autologous and 
allogeneic ex vivo expanded MSC have been utilised in studies where bone marrow 
derived MSC were co-transplanted with HSC in patients with both haematological or 
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non-haematological disorders.  Le Blanc et al. have used MSC transplantation in 
cases of repeat graft rejection/failure after HSC transplantation and in studies to 
enhance HSC engraftment (Le Blanc, 2007).  In the case of all patients, MSC 
infusion resulted in rapid engraftment and 100% donor chimerism (Le Blanc, 2007).   
 One of the most impressive in vivo effects of infused MSC has been for the 
treatment of GvHD after allogeneic stem cell transplantation.   Le Blanc et al. were 
the first to demonstrate a potential for MSC infusion for the treatment of GvHD (Le 
Blanc, 2004).  A 9 yr old patient received a matched but unrelated donor HSC 
transplant for the treatment of leukaemia, after developing severe acute steroid 
refractory GvHD of the gut and liver.  Haplo-identical MSC were generated and 
infused over two doses.  The infusion of MSC was effective in treating the GvHD, 
showing no reactivity between the haplo-identical MSC and recipient lymphocytes 
(Le Blanc, 2004).  Le Blanc’s group has also shown that MSC, regardless of their 
source, i.e. HLA-identical sibling, haplo-identical or third party mismatched 
unrelated donors; demonstrate similar results in treating GvHD (Le Blanc, 2008).  
However, optimism for MSC as a cell therapy has become tempered by recent 
clinical trials carried out by Osiris Therapeutics.  Prochymal 
TM 
cells, which are 
MSC-like cells, proved very safe and beneficial following their infusion into patients 
with aGvHD in a Phase II trial (Kebriaei, 2009).  However, in a Phase III clinical, 
the treatment of steroid refractory aGvHD patients was deemed unsuccessful and 
failed to reach its primary endpoint (Martin, 2010; Allison, 2009).  However, it is 
important to note here that Prochymal 
TM 
cells were beneficial for the treatment of 
aGvHD of the gut and liver but not aGvHD of the skin.  The reason for this lack of 
improvement in treating aGvHD of the skin remains unclear.  Why MSC therapy 
was found to be beneficial for the treatment of one aGvHD target organ (GI tract) 
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over another (skin) puts major emphasis on the need for more advantageous models 
for examining the exact mechanisms of MSC modulation.   
Table 1.3 Ongoing clinical trials for which MSC and MSC like cells are 
currently being used to treat conditions 
Condition** Cell type Sponsor Description* 
Acute Graft v Host 
Disease 
Allogeneic MSC University of 
Liege 
Phase II 
Ulcerative colitis Umbilical cord 
MSC 
Qingdao 
University 
Phase I/II 
Critical limb 
ischemia  
Human adipose 
derived MSC 
Fundacion 
Progreso y Salud 
Spain 
Phase I/II 
Multiple sclerosis Autologous MSC Royan Institute Phase I/II 
Parkinson’s disease Autologous MSC Guangzhou 
General Hospital 
Phase I/II 
Aplastic anaemia Allogeneic MSC Guangzhou 
General Hospital 
Phase I/II 
Osteoarthritis Allogeneic MSC Stempeutics 
Research Pvt Ltd 
Phase II 
Type 2 Diabetes Umbilical 
cord/placenta 
derived MSC 
Shandong 
University 
Phase I/II 
Myocardial 
ischemia 
Autologous MSC University 
Hospital Toulouse; 
Nautes University 
Hospital  
Phase I 
Crohn’s disease MSC (Prochymal) Osiris Therapeutics Phase III 
 
* Data based on http://clinicaltrials.gov as of 21.02.2012 
** Multiple trials ongoing at different sites with different types of MSC; table is 
representative of the vast numbers of clinical trials ongoing. 
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1.11 ANIMAL MODELS OF ACUTE GVHD 
Many non-human primates are used to model human disease.  However, non-
human primate models are associated with vigorous ethical constraints and can be 
very costly.  To combat these problems, the use of mouse models offers a more 
feasible alternative to human observations, especially when hypothesis driven studies 
are needed.  There are many mouse models available that model aGvHD 
development.  Most involve the transplantation of donor lymphocytes into lethally 
irradiated hosts.  The irradiation dose, the amount and type of donor lymphocytes 
transplanted into the host determine the severity of aGvHD development (Schroeder, 
2011).  MHC mismatched mouse models are the most straightforward tools for 
studying aGvHD (Table 1.4).  In this situation, the model involves the 
transplantation of murine lymphocytes into a murine model (i.e. mouse in mouse).  
However, recent advances in the development of humanised mouse models have 
allowed more sophisticated and relevant studies to be performed. 
Similar to human aGvHD, the pathology of aGvHD in murine models 
typically affects targets organs such as the lung, liver, skin and intestinal tract (both 
large and small).  One of the key features of murine aGvHD pathology is weight 
loss.  Extensive damage to the host’s intestinal tract results in an increase in 
diarrhoea, reduced food intake, resulting in extreme weight loss.  An increase in 
epithelial cell necrosis results in fibrosis in the lung, skin and liver, all visible 
following histological analysis.  Similar to humans, a well-designed scoring system 
is involved in determining the severity (grade/score) of aGvHD pathology in all 
murine models. 
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1.11.1 MHC-MISMATCHED MOUSE MODELS 
Differences in MHC haplotype are largely responsible for immune mediated 
rejection (Ferrara, 2009).  Even in an MHC matched setting, differences in miHA 
can cause the rejection of transplanted cells or tissues (Korngold, 1978).  The most 
common murine MHC-mismatched model for the study of aGvHD is C57BL/6 (H2
b
) 
donor into BALB.c (H2
d
) recipient.  With this model, the mismatch is at MHC class 
I, MHC class II and miHA loci.  Following conditioning irradiation, T cell depleted 
donor bone marrow cells and splenic T cells are administered to the recipient.  In 
most MHC mismatched mouse models, the numbers of donor splenic T cells 
administered are important in determining the level of aGvHD that develops (Table 
1.4).  In this model, lethal aGvHD involving both CD4
+
 and CD8
+
 T cells typically 
occurs by day 10 to 21 when 0.5-2 x 10
6
 splenic T cells are infused (van Leeuwen, 
2002).   
The C3H/HeJ (H2
k
) donor into C57/Bl6 (H2
b
) recipient is similar to the 
previous model, in that it is mismatched at MHC I, MHC II and miHA.  However, 
typically more splenic T cells (25 x 10
6
) are required for the development of lethal 
aGvHD between day 10 to 30 (Blazar, 1991).  There are also congenic models of 
aGvHD that involve only one T cell type contributing to the phenotype.  In this 
situation, the recipient mouse will have a limited defined mutation on their MHC 
background.  One model illustrating this involves C57BL/6 (H2
b
) donor into B6.C-
H2
bm12 
(H2
b
 background with mutation at MHC II).  In this case, the mismatch is on 
the MHC II background alone and following splenic T cell infusion, CD4
+
 T cells 
drive aGvHD development between day 20 to 40 (Sprent, 1986).   
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1.11.2 HUMANISED MOUSE MODELS 
One drawback to murine systems is that mouse models do not always reflect 
pathology of human diseases.  Furthermore the effector cell is different (human v 
mouse) and these models are not well aligned for the study of human cell therapy 
products.  The development of humanised mouse models has helped address these 
issues.  The history of the development of the humanised mouse model is interesting 
and describes how research tools have progressed and advanced over the past decade 
(Table 1.5).   
1.11.2.1 CB17-SCID HUMANISED MOUSE MODEL 
  The discovery of the Prkdc
scid
 mutation (protein kinase, DNA activated, 
catalytic polypeptide; severe combined immunodeficiency) mutation in CB17 mice 
was a milestone in the development of humanised mouse models of disease (Bosma, 
1983).  The absence of Prkdc expression results in the failure of the V(D)J 
rearrangement of lymphocyte antigen receptor genes which results in the absence of 
functionally mature T and B cells (Lieber, 1988).  CB17 Prkdc
scid 
mice allow 
engrafting human PBMC.  However, the engraftment of human cells was extremely 
low (0.01-0.1%) and was not sufficient for the study of the function of engrafted 
cells (Mosier, 1988).  Some mice bearing the scid mutation developed functional T 
and B lymphocytes over time, a phenomenon known as “leakiness” (Bosma, 1988).  
This leakiness allowed for enhanced innate immune activity, resulting in increased 
numbers of NK cells, which hampered the engraftment of human PBMC in the 
CB17-scid mouse model (Christianson, 1996; Greiner, 1998).  These findings led to 
the introduction of the scid mutation into mice of different backgrounds.  In 1995, 
the introduction of the scid mutation onto the NOD background, displayed 5 to 10 
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fold higher human PBMC engraftment when compared with other mouse models 
(Hesselton, 1995).  These findings allowed the NOD-scid mouse model to become 
the “gold standard” for human cell engraftment studies.  
1.11.2.2 NOD-SCID HUMANISED MOUSE MODEL 
 Non-obese diabetic (NOD) mice have multiple immune defects, including 
defects in macrophage development and function, reduced complement activity and 
decreased NK activity (Kataoka, 1983; Baxter, 1993; Serreze, 1993).  By introducing 
the scid mutation onto the NOD background, the NOD-scid model displayed 
defective lymphocyte development, similar to that of the CB17 mouse.  However, 
unlike the CB17 mouse model, the NOD-scid mouse had reduced “leakiness” levels, 
as only 10% of 6 month old mice developed lymphocytes over time and the levels of 
engraftment were much higher than that found in the CB17 mouse model (Shultz, 
1995; Hesselton, 1995).  Despite the improvements with the NOD-scid model 
compared to previous humanised models, some limitations remained.  The lifespan 
of the NOD-scid mouse was found to be around 8 months, due to the development of 
thymic lymphomas (Shultz, 1995).  Although the engraftment of human cells was 
more than in the CB17 humanised model (0.01%-0.1%), the levels still remained 
relatively low at 1-10% engraftment (Hesselton, 1995).  This may have been due to 
residual NK cell activity within the model (Shultz, 1995).  In an effort to increase 
human cell engraftment, methods for blocking NK cell activity in vivo were pursued.    
1.11.2.3 NOD-SCID β2MNULL AND NOD RAG1NULL PRF1NULL HUMANISED MOUSE 
MODELS 
 In an attempt to increase human cell engraftment, the blockade of NK cell 
activity in vivo was examined.  The NOD-scid β2mnull mouse, which lacked NK cell 
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activity, displayed increased human PBMC engraftment when compared to the 
NOD-scid mouse model.  However, similar to the NOD-scid mouse, the 
development of thymic lymphomas occurred much earlier in the NOD-scid β2mnull 
mouse, which decreased their lifespan considerably (Christianson, 1997).  In 
contrast, the NOD-Rag1
null 
Prf1
null
 mouse displayed defective NK cell activity.  NK 
loss was due to lack of the Prf1 gene, which is important in the production of 
perforin (the killing mediator used by NK cells) (Shultz, 2000).  Although NK cells 
were able to development, they were not functional.  As expected, human cells 
engrafted well in the model, however, due to high levels of variability of engraftment 
between donors, this model was still unreliable and therefore, more reliable 
humanised mouse models were developed.  
1.11.2.4 NOD-SCID IL-2RγNULL HUMANISED MOUSE MODEL  
 The next generation of humanised mouse models focused on targeting 
mutations in the cytokine receptor common γ-chain.  The NOD-scid mouse model 
was the best-humanised model to date, displaying increased lifespan, engraftment of 
human cells and reduced NK cell activity.  In humans, a disease known as X linked 
SCID occurs due to mutations in the IL-2rγ chain gene, which contributes to IL-2, 
IL-4, IL-7, IL-9, IL-15 and IL-21 receptor signalling (Kovanen, 2004).  Patients with 
X-linked SCID are characterised by the absence or marked reduction in T cells and 
NK cells (Sugamura, 1996).  This IL-2rγ mutation was introduced onto the NOD-
scid background.  This allowed the development of a humanised mouse model, 
NOD-scid IL2rγnull mouse (NSG), with deficient T and NK cell activity that could 
readily engraft  6 fold higher levels of human PBMC (Pearson, 2008).  The NSG 
mouse has an increased lifespan when compared to the NOD-scid mouse, which 
makes it ideal for long-term studies.     
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In 2005, Shultz et al. were among the first research groups to publish data 
that showed the development of a complete human immune system in NSG mice that 
were engrafted with human peripheral blood CD34
+
 cells (Shultz, 2005).  This 
finding highlighted the utility of this model in studying functional human immune 
diseases.  This model allowed researchers to investigate how human immune cells 
work in the pathology of many human diseases and how human cell therapies might 
be deployed.  For the purpose of this thesis, the NOD-scid IL2rγnull humanised 
mouse model was used to investigate stem cell therapies for the treatment of aGvHD.   
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Table 1.4 MHC-mismatched mouse models of aGvHD 
Donor 
strain 
Recipient 
strain 
Mismatch Main T cell 
effector type 
Outcome References 
C57/Bl6 
(H2
b
) 
 
BALB.c 
(H2
d
) 
MHC I, 
MHC II, 
miHA 
CD4
+ 
and 
CD8
+
 
Lethal aGvHD 
day 10-21 
Van Leeuwen, 
2002 
C3H/HeJ 
(H2
k
) 
C57/Bl6 
(H2
b
) 
MHC I, 
MHC II, 
miHA 
CD4
+ 
and 
CD8 
Lethal aGvHD 
day 10-30 
Blazar, 1991 
C57/Bl6 
(H2
b
) 
 
B6C3F1 
(H2
k/b
) 
MHC I, 
MHC II, 
miHA 
CD4
+ 
and 
CD8 
Lethal aGvHD Fowler, 1996 
C57/Bl6 
(H2
b
) 
 
B6.C-H2
bm1 
(Mutation on 
MHC I) 
MHC I CD8
+
 Lethal aGvHD 
from CD8
+
 T 
cells by day 
30-80 
Sprent, 1986 
C57/Bl6 
(H2
b
) 
B6.C-H2
bm12 
(Mutation on 
MHC II) 
MHC II CD4
+
 Lethal aGvHD 
from CD4
+
 T 
cells by day 
30-80 
Sprent, 1986 
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Table 1.5 Xenogeneic/humanised mouse models for human cell engraftment 
Mutant 
allele 
Strain 
name 
Strain 
classification 
Phenotype Advantages Disadvantages Ref 
Prkdcscid CB17-scid C.BKa lgh
b-
Prkdcscid/lcrSmn 
-No mature 
T and B 
cells 
-Lack mature 
T and B cells 
-High level of 
innate immunity 
-NK cell activity 
-Leakiness 
-Very low 
engraftment levels 
Bosma, 
1983 
Prkdcscid NOD-scid NOD.CB17- 
Prkdcscid 
-No mature 
T and B 
cells 
-Decreased 
innate 
immunity 
-Low level of 
innate 
immunity 
-Low NK cell 
activity 
-Increased 
engraftment 
-Residual innate 
immunity 
-Residula NK 
cells 
-Deceased 
lifespan and 
lymphomas 
Shultz, 
1995 
Prkdcscid 
B2mtm1Un
c-J 
NOD-scid 
B2m-/- 
NOD.Cg- 
Prkdcscid 
B2mtm1Unc/J 
-No mature 
T and B 
cells 
-No MHC 
class I 
expression 
-Very low NK 
cell function 
-Increased 
engraftment 
-Short lifespan 
and thymic 
lymphomas 
Christians
on, 1997 
Rag1tm1M
om 
NOD-
Rag1-/- 
NOD.129S7(B6
)- Rag1 tm1Mom/J 
-No mature 
T and B 
cells 
-Low NK cell 
activity 
-Residual innate 
immunity 
-Residual NK cell 
activity 
-Variable 
engraftment levels 
Shultz, 
2000 
Prkdcscid 
IL2rgtm1
Wjl 
NOD/LtS
z-scid 
IL2rg-/- 
NOD.Cg- 
Prkdcscid 
IL2rgtm1Wjl/SzJ 
-No mature 
T and B 
cells 
-IL2Rγ-
chain 
deficiency 
-Innate 
immune 
defects 
-Long lifespan 
-Deficient 
innate 
immunity 
-No NK cell 
activity 
-High levels 
engraftment 
-Develops 
functional 
immune 
system 
-Complete 
absence of 
IL2g gene 
-Lack appropriate 
MHC molecules 
for T cell 
selection in mouse 
thymus 
-Low and variable 
level of T cell 
dependent 
antibody 
responses 
Shultz, 
2005 
  
49 
 
1.12 AIMS & OBJECTIVES 
 This chapter has highlighted the many strands of enquiry that suggest a 
possible role for MSC in the modulation of immune responses through the induction 
of immune tolerance.    The hypothesis is that MSC can be used to treat aGvHD and 
that a rational basis for this can be discovered.  The goal is to build on previous work 
and identify both soluble and contact dependent factors involved in MSC 
immunomodulation and to investigate the effect of MSC in the prevention/treatment 
of aGvHD using a new humanised mouse model.  The goals are addressed under the 
following aims: 
i) To investigate the role of contact dependent signals and soluble 
factors involved in the induction of CD4
+
 CD25
+
 FoxP3
+
 T regulatory 
cells by human MSC in vitro (Chapter 3)  
ii) To identify a cell contact signal involved in the induction of 
tolerogenic DC by murine MSC in vitro (Chapter 4) 
iii) To develop and optimise a humanised mouse model of aGvHD and 
determine if human MSC administered as a cell therapy are beneficial 
(Chapter 5) 
iv) To define the possible mechanisms involved in MSC modulation of 
aGvHD development both in vitro and in vivo (Chapter 6) 
Overall, this study sets out to achieve a greater understanding of MSC 
suppression of immunity.  This knowledge will contribute to a broader 
understanding of immune regulation by MSC and provide a rational basis for 
ongoing and future clinical studies involving allogeneic human MSC as a cell 
therapy. 
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CHAPTER 2  
MATERIALS & METHODS 
51 
 
2.1 METHODS 
2.2  REGULATORY ISSUES 
2.2.1  ETHICAL APPROVAL 
All procedures involving animals or human material were carried out by 
licensed personnel. Ethical approval for all work was received from the ethics 
committee of NUI Maynooth. 
2.2.2 COMPLIANCE WITH GMO AND SAFETY GUIDELINES 
 All GMO/GMM work was performed according to approved standard 
operation procedures and recording protocols approved by the Environmental 
Protection Agency (Ireland).  Safe working practices were employed throughout this 
study as documented in the Biology Department of Safety manual NUI Maynooth. 
2.2.3 ANIMAL STRAINS 
The following mouse strains were used: BALB/c, C57BL/6 (Harlan, 
Bichester, Oxon, UK), FVB.Cg-Tg(GFPU)5Nagy/J, BALB/c-Tg(DO11.10)10Loh/J 
(Gift from Trinity College Dublin) and NOD.Cg-Prkdc
scid
IL2
tmlWjl
/Szj (Jackson Labs, 
Bar Harbour, Maine, USA).  All mice were housed according to Dept. of Health 
(Ireland) guidelines and used with ethical approval.  Sample sizes for animal 
experiments were determined by power statistic calculation.   
2.3 ISOLATION OF CELLS 
2.3.1  ISOLATION AND CULTURE OF ADULT MURINE MESENCHYMAL STEM CELLS 
(MMSC) 
 6-8 week old female BALB/c or C57BL/6 mice were sacrificed by cervical 
dislocation.  Femurs and tibias were removed intact under aseptic conditions in a 
class II safety cabinet using a sterile dissection kit.  Femurs and tibias were then 
separated using a sterile scissors.  The ends of each bone were cut to expose the 
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marrow.  Bone marrow was flushed into a sterile Petri dish from both the femur and 
tibia until the bones appeared white in colour and transparent.  This entailed using a 
27 gauge needle and Complete Isolation Media (CIM) (RPMI 1640 (Invitrogen-
Gibco, Carlsbad, CA) supplemented with 10 % (v/v) foetal bovine serum (FBS) 
(Biosera, Essex, UK), 10 % (v/v) horse serum (Hyclone, Hertfordshire, UK), 100 
U/ml penicillin (Invitrogen-Gibco), 100 µg/ml streptomycin and 2mM L-glutamine 
(Invitrogen-Gibco)) (Table 2.1) in a 5 ml syringe.  Cell aggregates were disrupted 
using a 19 gauge needle and syringe.  Cells were then centrifuged at 600 g for 5 min 
and resuspended in 5 ml CIM.   Bone marrow cells were counted by ethidium 
bromide/acridine orange (EB/AO) viable staining (section 2.2) and seeded at a 
concentration of 6.0-6.5 × 10
7
 cells in T75 flasks in 15ml of CIM or 2.0-2.5 × 10
7
 
cells in T25 flasks in 8 ml of CIM.   
 On day 1, non-adherent cells were removed by washing the flask with sterile 
PBS and fresh CIM was added.  Adherent cells (passage 0) were washed with PBS 
and fresh CIM was added every 3-4 days for 4 weeks.   At week 4, cells were 
washed with PBS and lifted by trypsinisation with 0.25 % (v/v) trypsin / 1 mM 
EDTA (Invitrogen-Gibco) for 2 minutes at 37 C.  Trypsin was neutralised by 
addition of CIM and cells were centrifuged at 600 g for 5 min.  Cells (passage 1) 
were counted and  re-seeded at 5-6 × 10
6
 cells in T75 flasks or 1-2 × 10
6
 cells in T25 
flasks in fresh CIM.  Media were replaced every 3-4 days.  This trypsinisation, wash, 
counting, and reculturing constituted a “passage” and that term will be used to 
describe the whole process hereon.  One to two weeks later, the cells were passaged 
(passage 2) at a low seeding density of 50 cells/cm
2
 in complete αMEM (CEM) 
(αMEM (Invitrogen-Gibco) supplemented with 10 % (v/v) foetal bovine serum 
(FBS), 10 % (v/v) horse serum, 100 U/ml penicillium, 100 µg/ml streptomycin and 
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2mM L-glutamine) (Table 2.1).  cαMEM was replaced every 3-4 days.  One to two 
weeks later, cells were passaged again (passage 3) and seeded at 50 cells/cm
2
 or 
cryopreserved (section 2.6.3).  
2.3.2 HUMAN MESENCHYMAL STEM CELLS (HMSC) ISOLATION AND CULTURE 
Bone marrow stem cells were generated by collaborators in NUI Galway.  
Briefly, bone marrow aspirates were taken from the iliac crest of donor patients 
according to an approved clinical protocol (Murphy et al. 2002).  Isolated human 
MSC were resuspended in complete DMEM (DMEM (Invitrogen-Gibco) 
supplemented with 10 % (v/v) foetal bovine serum (FBS), 200 U/ml penicillium and 
200 µg/ml streptomycin (Table 2.1) and seeded at 1 × 10
6 
cells in a T175 flask.  
cDMEM was replaced every 3-4 days.  Once cells reached 70-90 % confluence, 
human MSC were washed with sterile PBS and trypsinised as normal with 0.25 % 
trypsin / 1 mM EDTA (Invitrogen-Gibco) and seeded
 
at 50 cells/cm
2
 or 
cryopreserved (section 2.6.3).  
2.3.3 DENDRITIC CELL ISOLATION AND CULTURE 
 6-8 week old female BALB/c or C57BL/6 mice were sacrificed by cervical 
dislocation.  Femurs and tibias were removed intact under aseptic conditions as 
described in section 2.3.1.  Cells were then centrifuged at 600 g for 5 min and 
resuspended in 5 ml cRPMI.   Bone marrow cells were counted and seeded at a 
concentration of 6 × 10
6
 cells per 10cm tissue culture grade Petri dish (Falcon BD) in 
10 ml cRPMI supplemented with 20 ng/ml Granulocyte Macrophage-Colony 
Stimulating Factor (GM-CSF) (PeproTech, Rocky Hill, NJ).  On day 3, 10 ml of 
fresh cRPMI supplemented with 20 ng/ml GM-CSF was added to each dish.  On day 
6, 10 ml of cell suspension was removed from each dish and discarded.  10 ml of 
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fresh cRPMI supplemented with 20 ng/ml GM-CSF was added.  After 8 days, cells 
were harvested by gentle aspiration and centrifuged at 600 g for 5 min.  Cells were 
resuspended in cRPMI (Table 2.1) and counted.  Cells were seeded at appropriate 
concentrations relevant to experimental assays.   
2.3.4 MURINE SPLENOCYTE ISOLATION 
Murine spleens were removed aseptically from mice into cRPMI 
supplemented with 10% (v/v) heat inactivated FBS, 100 U/ml penicillium, 100 
µg/ml streptomycin and 2 mM L-glutamine (Table 2.1).  Splenocytes were isolated 
by homogenising spleens through a 70 µm filter and were then suspended in 8 ml 
cRPMI containing 0.1 % v/v beta-mercaptoethanol (Invitrogen-Gibco).  The 
homogenate was centrifuged at 300 g for 5 min and resuspended in 2 ml of red blood 
cell lysis buffer solution (BioLegend, San Diego, CA,) for 10 min at room 
temperature.  2 ml of medium was added to the suspension to neutralise the lysis 
solution which was then centrifuged at 600 g for 5 min.  Supernatant was removed 
and the cells were then resuspended in fresh cRPMI and counted.   
2.3.5 HUMAN PERIPHERAL BLOOD MONONUCLEAR CELL (PBMC) SEPARATION  
Whole blood buffy coat packs, which contained red blood cells, white blood 
cells and platelets, were supplied by St. James’s Hospital, Dublin.  In parallel, 
freshly isolated blood was collected in heparin coated blood collection tubes 
(Sarstedt, Germany) from healthy donor volunteers in NUI Maynooth.  PBMC were 
isolated from whole blood by density gradient centrifugation.  The contents of buffy 
coat packs were diluted 1 in 4 with Hanks’ Balanced Salt Solution (HBSS) 
(Invitrogen-Gibco) supplemented with 5 % (v/v) FBS (PAA) and 1 % HEPES 
(Invitrogen-Gibco), while fresh blood was diluted 1 in 2 with the same buffer.  Buffy 
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coat packs were treated with 5 % (w/v) EDTA (Sigma-Aldrich) to prevent 
coagulation.  40 ml diluted blood was carefully layered on top of 10 ml lymphoprep 
(Axis-Shield, Oslo, Norway) in a 50 ml centrifugation tube (Sarstedt).  Tubes were 
centrifuged at 400 g for 25 min with no brake and low acceleration.  After 
centrifugation, the white buffy coat layer containing PBMC was removed into a new 
sterile 50 ml tube, leaving red blood cells and remaining plasma behind.  PBMC 
were centrifuged at 800 g for 5 min with brake and acceleration at high settings.  
Supernantant was removed and the PBMC pellet was washed in 10 ml of HBSS and 
centrifuged at 600 g for 5 min a total of two times.  The washed PBMC were 
resuspended in 10 ml of cRPMI (Table 2.1) and counted.   
2.3.6 CD4
+
 T CELL ISOLATION 
Human/mouse CD4
+
 T cells were isolated using MagCellect CD4
+
 T cell 
isolation kit according to manufacturer’s instructions (R & D Systems, Minneapolis, 
MN).  Briefly, PBMC/splenocytes were resuspended in 1X MagCellect buffer to a 
cell density of 1.0 × 10
8
 cells/ml.  For every 1 × 10
7
 cells processed, 10 μl of CD4+ T 
cell biotinylated antibody cocktail was added and cells incubated for 15 min at 4 ˚C.  
After incubation, 12.5 μl of streptavidin ferrofluid per 1 × 107 cells was added and 
further incubated for 15 min at 4 ˚C.  Following the incubations, the final volume of 
3 ml was made by adding MagCellect buffer.  The tubes were placed into a magnetic 
stand for 6 min at RT.  The magnetically labelled cells migrated towards the magnet, 
leaving the desired CD4
+
 T cells behind in suspension.  This incubation was repeated 
for another 6 min to ensure a pure CD4
+
 T cell population was obtained.  The CD4
+
 
T cell suspension was centrifuged at 300 g for 5 min then resuspended in cRPMI and 
counted.  
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2.4 CELL VIABILITY & APOPTOSIS ASSESSMENT 
2.4.1 MEASUREMENT OF CELL VIABILITY (FLUORESCENT MICROSCOPY)  
A sample of cells was suspended in their specific growth media and diluted 
1/10 in 2 % (w/v) ethidium bromide/acridine orange (EB/AO) (Sigma-Aldrich, 
Arklow, Ireland).  10 µl was pipetted onto a haemocytometer chamber and viable 
cells (green) were counted using a fluorescent light microscope. 
2.4.2 APOPTOSIS IN VITRO 
Apoptosis was detected by the binding of Annexin V/Propidium iodide (PI) 
staining.  Cells were harvested, resuspended in PBS for washing and centrifuged at 
300 g for 5 min.  Cells were resuspended in 1 X binding buffer at a concentration of 
1 x 10
6
 cells/ml.  1 x 10
5
 cells (100 µl) were transferred to a 5 ml tube.  5 µl of 
Annexin V-FITC (0.5 mg/ml) and 5 µl of propidium iodide (PI) (20 μg/ml) 
(BDBioscience) were added to each tube.  Cells were gently vortexed and incubated 
for 15 min at room temperature in the dark.  After 15 min, 400 µl of assay buffer 
(BDBioscience) was added to each tube and analysed by flow cytometry within 1 h.   
2.5 CELL CHARACTERISATION BY FLOW CYTOMETRY 
2.5.1  GENERAL FLOW CYTOMETRY 
For analyses by flow cytometry, cells (MSC, DC or CD4
+
 T cells) were 
harvested, washed in sterile PBS and resuspended in an appropriate volume of PBA 
(phosphate buffer saline solution (PBS) supplemented with 10 % (v/v) heat 
inactivated bovine serum albumin (BSA)) to yield approximately 1 x 10
5
 cells/FACS 
tube (4 ml polypropelyene tubes) (Falcon, BD Biosciences).  In directly labelled 
approaches, fluorochrome conjugated antibodies (Tables 2.4 & 2.5) or isotype 
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controls were incubated with cells for 15 min at 4 C.  After 15 min, cells were 
washed in 2 ml of PBA, vortexed and centrifuged at 250 g for 5 min.  The 
supernatant was removed and cells resuspended in 200 l PBA or 300 l of cell 
fixative (PBS supplemented with 1 % (v/v) paraformaldehyde (PFA) (Sigma-
Aldrich)).   
A similar approach was used for indirect labelling. The primary biotinylated 
(eBioscience, San Diego, CA) (Table 2.4 & 2.5) antibody was incubated with cells 
as above.  Secondary conjugated antibodies (eBioscience) were added to appropriate 
tubes and further incubated for 15 min at 4 C.  Cells were then washed with 2 ml 
PBA and vortexed before centrifugation at 250 g for 5 min.  The supernatant was 
removed and cells resuspended in 200 l PBA for immediate analysis or in 300 l of 
cell fixative for storage at 4 C overnight.  Cells were analyzed by flow cytometry 
using a FACSCalibur cytometer using CellQuest software (BD Biosciences).  A 
minimum of 1 x 10
5
 cells were analysed for surface expression of markers and 
10,000 events were acquired for each marker.   
2.5.2 INTRACELLULAR FLOW CYTOMETRY FOR HUMAN FOXP3 EXPRESSION 
FoxP3 expression was analysed intracellularly.  Briefly, CD4
+
 T cells or 
PBMC, recovered from coculture assays, were washed in PBA.  CD4
+
 T cells were 
labelled with CD4 PerCP or CD4 APC and CD25 PE or corresponding isotype 
control antibodies for 15 min at 4 °C.  CD4
+
 T cells or PBMC were washed and 
fixed with 2 % (v/v) PFA (Sigma-Aldrich).  CD4
+
 T cells or PBMC were then 
permeabilised using cold PBS and 0.2 % (v/v) Tween 20/PBS (Sigma-Aldrich).  
After permeabilisation, CD4
+
 T cells or PBMC were incubated with FoxP3 FITC 
antibody or isotype control for 30 min at 4 °C.  At the end of the incubation, CD4
+
 T 
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cells or PBMC were washed with PBA and placed in 300 μl of cell fixative.  
Analysis was performed within 4 h of preparation using a FACSCalibur cytometer 
and CellQuest software (BD Biosciences). 
2.6  CELL CULTURE 
2.6.1 PROLIFERATION ASSAY 
DC, CD4
+
 T cells, splenocytes or PBMC were seeded in a 96-well tissue 
culture plate (1 x 10
6
 cells/ml) in the presence or absence of MSC (1 x 10
5
 cells/ml) 
in 200 µl final volume.  In a mitogen driven proliferation assay, PBMC or 
splenocytes from one MHC donor or strain were stimulated with concanavalin A 
(ConA) or phytohaemagglutinin (PHA) (Sigma-Aldrich) at 5 µg/ml for 72 h.  After 
72 h, 100 µl of supernatant was carefully removed and stored at -20 °C for cytokine 
analysis.  [
3
H]-Thymidine (Amersham Biosciences, Buckinghamshire, England) at 
0.5 µCi/ml was added for the final 6 h of culture and incubated at 37 °C 5 % CO2.  
Cultures were harvested using an automatic cell harvester (Micro96 Harvester, 
Skatron Flow Laboratories, Oslo, Norway) onto glass fibre filter mats.  The mats 
were dried and placed in plastic sample bags (Wallac– PerkinElmer, Waltham, MA, 
USA).  3 ml of β-scintillation fluid (Beta-Plate Scint, Wallac-PerkinElmer) was 
added to the bag containing the filter mat after which it was sealed and placed in a 
cassette.  [
3
H]-Thymidine incorporation was quantified by a β-scintillation counter 
(1450 Microbeta Liquid Scintillation Counter; Wallac-Perkin Elmer) and results 
were expressed in counts per minute (cpm).   
2.6.2 MIXED LYMPHOCYTE REACTION (MLR): HUMAN AND MURINE 
 Freshly isolated PBMC or murine splenocytes were seeded at a density of 1 x 
10
6
/ml and added to a 96-well tissue culture plate in 200 µl final volume (1 x 
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10
5
cells/well).  PBMC from two HLA mismatched donors or splenocytes from two 
MHC mismatched strains were cocultured in a two-way MLR.  The effect of MSC 
on lymphocyte proliferation was assessed by adding MSC to the MLR at a density of 
1 x 10
5
 cells/ml (1 x 10
4
cells/well).  The 96 well plate was incubated at 37 °C for 72 
h after which 100 µl of supernatant was carefully removed and stored at -20 °C for 
cytokine analysis.  [
3
H]-Thymidine at 0.5 µCi/ml was added for the final 6 h of 
culture and incubated at 37 °C 5 % CO2.  Cell were harvested as stated in section 
2.6.1. 
2.6.3  CRYOPRESERVATION AND RECOVERY OF CELLS FROM LIQUID NITROGEN 
Cells were suspended at 1 x 10
6
/ml of freezing medium and temperature 
reduced 10 °C per minute overnight and stored in liquid Nitrogen within 24 h.  
Freezing medium consisted of cRPMI containing 20% (v/v) FCS supplemented with 
10 % (v/v) Dimethyl Sulfoxide (DMSO) (Sigma-Aldrich).  To recover cells, vials 
were quickly thawed at 37 °C.  Just as the vial contents thawed, 8 ml of warmed 
medium was added and cells were centrifuged at 600 g for 5 min.  Supernatant was 
discarded and the cells washed once more.  The final pellet was resuspended in 2 ml 
of cRPMI and placed in T175 flask for culturing in cell specific media. 
2.7 DIFFERENTIATION OF MSC 
2.7.1 OSTEOGENIC 
MSC were seeded at a density of 1 x 10
3
cell/cm
2 
in a 6-well tissue culture 
plate in 2 ml cDMEM (hMSC) or cα-MEM (mMSC).  Once 70 % confluence was 
reached (typically 2-3 days), cells were incubated in osteogenic differentiation 
medium (Table 2.1).  Fresh medium was added every 3-4 days for 21 days.  At day 
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21, the medium was removed and the cells were washed in PBS and then fixed in 10 
% (v/v) neutral buffered formalin for 20 min at room temperature.  Formalin was 
removed and cells were washed in 2 ml of PBS.  1 ml of 1 % Alizarin Red (Table 
2.2) was added to the fixed cells and allowed to stain for 20 min at RT.  Excess stain 
was removed and the cells were washed with dH2O.  Finally, 1 ml of dH2O was 
added to each well and cells were examined under the microscope for red deposits 
indicating the presence of osteocyte like cells (Pittenger, 1999). 
2.7.2 ADIPOGENIC 
MSC were seeded at a density of 1 x 10
3
cell/cm
2 
in a 6-well tissue culture 
plate (BD Falcon) in 2 ml cDMEM (hMSC) or cα-MEM (mMSC) as above and at 70 
% confluence, cells were incubated in adipogenic differentiation medium (Table 2.1) 
with fresh medium added every 3-4 days for 21 days.  At day 21, the medium was 
removed and the cells were washed in PBS and then fixed in 10 % neutral buffered 
formalin for 20 min at room temperature.  Formalin was removed and cells were 
washed in 2 ml of PBS.  1ml of 0.5 % Oil Red O (Table 2.2) was added to the fixed 
cells and allowed to stain for 20 min.  Excess stain was removed and the cells were 
washed with PBS.  Finally, 1 ml of PBS was added to each well and cells were 
examined under the microscope for red fat globules indicating the presence of 
adipocyte like cells (Pittenger, 1999) 
2.7.3 CHONDROGENIC 
MSC were seeded at 2.5 x 10
5
cells/pellet culture in 15 ml tube.  MSC were 
centrifuged at 100 g for 5 min.  Pellets were resuspended in complete human MSC 
media (control) or in complete chondrocyte media (Table 2.1).  Tubes were placed in 
incubator at 37 
◦
C, 5 % CO2 in 15 ml tubes with caps loosened to allow for gaseous 
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exchange for 21 days.  Media was changed every 2-3 days.  On day 21, cell pellets 
were harvested by aspirating off all the media and washing pellets twice with PBS.  
Pellets were placed in 1 ml of trizol and stored at -20
◦
C.  Chondrocyte pellets were 
analysed for the expression of collagen II and aggrecan by RT-PCR (Table 2.7 & 
2.8).  Briefly, RNA was isolated from the pellets (section 2.9.1), reversed transcribed 
into cDNA (section 2.9.3) and the expression of chondrocyte markers were analysed 
by RT-PCR (section 2.9.4).    
2.8 IMMUNOCHEMICAL TECHNIQUES 
2.8.1 ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) 
 All ELISA were carried out according to manufacturer’s instructions.  
Specific capture antibodies (human IFNγ & TNFα or murine IL-12p70 & IL-10) in 
PBS were added to 96 well microtitre plates (NUNC) and incubated overnight at 
room temperature.  Plates were then washed 3 times in wash buffer (PBS 
supplememnted with 0.05 % v/v Tween 20) and then incubated in blocking solution 
(PBS supplemented with 1 % w/v BSA) for a minimum of 1 h.  Plates were then 
washed and incubated with 100 µl/well of sample supernatant or corresponding 
cytokine standard for 2 h at room temperature.  After washing, plates were incubated 
with specific detection antibodies for a further 2 h at room temperature.  Plates were 
washed again and incubated with 100 µl/well of streptavidin horseradish peroxidase 
(HRP) (R & D Systems) conjugate diluted 1/200 in specific reagent diluent (Tris 
buffered solution (TBS) (Sigma-Aldrich) supplemented with BSA for 20 min.  After 
washing, plates were incubated with 100 µl/well of tetramethylbenzidine (TMB) 
substrate (Sigma-Aldrich) for 20 min at room temperature out of direct light.  The 
reaction was stopped after 20 min by adding 50 µl/well of 1 M H2SO4.  The 
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absorbance (optical density (O.D)) of the samples and standards were measured at 
450 nm for all ELISA using a plate reader (Labsystems, Helsinki, Finland).  The 
cytokine concentration of each sample was determined by comparison to the 
standard curve of known cytokine concentrations.  
2.8.2  MEASUREMENT OF CYTOKINES BY BEAD ARRAY ANALYSIS 
 Bead array technology is a method for quantifying multiple cytokines 
simultaneously in a single sample volume (25 µl).  This technique is based on the 
same premise as enzyme-linked immunosorbent assay (ELISA).  Bead array analysis 
uses fluorescence, instead of colorimetric intensity for quantification.  Beads are 
internally labelled with varying intensities of fluorescent dye, corresponding to each 
specific cytokine, which allows for the differentiation of multiple analytes by flow 
cytometry.  Analysis of cytokines from serum (human IFNγ & TNFα) was carried 
out using Flow Cytomix kits (BenderMedSystems) and analysed using a 
FACSCaliber flow cytometer (Becton Dickinson,).  Standard curves and raw data 
were generated for each cytokine using FlowCytomix Pro 2.2 software 
(BenderMedSystems).   
 Cytokines were quantified as per manufacturer’s instructions.  Briefly, 
standards, samples or control (PBS) were added to 4 ml polypropylene FACS tubes 
(Falcon, BD Biosciences).  Beads coated with primary antibodies for each individual 
cytokine were mixed together and added to each tube.  Biotin-conjugated secondary 
antibodies were added to all tubes and allowed to incubated for 2 h at room 
temperature, protected from light.  Following incubation, samples were washed with 
1 ml of FACS buffer and centrifuged at 200 g for 5 min.  After centrifugation, 
supernatant was carefully discarded and wash step was repeated.  Streptavidin-PE 
63 
 
was added to the tubes and allowed to incubate fro 1 h at room temperature and 
protected from light.  Following this incubation, samples were washed twice more 
and then sample tube was resuspended in 500 µl of assay buffer.  Cytokines were 
quantified from samples based on fluorescence intensity and comparison to the 
standard samples. 
2.9 MOLECULAR TECHNIQUES 
2.9.1 RNA ISOLATION 
Total RNA was extracted using trizol® reagent (Invitrogen) according to the 
manufacturer’s instructions.  Briefly, 1 x 106 cells were lysed in 1ml trizol at room 
temperature for 5 min.  100 µl of RNA-grade 1-Bromo-3-chloropropane (Sigma-
Aldrich) was added to the cells, mixed vigorously and incubated at room temperature 
for 5 min.  Samples were centrifuged at 12,000 g for 15 min at 4 °C.  Two distinct 
layers resulted with RNA remaining in the clear, aqueous upper layer.  350-400 µl of 
RNA was carefully removed, ensuring the lower white DNA layer was not disturbed, 
and precipitated with 500 µl isopropanol (Riedel-deHaen).  The samples were 
incubated at room temperature for 10 min and followed by centrifugation for 10 min 
at 4 °C.  The resulting RNA pellet was washed with 1 ml 75 % (v/v) ethanol and 
centrifuged at 7,500 g for 5 min at 4 
o
C.  The ethanol was aspirated and the RNA 
pellet was allowed to briefly air dry prior to resuspension in 30 μl RNase-free water 
(Promega, Southhampton, UK).  The purity and concentration of RNA was 
determined using a spectrophotometer (Nanodrop 2000, ThermoScientific, 
Wilmington, DE, USA) which calculated the ratio of absorbance at 260 nm to 280 
nm.  A ratio between 1.8 and 2.0 indicated sufficient purity of the RNA.   Samples 
outside this range were discarded.  
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2.9.2 DNASE TREATMENT OF RNA  
 Genomic DNA was removed from RNA samples by treatment with DNase I 
(Invitrogen, Paisley, UK).  1 μl of DNase (Amplification grade) was added to 500 ng 
of RNA and incubated for 15 min at room temperature.  1 μl of 25mM EDTA 
(Promega), to inactivate the DNase, was added to the mixture and incubated at 65
◦
C 
for 10 min.   
2.9.3 CDNA SYNTHESIS  
Following DNase treatment of RNA, total RNA was reverse transcribed 
using 25 Units Superscript II (Invitrogen).  Each reaction contained a 1 x GoTaq 
reaction buffer (Promega), 2.5 mM MgCl2 (Promega) , 10 mM dNTP mix (Promega), 
50 U/ml of ribonuclease inhibitor (Invitrogen) and 20 µg/ml Oligo (dT) 12-18 primer 
(Invitrogen)  diluted in nuclease-free water (Promega).  The conditions for cDNA 
synthesis were as follows: 25 
o
C for 10 min, 42 
o
C for 60 min, 95 
o
C for 5 min and 4 
o
C for 10 min.  Quantification of cDNA was performed by measuring the absorbance 
value of the sample 260 nm.  Samples were stored -20 
o
C until required.  
2.9.4 REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION (RT-PCR) 
 PCR was used to determine the presence of specific DNA sequences (or 
mRNA following reverse transcription) using primers summarised in Table 2.6 and 
2.7.  Expression of the housekeeping gene, Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used as a positive control.  PCR reactions contained 
2.5 mM MgCl2 (Promega), 25 mM dNTP (Promega), 1 x GoTaq reaction buffer 
(Promega), 40 U/ml Taq polymerase (Promega) and 0.4 pM of the appropriate 
primer (NCBI:BLAST).  The reaction mastermix was adjusted to a final volume of 
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24 µl with nuclease-free water.  The PCR conditions were as follows: denaturation at 
95 °C for 45 sec (10 min for first cycle), annealing for 45 sec (optimal annealing 
temperatures are summarised in Table 2.7 and 2.8 and extension for 1 min at 72°C.  
DNA products were resolved on a 1.3 % w/v agarose gel and detected by binding of 
gel red (Biotium, Hayward, CA). 
2.9.5 REAL TIME-POLYMERASE CHAIN REACTION (QRT-PCR) 
 cDNA was analysed for the quantification of mRNA expression.  Briefly, 
cDNA (500 ng) were amplified in the presence of SYBR
® 
Green PCR mastermix 
(Qiagen).  Accumulation of gene-specific products were measured continuously by 
means of fluorescence detection over 35 cycles. Each cycle consisted of: 
denaturation at 95 
°
C for 15 min, annealing at 95 
◦
C for 30 sec, optimum temperature 
(Table 2.7 & 2.8) for 30 sec, 72 
°
C for 30 sec, extension at 72 
◦
C for 10 min and then 
4 
◦
C forever.   Standard curves for FoxP3 and TGF-β1 expression were generated by 
amplifying 10-fold serial dilutions of known quantities of FoxP3 or TGF-β1 standard 
generated previously in the laboratory.  The expression of Notch, ICOS, LICOS, PD-
1 and PDL-1 were quantified in relation to the housekeeper GAPDH.  Quantification 
of target gene expression was obtained using sequence detector software (DNA 
Opticon ™).  The resultant target mRNA concentration was expressed as fg 
product/500ng cDNA.  
2.9.6 SILENCING OF RNA (SIRNA) 
 MSC were seeded at 4 × 10
4
/ well in 24 well plates in duplicate until 
approximately 60% confluent.  siRNA for murine Jagged-1 was pre-designed 
(Silencer® Select siRNA, Applied Biosystems, Warrington, UK)  and diluted in 
RNase free water (supplied with kit)  to different concentrations, as per 
66 
 
manufacturer’s instructions.  Lipofectamine (Invitrogen, Paisley, UK) was used as a 
transfection reagent for all siRNA experiments, as per manufacturer’s instructions.  
MSC with or without siRNA were cultured in Opti-Mem®I media (Gibco-
Invitrogen, Paisley, UK).  After 24 h, MSC RNA was isolated (Section 2.9.1) and 
transcribed into cDNA (Section 2.9.3).  Murine Jagged-1 expression on MSC was 
examined by RT-PCR (Section 2.9.4) (Table 2.8).  
2.10  MSC FUNCTIONAL ASSAYS IN VITRO 
2.10.1 IN VITRO MATURATION OF DC AND COCULTURE WITH MSC 
Immature DC were harvested on day 8 and matured in the presence of 
lipopolysaccharide (LPS) (Sigma-Aldrich) at 100 ng/ml for 24 or 48 h in the 
presence or absence of mMSC.  The seeding densities used were, 1 x 10
5
 MSC: 3 x 
10
5
 DC in 24 well plate for 24 h RT-PCR analysis or 3 x 10
5
 MSC: 1 x 10
6
 DC in 6 
well plate for 48 h flow cytometry analysis.  For transwell experiments, MSC were 
seeded in the bottom of the well (6 well or 24 well) and DC were placed in the 
transwell inserts (0.4μM) (Nunc).  The expression of regulatory molecules (ICOS, 
LICOS, PD-1, PDL-1 & CTLA4), notch receptors (Notch 1 & 2), Notch ligands 
(Jagged 1, 2 & Delta like ligand 1) and notch target gene (Hes 1) on DC were 
analysed by RT-PCR after 24 h (Table 2.8).  After 48 h, maturation markers (MHCII 
and CD86), CD11c and corresponding isotype controls were analysed by flow 
cytometry on DC (Table 2.4).  For the neutralisation study, mouse anti-Jagged 1 (8 
µg/ml & 5 µg/ml) or corresponding control antibody was added to the co-cultures 
and the expression of maturation markers were analysed by flow cytometry (Table 
2.4).  In some experiments, the Notch inhibitor, γ-secretase inhibitor (GSI) 
(Calbiochem, Merck, Germany) reconstituted in DMSO (Sigma-Aldrich), at 1 µM 
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was added to DC: MSC cocultures for 48 h and the expression of maturation markers 
were analysed by flow cytometry.  Supernatants from coculture were analysed for 
the presence of IL-10 and IL-12p70 by ELISA (section 2.8.1) 
2.10.2 ANTIGEN PRESENTATION ASSAY (EΑ: I-A
B
 DETECTION) 
 Immature DC were isolated from C57/Bl6 mice and harvested on day 8 of 
culture by gentle aspiration.  DC at 3 x 10
5
/well were incubated with 10 µg/ml I-Eα 
peptide 52-68 (ASFEAQGALANIAVDKA) (Anaspec, San Jose, CA) for 48 h in the 
presence or absence of MSC (1 x 10
5
/well) in a 24 well plate.  As a control, DC were 
cultured with MSC alone or MSC and diluted DMSO (vehicle for Eα peptide) for 48 
h in 24 well plate.  Peptide binding was detected using the biotin-conjugated anti-I-
A
b: Eα complex specific antibody, Y-Ae (eBioscience).  Binding of biotin-
conjugated antibody was detected by FITC conjugated extravadin (Sigma-Aldrich) 
and analysed by flow cytometry.   
2.10.3  OVALBUMIN (OVA) SPECIFIC ANTIGEN PROLIFERATION ASSAY 
 Immature DC from C57/Bl6 mice were isolated and harvested on day 8 of 
culture by gentle aspiration.  DC at 1 x 10
6
/well of a 6 well tissue culture plate were 
pulsed with 20 µg/ml OVA (Sigma-Aldrich) in the presence or absence of MSC (3 x 
10
5
/well) for 24 h.  After 24 h, DC were harvested by gentle aspiration and 
centrifuged at 300 g for 5 min.  DC were further cultured with 4 x 10
5
/ml naïve 
OVA-specific I-Ad restricted CD4
+
 DO11.10 T cells isolated from the spleens of 
DO11.10 mice.  Cells were cultured for 72 h and a proliferation assay performed as 
stated in section 2.6.1. 
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2.10.4 STIMULATION OF MURINE MSC WITH INFLAMMATORY CYTOKINES 
Murine MSC at 3 x 10
5
/well of a 6 well tissue culture plate were allowed to 
adhere overnight.  mMSC were stimulated with prolactin (PeproTech, London, UK), 
IFNγ (R&D Systems), LPS (Sigma-Aldrich) or TNFα (R&D Systems) at 50 ng/ml 
for 24 h.  The expression of Notch receptors (Notch 1 & 2), Notch ligands (Jagged 1, 
2 & Delta like ligand 1) and regulatory molecules (PD-1, PDL-1, ICOS, LICOS and 
CTLA4) were analysed by RT-PCR (Table 2.8). 
2.10.5 IN VITRO COCULTURE OF HUMAN PBMC/CD4
+
 T CELL AND MSC  
 Whole PBMC or freshly isolated CD4
+
 T cells (1 × 10
6
/well) were cocultured 
with hMSC (3 × 10
5
/well) for 24 or 72h in 6 well plates (Nunc) or in transwell plates 
(0.4μM)  (Nunc).  Neutralisation or antagonist studies were performed using anti-
TGFβ1 at 4 μg/ml (R & D Systems) or indomethacin at 40 μM (Sigma-Aldrich) 
(Table 2.5).  The expression of forkhead box P3 (FoxP3) and transforming growth 
factor beta 1 (TGFβ1) were analysed by qRT-PCR (Table 2.7) after 24 h.  The 
expression of CD4, CD25 and FoxP3 were analysed by flow cytometry (Table 2.5) 
72 h after co-culture.   
2.10.6 COMPLEMENT INDUCED KILLING IN VITRO 
Human MSC were cultured at 2 x 10
5
/well of a 24 well tissue culture plate 
overnight in complete medium to allow cells to adhere.  Human lung epithelial cells 
(A549) or mouse splenocyte control cells were cultured at 2 x 10
5
/well of a 24 well 
tissue culture plate in serum free media (RPMI supplemented with 1 % v/v ITS and 1 
% v/v penicillium streptomycin).  Medium was removed from human MSC and 
replaced with serum free medium.  Cells were then exposed to either human or 
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mouse complement at 1/16 dilution of final volume for 4 h.  Cells were then washed 
out of the complement solution after 4 h, and dying/apoptotic cells were detected 
using by flow cytometry as described in section 2.4.2.  Times and concentrations 
were arrived at after prior optimisation experiments. 
2.10.7 ASSESSMENT OF HUMAN MSC INDUCED APOPTOSIS OF PBMC 
 Human PBMC at 1 x 10
6
/well were cocultured with MSC at 3 x 10
5
/well of a 
6 well for 24 h in cRPMI.  The analysis of MSC induced apoptosis was analysed by 
flow cytometry.  As a positive control, a chemotherapy drug, cisplatin (Sigma-
Aldrich) at 500 µg/ml was added to some wells.  After 24 h, all human PBMC were 
recovered from culture by gentle aspiration from adherent MSC and apoptotic cells 
were detected using FITC Annexin V apoptosis detection kit as described in section 
2.4.2. 
2.10.8 ASSESSMENT OF HUMAN MSC INDUCED CD4
+
 T CELL ANERGY 
 Murine DC were isolated using the protocol outline in section 2.3.4 from 
BALB/c mice.  Human CD4
+
 T cells were isolated from human PBMC as stated in 
section 2.3.6 & 2.3.7.  Murine DC (1.5 x 10
5
/ml) were cocultured with human CD4
+
 
T cells (1 x 10
6
/ml) and stimulated with poly IC (20 µg/ml) in the presence or 
absence of human MSC (1 x 10
5
/ml) for 5 days in cRPMI supplemented with 0.1% 
v/v beta-mercaptoethanol.  After 5 days, human CD4
+
 T cell were repurified from 
cocultures using MagCellect CD4 isolation kit and allowed to rest for 24 h in 
cRPMI.  Following the rest period, a proliferation assay was performed.  Repurified 
human CD4
+
 T cells (1 x 10
6
/ml) were cocultured with irradiated BALB.c DC (1 x 
10
5
/ml) in a 96 well plate and restimulated with polyIC (20 µg/ml) in the presence or 
absence of recombinant human interleukin 2 (rhIL-2) (100 U/ml) for 72 h.  After 72 
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h, 100 µl of supernatant was carefully removed and stored at -20 °C for cytokine 
analysis.  
3
H]-Thymidine (Amersham Biosciences, Buckinghamshire, England) at 
0.5 µCi/ml was added for the final 6 h of culture and incubated at 37 °C 5 % CO2.  
Cultures were harvested using an automatic cell harvester as stated in section 2.6.1. 
2.11 HUMANISED MOUSE MODEL OF AGVHD 
2.11.1  ACUTE GRAFT VERSUS HOST DISEASE HUMANISED MOUSE MODEL 
A humanised  mouse model was developed and optimised from a protocol 
described by Pearson et al. (Pearson, 2008).  NOD.Cg-Prkdc
scid
IL2
tmlWjl
/Szj (NOD-
Scid IL-2rγnull) (NSG) were exposed to a conditioning dose of 2.4 Gray (Gy) of 
whole body gamma irradiation.  Freshly isolated human PBMC were administered 
by intravenous injection to the tail vein using a 27 gauge needle and a 1 ml syringe 
between 4 h but no longer than 24 h following irradiation.  Before infusion, PBMC 
were washed three times with sterile PBS.  PBMC in varying amounts ranging from 
2 x 10
5
 to 4 x 10
7
 cells per mouse were administered on day 0.  This allowed for the 
identification of the optimum amount of PBMC required for consistent acute graft 
versus host disease (aGvHD) development between 10 and 20 days.  The optimum 
dose for PBMC for aGvHD development was found to be 6.3 x 10
5
 g
-1
.  aGvHD 
development was determined by examining features including weight loss exceeding 
15 % total body weight, ruffled fur, hunched posture.  Animals were returned to their 
cages where they were monitored closely for the first hour and at regular intervals 
thereafter for any signs of distress or ill health.  Animals were weighed daily and 
weigh loss was documented accordingly.  Any animals which displayed greater than 
15 % total body weight loss were sacrificed humanely. 
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2.11.2 PATHOLOGICAL SCORING SYSTEM FOR ACUTE GRAFT VERSUS HOST 
DISEASE 
 The development of aGvHD was assessed using a series of pathological 
features.  Weight loss greater than 15 % total body weight were consider to have 
aGvHD and were sacrificed.  Other pathological features taken into consideration 
were; posture (hunching), activity, fur texture and diarrhoea.  Any animals scoring a 
cumulative score of 8 for the pathological features were considered to have aGvHD 
and were sacrificed humanely.  The scoring system used were; posture: 0; normal, no 
hunching; 0.5; slight hunching that straightens when walking; 1.0; animal stays 
hunched when walking; 1.5; animal does not straighten out; 2.0; animal tends to 
stand on rear toes.  Activity: 0; normal, very mobile and hard to catch; 0.5; slower 
than normal and little easier to catch; 1.0; no activity, but will move when touched; 
1.5; no activity, very little movement when touched; 2.0; no activity at all, not even 
when touched.  Fur: 0; normal, no fur pathology; 0.5; ridging on the side of belly and 
neck; 1.0; ridging across and side of belly and neck; 1.5; fur is matted and ruffled; 
2.0; badly matted on belly and top. Diarrhoea: 0; normal; 0.5 mild change in bowel 
movement; 1.0; moderate change in bowel movement; 1.5; severe change in bowel 
movement; 2.0; extensive diarrhoea.  
2.11.3  INTRAVENOUS TRANSFER OF HUMAN MSC AND PBMC  
 Before infusion, human PBMC or MSC were washed three times with sterile 
PBS.  PBMC were administered to mice at 6.3 x 10
5
 g
-1
 and MSC were administered 
at 4.4 x 10
4
 g
-1
.  PBMC or MSC were delivered to the tail vein using a 27 gauge 
needle and a 1 ml syringe.  Each mouse received a total of 0.2 ml.  PBMC were 
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given on day 0 while MSC were given on day 0, 7 or 14.  Following i.v injection, 
animals were returned to their cages where they were monitored as above. 
2.11.4  ISOLATION OF LUNG OR LIVER CELLS FROM HUMANISED MOUSE MODEL 
 Lungs or livers were removed aseptically from NOD-Scid IL-2rγnull and 
transferred to a 15 ml tube containing complete RPMI (cRPMI).  Using a sterile 
forceps, the organs were transferred to a Petri dish and sectioned using a sterile 
scalpel.  The small lung or liver pieces were then digested in 10 ml of collagenase 
from Clostridium histolyticum (300 U/ml) (Sigma-Aldrich) and DNase I (10 mg/ml) 
(Roche Diagnostics, Germany) digestion solution at 30°C under constant horizontal 
shaking at 300 rpm.  After 1 h of digestion, the homogenates were passed through a 
40 µm filter into a 50 ml tube using a sterile plunger and 10 ml of cRPMI.  The 
digested tissue samples were then centrifuged at 300 g for 5 min.  The supernatants 
were discarded and the pellets resuspended in 3 ml of lysis buffer and incubated at 
room temperature for 5 min.  After 5 min, the cells were centrifuged for 5 min at 300 
g and resuspended in PBS for FACS analsyis. 
2.11.5  DETECTION OF HUMAN CELLS IN VIVO BY FLOW CYTOMETRY 
PBMC at a concentration of 6.3 x 10
5
 g
-1
 were delivered to the tail vein of 
mice on day 0.  After 15 days, animals were sacrificed and splenocytes were 
harvested (section 2.3.5).  Splenocytes were analysed b y flow cytometry for 
expression of murine and human CD4, CD8 and CD45 or corresponding isotype 
controls.  Facs analyses was performed within 4 h of preparation using a 
FACSCalibur cytometer and CellQuest software (BD Biosciences). 
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2.11.6  CFSE STAINING OF CELLS 
 Freshly isolated human PBMC were washed twice in PBS and resuspended at 
5 x 10
7
/ml in warm PBS.  Carboxyfluorescein succinimidyl ester (CFSE) was 
prepared at 5 mM stock was by dissolving the supplied powder in 18 µl of DMSO 
(Invitrogen).  PBMC at 2 x 10
7
 were labelled with various concentrations of diluted 
CFSE, 2.5 µM, 5 µM or 10 µM.  Cells were incubated for 10 min at room 
temperature in the dark.  After 10 min, 2 ml of cold PBS was added and PBMC 
centrifuged at 600 g for 5 min then washed twice in PBS.  CFSE labelled PBMC 
were then used in further experiments. 
2.11.7  IN VITRO PROLIFERATION USING CFSE STAINED PBMC 
 Human PBMC were stained with various concentrations of CFSE as 
described in section 2.11.6.  CFSE labelled PBMC (4 x 10
6
/ml) were cultured in the 
presence or absence of recombinant human IL-2 (rhIL-2) at 100 U/ml (R & D 
Systems) and PHA at 5 µg/ml (Sigma-Aldrich) in a 6 well tissue culture plate pre-
coated with human anti-CD3 at 2.0 µg/ml (eBioscience).  To determine the effect of 
MSC on CFSE labelled PBMC proliferation, MSC were added to wells at 4 x 
10
5
/ml.  After 5 days, PBMC were harvested and the level of CFSE labelled cell 
proliferation was analysed by flow cytometry, with a minimum of 100,000 cells 
acquired.  A decrease in CFSE staining was indicative of PBMC proliferation.  
2.11.8  DETECTION OF CFSE LABELLED PBMC IN VIVO 
 PBMC were labelled with 10 µM CFSE as described in section 2.11.6.  
CFSE labelled PBMC were washed twice with PBS and administered at 6.3 x 10
5
 g
-1
 
to irradiated NOD-Scid IL2rγnull mice on day 0.  After 5 days and 12 days, the lung, 
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liver and spleen were harvested from each mouse.  Splenocytes were isolated 
following protocol described in section 2.3.5, with lung and liver cells isolated as 
described in section 2.11.4.  A single cell suspension of 1 x 10
6
 cells/ml were 
counterstained with anti-human CD4 APC for 15 min at 4 °C.  Cells were 
centrifuged at 300 g for 5 min and resuspended in 300 µl of cell fixative.  Cells were 
analysed for CFSE staining (FL-1) and the expression of human CD4 (FL-4) by flow 
cytometry with a minimum of 100,000 cells acquired. 
2.11.9  DETECTION OF APOPTOTIC CELLS IN VIVO 
 PBMC at a concentration of 6.3 x 10
5
g
-1
 were delivered via the tail vein of 
2.4 Gy irradiated NOD-Scid IL2rγnull mice on day 0.  “Licensed” MSC at 4.4 x 104 g-
1
 were administered i.v on day 0 or unlicensed MSC at 4.4 x 10
4
 g
-1 
were 
administered on day 7.  On day 12, 8 µg (100 µl) of FAM-FLIVO™ green dye (FL-
1) was injected per mouse and left to circulate for 1 h.  After 1 h, the lung and liver 
were harvested and cells were isolated as described in section 2.11.4.  Cells were 
counterstained with anti-human CD4 APC (FL-4) and analysed by flow cytometry 
with a minimum of 10,000 cells acquired.  To optimise the FLIVO dye, BALB/c 
mice were lethally irradiated with 12 Gy gamma irradiation.  After 24 h, 8 µg (100 
µl) of FAM-FLIVO™ green dye (FL-1) was injected per mouse and left to circulate 
for 1 h.  After 1 h, the lung and liver were harvested.  Cells were analysed for the 
expression of FLIVO™ green dye (FL-1). 
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2.12 HISTOLOGY 
2.12.1  TISSUE PREPARATION  
Livers, lungs and GI tract were removed from experimental mice and fixed in 
10% (v/v) formalin (Sigma-Aldrich).  Tissues were processed for histology using an 
automated processor (Shandon Pathcentre, Runcorn, UK), which immerses the 
tissues in fixatives and sequential dehydration solutions, including ethanol (70%, 
80%, 95% x 2, 100% x 3) and xylene (x 2) (BDH AnalaR® Laboratory Supplies 
Poole, UK).  Tissues samples were then embedded in paraffin wax using the 
Shandon Histocenter 2 (Shandon) and left to set overnight at 4 °C.  4µm sections 
were cut using a microtome (Shandon Finesse 325, Thermo-Shandon, Waltham, 
MA, USA).  Sections were placed in cold water containing ethanol followed by 
transfer to a hot water bath (42 °C) to smooth out any folding in the sections.  
Sections were placed on microscope slides (Thermo Scientific), air-dried overnight 
at RT before staining with H &E (Section 2.12.2) and blindly scored using the 
system detailed in section 2.12.3.   
2.12.2  HAEMATOXYLIN/EOSIN STAINING 
Prior to staining, 5 µm tissues section slides were incubated at 56 °C for a 
minimum of 1 h to aid clearance of wax.  Slide sections were immersed in two 
changes of xylene for 10 min each, following by re-hydration in three decreasing 
concentrations of ethanol (100% x 2, 95% (v/v) and 80%) for 5 min each.  Sections 
were then placed in two changes of water to rinse off excess xylene and immersed in 
Haematoxylin (Sigma-Aldrich) solution for 3 min.  Slides were washed in water for 
2 min and placed in 1 % acid alcohol for 20 seconds, followed by a further wash step 
in water.  Slides were then counterstained in Eosin Y (Sigma-Aldrich) for 3 min and 
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washed again in water (Table 2.3).  Finally, slides were put through a series of 
dehydration steps in ethanol (80%, 95% and 100%) for 5 min each.  Slides were then 
mounted with DPX mountant (BDH) and examined under a light microscope. 
2.12.3  HISTOLOGICAL SCORING 
 Following H & E staining, slides were coded without reference to prior 
treatment and examined in a blind fashion.  A semi-quantitative scoring system was 
used to assess abnormalities in the lung, liver and GI tract (Hill, 1997; Grass, 1999; 
Polchert, 2008).  The scoring was carried out as follows:  
Lung: 0; normal; 0.5; rare scattered areas of mononuclear cells; 1.0; minimal 
or focal areas of cellular infiltrate; 2.0; mild and more diffuse cellular infiltration; 
3.0; moderate amount of mononuclear cell infiltration; 4.0; extensive mononuclear 
cell infiltration.  Liver: 0; normal; 1.0; rare collections of mononuclear cells in the 
parenchyma; 2.0;  endothelialitis present in at least one vessel, with an increase in 
mononuclear cell infiltration; 3.0; endothelialitis present in more than one vessel, 
with a further increase in mononuclear cell infiltration; 4.0; endothelialitis present in 
virtually all vessels, with extensive mononuclear cell infiltration.  GI tract: 0; 
normal; 1.0; mild necrotic cells with minor cell infiltration; 2.0; diffuse, but mild 
villous blunting, necrotic cells and increase in cell infiltration; 3.0; diffuse, but 
moderate villous blunting, necrotic cells and further increase in cell infiltration; 4.0; 
diffuse but severe villous blunting, necrotic cells and extensive cell infiltration.   
2.13 STATISTICAL METHODS 
The students paired t test was used when statistical analysis was required 
between two experimental groups.  One way ANOVA was used to test for statistical 
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significance of differences when multiple experimental groups were compared.  
Kaplan Meier curves (log rank test) were used to compare survival between 
treatment groups.  Power analysis was carried out to determine the number of 
animals that would yield a significant difference in the in vivo studies.  Statistical 
methods (Power analysis (SISA)) were used to determine the minimum number of 
animals per treatment group to obtain a power in the study.  SISA software is online 
at http://home.clara.net/sisa/power.htm. 
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Table 2.1 Summary of media for cultured cells 
Medium Name Description Supplier  
Murine MSC 
isolation medium 
(CIM) 
RPMI 1640 
100 U/ml penicillin 
100 µg/ml streptomycin  
2 mM L-glutamine 
10 % (v/v) horse serum  
10 % (v/v) heat inactivated, low-endotoxin 
foetal calf serum (FCS) 
Invitrogen-Gibco  
Invitrogen-Gibco  
Invitrogen-Gibco 
Invitrogen-Gibco  
Hyclone 
Biosera 
Murine MSC 
expansion 
medium(cαMEM) 
 
 
10 % (v/v) heat inactivated low endotoxin 
FCS  
10 % (v/v) horse serum  
100 U/ml penicillin 
100 µg/ml streptomycin  
2 mM L-glutamine 
Invitrogen-Gibc 
Biosera 
 
Hyclone 
Invitrogen-Gibco  
Invitrogen-Gibco  
Invitrogen-Gibco 
Human and 
murine osteoblast 
differentiation 
medium  
 
Dulbecco’s Modified Eagle’s Media 
(DMEM) containing 100 mg/ml glucose 
(human) or Minimum Essential Medium 
alpha (MEM) (murine) 
1 mM dexamethasone,                        
20 mM β-glycerolphosphate,  
50 µM L-ascorbic acid-2-phosphate,  
50 ng/ml L-thyroxine sodium pentahydrate 
Invitrogen-Gibco 
 
 
 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
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Table 2.1 Summary of media for cultured cells continued 
Medium Name Description Supplier 
Chondrogenic 
medium 
 
Dulbecco’s Modified Eagle’s 
Media (DMEM) containing 100 
mg/ml glucose 
100 nM dexamethasone 
50 μg/ml ascorbic-acid-2-
phosphate 
40 μg/ml proline 
1 mM sodium pyruvate 
1 % v/v ITS + supplement 
10 ng/ml TGF-β3 
Invitrogen-Gibco- 
 
 
Sigma-Aldrich 
Sigma-Aldrich 
 
Sigma-Aldrich 
Sigma-Aldrich 
BD Biosciences 
TS:beta 
Human and murine 
adipocyte 
differentiation 
medium 
 
Dulbecco’s Modified Eagle’s 
Media (DMEM) containing 100 
mg/ml glucose (human) or 
Minimum Essential Medium 
alpha (MEM ) 
5.0 µg/ml insulin in 0.1N acetic 
acid 
50 µM indomethacin 
1 µM dexamethasone 
0.5 µM IBM x in MeOH 
Invitrogen-Gibco 
 
 
 
 
Sigma-Aldrich 
 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
Serum free medium RPMI 1640 
100 U/ml penicillin 
100 µg/ml streptomycin 
1 % v/v ITS + supplement 
Invitrogen-Gibco 
Invitrogen-Gibco 
Invitrogen-Gibco 
BD Biosciences 
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Table 2.1 Summary of media for cultured cells continued 
Media Culture media Supplier 
Murine Dendritic 
Cell Medium 
RPMI 1640 
100 U/ml penicillin 
100µg/ml streptomycin  
2mM L-glutamine 
10% (v/v) heat inactivated low-endotoxin 
FCS 
20 ng/ml recombinant murine GM-CSF 
Invitrogen-Gibco 
Invitrogen-Gibco  
Invitrogen-Gibco  
Invitrogen-Gibco  
Biosera 
 
PeproTech 
Murine/Human 
CD4
+
 T Cell or 
Murine  
Splenocyte 
Medium (cRPMI) 
RPMI 1640 
100 U/ml penicillin 
100 µg/ml streptomycin  
2mM L-glutamine 
10% (v/v) heat inactivated low-endotoxin 
FCS 
0.01% (v/v) beta mercaptoethanol 
Invitrogen-Gibco 
Invitrogen-Gibco 
Invitrogen-Gibco 
Invitrogen-Gibco 
Biosera 
 
Invitrogen-Gibco 
Human MSC 
culture Medium 
(cDMEM) 
Dulbecco’s Modified Eagle’s Media 
(DMEM) containing 100 mg/ml glucose 
10% (v/v) FCS 
200 U/ml penicillin 
g/ml streptomycin 
Invitrogen-Gibco 
 
PAA 
Invitrogen-Gibco 
Invitrogen-Gibco 
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Table 2.2 Reagents used to detect human and murine MSC Differentiation. 
Reagent Components Concentration Supplier 
MSC 
Osteoblast 
Differentiation 
 
Alizarin Red S stain  
dH2O 
pH adjusted to between 
4.1-4.3 using 0.1% v/v 
ammonium hydroxide 
 
1 % (w/v) 
100 ml 
Sigma-Aldrich 
 
 
 
Sigma-Aldrich 
 
MSC Adipocyte 
Differentiation 
 
Oil Red O  
Isopropanol  
Working solution: 
0.5% w/v Oil Red O 
stock  
PBS 
0.5 % (w/v) 
30 ml  
 
 
 
20 ml 
Sigma-Aldrich 
Sigma-Aldrich 
 
 
 
Sigma-Aldrich 
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Table 2.3 Histological staining solutions  
Reagent Components Concentration Supplier 
Harris 
Hematoxylin 
Eosin 
 
 
Acid alcohol 
Hematoxylin 
 
Eosin Y 
Potassium dichromate 
dH2O 
Hydrochloric acid 
2-propanol 
dH20 
Neat 
 
1 % (w/v) 
1.6 % (w/v) 
100 ml 
1 % (v/v) 
69.3 % (v/v) 
29.7 % (v/v) 
Sigma-Aldrich 
 
Sigma-Aldrich 
Sigma-Aldich 
 
WVR 
WVR 
 
Table 2.4 Antibodies directed against murine markers 
Antibody Conjugate Concentration Clone Source 
CD3e FITC 5 µg/ml 145.2C11 eBioscience 
CD4 FITC 5 µg/ml GK1.5 eBioscience 
CD8 FITC 5 µg/ml 53-6.7 eBioscience 
CD11b Biotin 5 µg/ml M1/70 eBioscience 
CD34 Biotin 5 µg/ml RAM34 eBioscience 
CD40 PE 2 µg/ml 1C10 eBioscience 
CD44 Biotin 2 µg/ml IM7 eBioscience 
CD45 Biotin 5 µg/ml 30-F11 eBioscience 
CD80 PE 2 µg/ml 16.10A1 eBioscience 
CD86 PE 5 µg/ml GL1 eBioscience 
CD90 FITC 5 µg/ml LT84EC eBioscience 
CD105 Biotin 5 µg/ml MJ7/18 eBioscience 
CD106 FITC 5 µg/ml 429 eBioscience 
CD117 FITC 5 µg/ml 2B8 eBioscience 
MHC class I FITC 5 µg/ml 28-14-8 eBioscience 
MHC class II PE 1 µg/ml NIMR-4 eBioscience 
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Sca-1 PE 5 µg/ml D7 eBioscience 
YA-e Biotin 5 µg/ml EBioY-Ae eBioscience 
 
Table 2.5 Antibodies directed against human markers 
Antibody Conjugate Concentration Clone Source 
CD3 FITC 5 µg/ml HIT3a eBioscience 
CD4 APC/PE/PerCp 5 µg/ml SK3/OKT4 eBioscience 
CD8 FITC 2.5 µg/ml RPA-T8 eBioscience 
CD25 PE 1.25 µg/ml BC96 eBioscience 
CD29 FITC 2.5 µg/ml TS2/16 eBioscience 
CD34 FITC 5 µg/ml 4H11 eBioscience 
CD40 PE 5 µg/ml 5C3 eBioscience 
CD44 FITC 5 µg/ml IM7 eBioscience 
CD45 FITC 5 µg/ml H30 eBioscience 
CD54 FITC 5 µg/ml HA58 eBioscience 
CD80 PE 5 µg/ml 2D10.4 eBioscience 
CD86 PE 5 µg/ml IT2.2 eBioscience 
CD90 FITC 5 µg/ml eBio5E10 eBioscience 
CD105 FITC 5 µg/ml SN6 eBioscience 
CD106 PE 5 µg/ml STA eBioscience 
CD117 PE 2.5 µg/ml YB5.B8 eBioscience 
CD154 FITC 2.5 µg/ml 24.31 eBioscience 
HLA-ABC FITC 10 µg/ml W6/32 eBioscience 
HLA-DR PE 0.075 µg/ml L243 eBioscience 
FoxP3 FITC 5 µg/ml PCH101 eBioscience 
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 Table 2.6 Neutralisation Antibodies and Antagonists 
Antibody/Antagonist Concentration Supplier 
anti-human TGFβ1 
Indomethacin 
4 µg/ml 
40 µM 
eBioscience 
Sigma-Aldrich 
 
Table 2.7 Summary of primer sequences: Human 
GAPDH 
 
Collagen II 
 
Aggrecan 
GGTGAAGGT
CGGAGTCAA
CG 
 
GCCCAAGAG
GTGCCCCTGG
AATA 
TGAGGAGGG
CTGGAACAA
GTACC 
AAAGTTGTCA
TGGATGACC 
 
CCTGAGAAAG
AGGAGTGGAC
ATA 
GGAGGTGGTA
ATTGCAGGGA
AC 
540 
 
 
703 
 
350 
55 
 
 
57 
 
55 
2.5  
 
 
2.5 
 
2.5 
TGF-β1 CAGATCCTGT
CCAAGCTG 
TCGGAGCTCT
GATGTGTT 
270 54 2.5 
FoxP3 AGGTGGCAG
GATGGTTTCT 
AACAGCACAT
TCCCAGAGTT
C 
223 57 2.5  
 
Primer Forward 5’-3’ Reverse 3’-5’ Product 
size (bp) 
Anneal 
temp 
(°C) 
MgCl2 
Conc 
(mM)
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Table 2.8 Summary of primer sequences: Murine 
Primer Forward 5’-3’ Reverse 3’-5’ Product 
size (bp) 
Anneal 
temp 
(°C) 
MgCl2 
Conc 
(mM)
 
IL-10 AGGTGCGTTCCT
C 
AAAGCCAACC
AA 
241 55 2.5  
IL-4 TCAACCCCCAGC
TAGTTGTC 
CCTTCTCCTGT
GACCTCGTT 
124 57 2.5 
E-cadherin GGCTGGACCGA
GAGAGTT 
CTGCTTGGCCT
CAAAATC 
350 58 1.5  
GAPDH GGTGAAGGTCG
GAGTCAACG 
AAAGTTGTCA
TGGATGACC 
540 55 2.5  
CCR7 AGTCTTCCAGCT
GCCCTACA 
CAGCCCAAGT
CCTTGAAGAG 
219 55 2.5  
Notch-1 GTCGCTGGATAC
AAGTGCAA 
TGTGGGACAG
ACACAGGAAA 
150 55 2.5  
Notch-2 CGTGTGAGAAT
GCTGCTGTT 
TTGTGGCAGA
CACCATTGTT 
148 60 2.5  
Jagged-1 AGTCTTCCCCTT
GTGCCTTT 
CACTTGGCCC
CATCAAGTAT 
154 55 2.5  
Jagged-2 AGGCACCTACT
GCCATGAAA 
CGTTGGGATT
GATGTCACAG 
143 55 2.5  
Delta like 
ligand-1 
CAACAAGAAGG
CGGACTTTC 
CACTTGGTGTC
ACGTTTGCT 
150 57 2.5 
 
Hes-1 GCCTTGGCTCAC
TCCGCGTT 
TCTGCCACCCC
TAGTCCCGC 
304 60 2.5  
ICOS AATGGGCAAAC
ATTCTCCTG 
AGTGCTAGGG
CTGACTTCCA 
285 58 2.5  
LICOS GGACTCCATGA
AGCAGGGTA 
TCAGAGGTGC
TGATGACAGG 
180 60 2.5  
PD-1 TGGGCAGCTGT
ATGATCTGC 
TTCACCTGCA
GCTTGTCCAA 
149 55 2.5 
PDL-1 AAAGTCAATGC
CCCATACCG 
TTCTCTTCCCA
CTCACGGGT 
151 55 2.5 
CTLA-4 CAGGTGACCCA
ACCTTCAGT 
CAGTCCTTGG
ATGGTGAGGT 
243 58 2.5  
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Siglec E CCCAGTTCATGG
ATTCTGGT 
TTCAGGGAGC
AGTCATTCCT 
150 62 2.5  
Siglec F TGCCTCTGCCTC
ATCTTTTT 
CAACGCATTG
TTGGATGAAG 
144 58 2.5  
Siglec G CGGATGGAGAG
AGGATTTGA 
AAGGTCCAGG
AAAACAAGCA 
149 60 2.5  
Siglec H 
 
Aggrecan 
GGTTCCATGAA
GGGGAAAAT 
GTTGGTTACTTC
GCCTCCAG 
AACCGTTGTC
ACCCTTTTGT 
GTCCTCCAAG
CTCTGTGACC 
150 
 
103 
55 
 
55 
2.5 
 
2.5  
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CHAPTER 3 
HUMAN MSC SUPPRESS INNATE AND ADAPTIVE IMMUNITY 
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3.1  INTRODUCTION 
MSC display potent immunosuppressive qualities (Barry, 2003; Pittenger, 
1999), which makes MSC a promising tool for cellular immunotherapy (Heng, 
2009).  Unlike other stem cells types, MSC do not aggressively activate innate or 
adaptive immune responses, allowing for their acceptance into an allogeneic host 
without rejection.  At the commencement of this work, MSC modulation of innate 
responses was known to include the inhibition of dendritic cell (DC) maturation 
(English, 2008), and the prevention of natural killer (NK) cell activation (Spaggiari, 
2006).    MSC had been described as  being involved in the modulation of adaptive 
immune cells, including the skewing of T cell phenotypes (Ryan, 2007) and the 
inhibition of B cell proliferation (Corcione, 2006).  More recently, the inhibition of 
complement activation through factor H has been described (Tu, 2010). 
Modulation of allogeneic responses by MSC involves multiple factors; cell: 
cell contact and the release of soluble factors play non-redundant roles in MSC 
immunomodulation (Djouad, 2003; Krampera, 2003).  For example, IL-6 along with 
a contact dependent signal are required for MSC modulation of DC maturation 
(Djouad, 2007; English, 2008).  MSC derived transforming growth factor beta (TGF-
β), prostaglandin E2 (PGE2) (English, 2007; Ryan, 2007), suppress T cell 
proliferation in conjunction with a cell contact signal.  In this chapter, the goals 
were: 
 (1) to define the phenotype of human MSC (hMSC) used in this study by 
evaluating surface marker expression, differentiation capacity and 
immunosuppressive ability in vitro.   (2) To analyse the influence of innate immune 
mechanisms, in particular complement activation, on the survival of hMSC in vitro.   
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(3) To investigate the mechanism(s) involved in hMSC suppression of 
adaptive immunity 
(4) To investigate the role of hMSC-derived soluble factors on T reg cell 
induction in vitro. 
  (5) To examine the functional capacity of hMSC-derived T reg cells to 
suppress immune responses in vitro. 
 
3.2  CHARACTERISATION OF ADULT HUMAN MSC BY FLOW CYTOMETRY 
There are no specific surface markers that uniquely identify hMSC, therefore 
a range of markers were used to validate the hMSC isolation techniques employed.  
The ISCT have proposed specific criteria for the characterisation of multipotent 
MSC (Horwitz, 2005; Dominici, 2006).  For this study, human bone marrow derived 
MSC were isolated and expanded from an aspirate of bone marrow taken from the 
iliac crest of donor patients from a collaborating laboratory in NUI Galway (as 
described by Barry & Murphy, 2004).    
Candidate populations of hMSC, received from NUIG at passage 1, were 
grown in DMEM medium for up to eight passages.  hMSC cultured at passage 1 
were adherent to plastic of tissue culture flasks and were spindle shaped/fibroblast-
like in morphology (Fig 3.1).  However, morphology is a subjective criterion and 
therefore the expression of specific surface markers (eg, stem cell antigen-1 (Sca-1) 
and CD44) and the lack of expression of other surface markers (CD45 and CD11b) 
are typically used for the identification of MSC (Peister, 2004).  hMSC isolated in 
this chapter were characterised by flow cytometry.  hMSC batches displayed 
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consistent expression of specific surface marker proteins typical of adult hMSC; 
HLA-ABC, Thy 1.1 (CD90), CD106, CD29, CD44, CD54 and CD105 (Fig 3.2).  
hMSC did not express HLA-DR, CD45, CD11b, the haematopoietic cell markers 
CD34, CD117 or the costimulatory markers CD40 or CD86 (Fig 3.2).  The stability 
of typical hMSC marker expression was examined from passages 3-8 (Fig. 3.2).  The 
hMSC batches used here had no evidence of haematopoietic stem cell contamination, 
which provided some confidence, that a pure population of hMSC was present.  
 
 
 
 
Fig 3.1 Adult Human Bone Marrow-Derived Mesenchymal Stem cells (hMSC) 
have a morphology similar to fibroblasts.  hMSC were isolated and cultured in 
DMEM media until 80-90% confluent.  The appearance of spindle shaped cells was 
characteristic of a homogenous population of hMSC.  This population is 
representative of hMSC at passage 5, however, each passage from 3-8 was found to 
have similar morphology. Magnification × 100, phase contrast light microscopy. 
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Fig 3.2 Characterisation of surface marker protein expression by human MSC.  
MSC were characterised for the expression of specific surface protein by flow 
cytometry.  MSC typically expressed HLA-ABC, CD90, CD105, CD106 and CD44.  
MSC did not express HLA-DR, haematopoietic markers CD34, CD117 or 
costimulatory markers CD40 and CD86.  Isotype controls are represented by purple 
filled plots while cell specific markers by open green plots.  Data are representative 
of hMSC marker expression at passage 5, however, it was examined at each passage 
from 3-8.  
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3.3  DIFFERENTIATION CAPACITY OF MSC 
The “stemness” of hMSC was determined through their capacity to 
differentiate into a number of mesodermal cell lineages.  hMSC isolated as described 
above were cultured in specific differentiation media (Table 2.2) to stimulate the 
differentiation of hMSC into adipocytes, osteocytes or chondrocytes.  Adipocytes 
were visualised by staining with Oil Red O, which stains lipid vacuoles red (Fig 3.3 
A).  Osteoblasts were stained using Alizarin Red S, which when combined with 
calcium ions, forms a red product (Fig 3.3 B).  Chondrocyte differentiation was 
determined through the expression of collagen II and aggrecan by semi-quantitative 
RT-PCR (Fig 3.3 C).  Control cells (hMSC not cultured in differentiation media) 
were stained with the corresponding dyes or analysed for equivalent mRNA 
expression (Fig 3.3).  hMSC used in this study differentiated along each pathway and 
maintained their multilineage potential through each subsequent generation for 
batches of hMSC used in this study from passage 3 to 8 (Fig. 3.3).   
 
3.4  ALLOGENEIC MSC SUPPRESS PROLIFERATION IN A MIXED LYMPHOCYTE 
REACTION (MLR) 
The ability of MSC to modulate immune responses was previously examined 
and confirmed by others (Ryan, 2007, English, 2008; DiNicola, 2002).  However, it 
was important to confirm this characteristic on the hMSC used here, prior to their 
use in further in vitro studies.  The immunosuppressive capacity of hMSC was 
investigated in two ways.  Firstly, the ability of hMSC to modulate a mitogen driven 
lymphocyte proliferation was studied.  This involved human PBMC from a single 
donor that were stimulated with Concanavalin A (ConA) in the presence or absence 
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of allogeneic hMSC.  The level of proliferation was measured using 
3
H thymidine 
incorporation.  hMSC significantly inhibited the mitogen driven proliferation of 
PBMC in vitro (p<0.0001) (Fig 3.4 A).   
Secondly, the ability of hMSC to suppress alloreactivity was examined using 
a two-way mixed lymphocyte reaction (MLR).  PBMC from two MHC-mismatched 
donors were cocultured in the presence or absence of hMSC allogeneic to both 
PBMC populations.  In the presence of hMSC, PBMC proliferation was significantly 
reduced (p<0.05), when compared to the coculture of allogeneic PBMC without 
hMSC (Fig 3.4 B).  These data indicated that the hMSC populations (passage 3 to 8) 
used here were capable of suppressing both mitogen driven and alloantigen driven 
proliferation and the batches selected were characteristic of those used previously by 
others.    
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Control human MSC  
 
 
 
 
Fig 3.3 Differentiation capacity of hMSC.  hMSC were cultured in specific 
differentiation media for 21 days for the characterisation of (A) adipocytes, (B) 
osteocytes and (C) chondrocytes.  (A) hMSC were differentiated into adipocytes and 
stained using oil red O.  (B) hMSC were differentiated into osteocytes and visualised 
by alizarin red S staining.  Magnification × 100 using Phase contrast light 
microscopy.  (C) hMSC were differentiated (+TGFβ3)  into chondrocytes and 
compared to controls (-TGFβ3) for the expression of aggrecan and collagen II by 
semi-quantitative RT-PCR.  Data are representative of hMSC differentiation capacity 
from passage 5.  Similar data were obtained from hMSC between passages 3 to 8.  
C              
 
  
350bp 703bp 
95 
 
 
Fig 3.4 Allogeneic MSC inhibit mitogen and alloantigen driven proliferation. 
hMSC were examined for their capacity to inhibit (A) mitogen driven (ConA) and 
(B) alloantigen driven proliferation of PBMC.  (A) hMSC (1 x 10
5
/ml) were 
cocultured with MHC mismatched donor PBMC (1 x 10
6
/ml). (B) hMSC were 
cocultured with two MHC mismatched donor PBMC in a two way mixed 
lymphocyte reaction.  Proliferation was assessed by 
3
H Thymidine incorporation.  
hMSC significantly inhibited both (A) mitogen driven proliferation (p<0.0001) and 
(B) alloantigen driven proliferation (p<0.05).  Results are representative of three 
independent experiments performed in triplicate.  Statistical analysis was carried out 
using the student paired t test.  Similar data were obtained for hMSC from passage 3 
to 8.  
A 
B 
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3.5  MURINE COMPLEMENT DID NOT AFFECT THE SURVIVAL OF HUMAN MSC 
IN VITRO 
 For use in cell therapy, hMSC must possess potent immunosuppressive 
abilities that span both the innate and adaptive immune system.  The complement 
system is a vital component of innate immunity that plays a role in hyperacute and 
acute transplant rejection (Baldwin, 1995).  As later work would require use of 
hMSC in murine models, it was necessary to determine whether suppression 
extended to the action of complement.  In this study, the effect of human and murine 
complement on the survival of hMSC in vitro was investigated.  The induction of 
hMSC apoptosis after exposure to complement was examined by flow cytometry 
using a well-optimised apoptosis kit (BDBioscience). 
   Human lung epithelial cells, (A549, control cells), murine splenocytes 
(control cells) or hMSC were cultured in the presence or absence of murine (mC’) or 
human complement (hC’) for 4 h. The complement concentration (1/16 batch 
dilution) was arrived at after a series of optimisation experiments.  After 4 h, the 
induction of apoptosis was analysed by flow cytometry through annexin V (FL-1) 
and propidium iodide (PI) staining (FL-2) (Table 3.1) (Fig 3.5).  As expected, 
murine complement induced the apoptosis of human A549 cells in vitro (11% cells), 
while human complement had no effect (4% cells) (Fig 3.5 A).  Unsurprisingly, 
human complement induced the apoptosis of murine splenocytes (69% cells), with 
murine complement having no effect on the survival of murine splenocytes (3% 
cells) after 4 h (Fig 3.5 B) (Table 3.1).   
 After identifying that human complement induced destruction of murine cells 
and murine complement lysed human cells in vitro (Fig 3.5 A & B), hMSC were 
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cultured in the presence of human or murine complement for 4 h.  Murine (0.6% 
cells) or human (0.6% cells) complement had no effect on hMSC survival in vitro 
(Fig 3.5 C) (Table 3.1).  These data suggested that hMSC are resistant to the lytic 
effects of the alternative complement pathway and indicated another mechanism by 
which MSC suppress innate immune responses.  These data were important to note 
for future animal and clinical studies as it suggested that the use of xenogeneic or 
humanised mouse models would be viable for studying MSC as a cell therapy 
(Chapter 6).  
 
TABLE 3.1 HUMAN MSC ARE NOT SUSCEPTIBLE TO MURINE OR HUMAN 
COMPLEMENT KILLING   
 
 % Cells lysed (MFI) 
Target Cell Type No Complement Human 
Complement 
Murine 
Complement 
 
Human A549 
Murine Splenocytes 
Human MSC 
 
6.3 (490) 
7.0 (1416) 
0.6 (119) 
 
4.0 (391) 
69.0 (2633) 
0.6 (111) 
 
11.0 (384) 
3.0 (1244) 
0.6 (128) 
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Fig 3.5 Murine complement did not kill human MSC in vitro. (A) Human A549 
(3 x 10
5
/well), (B) murine splenocytes (1 x10
6
/well) or (C) hMSC (3 x 10
5
/well) 
were exposed to human (hC’) or murine complement (mC’) (1/ 16 dilution) for 4 h.  
After 4 h, cells were harvested and analysed for cell apoptosis using annexin V (FL-
1) and PI (FL-2) staining by flow cytometry.  (A) Murine complement induced cell 
apoptosis of human A549 cells.   (B) Human complement induced cell apoptosis of 
murine splenocytes.  (C) hMSC survival was not affected by the presence of human 
or murine complement.  Data are representative of three studies. 
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3.6  ALLOGENEIC HMSC INDUCE T CELLS WITH A REGULATORY PHENOTYPE  
The study above showed that hMSC suppressed innate immunity; however, 
the remaining focus of this chapter concerns adaptive immunity and the effect of 
MSC on lymphocytes.  MSC modulate many aspects of adaptive immunity (Chapter 
1.7.2).  There are multiple cell types in a population of PBMC used in an MLR, 
therefore it is difficult to determine which of the multiple suppressive effector 
functions hMSC are modulating in this system.  In this chapter, the ability of 
allogeneic hMSC induction of T cells with a regulatory phenotype from a purified 
population of human CD4
+
 T cells was investigated.  The expression of the T cell 
regulatory transcription factor, forkhead box P3 (FoxP3) and CD25 were examined 
as typical markers of T reg-like populations. 
Human CD4
+
 T cells purified by magnetic bead separation, as described in 
section 2.3.7, were cultured in the presence or absence of hMSC for 24 h and the 
expression of FoxP3 examined by qRT-PCR (Fig 3.6 A & B).  hMSC induced 
significantly more CD4
+
 T cells that expressed FoxP3 (p<0.02) when compared to 
CD4
+
 cells that did not encounter hMSC (Fig 3.6 B).  The expression of FoxP3 and 
CD25, at the protein level was examined.  Purified human CD4
+
 T cells were 
cultured in the presence or absence of hMSC for 72 h.  After 72 h, CD4
+
 T cells were 
pulled back from coculture by gentle aspiration from adherent hMSC and examined 
for the expression of FoxP3 and CD25 by intracellular flow cytometry.  Fewer CD4
+
 
T cells expressed FoxP3 (7.93% cells) (Fig 3.7 A) and CD25 (0.4% cells) (Fig 3.7 B) 
when cultured in the absence of hMSC.  In contrast, there was a consistent increase 
in the FoxP3
+
 CD25
+
 CD4
+
 T cells after coculture with hMSC (9.27% FoxP3 and 
1.3% CD25) (Fig 3.7 A & B).  These data indicated that hMSC induce a 
CD4
+
CD25
+
FoxP3
+
 T population typical of T reg cells.   
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Fig 3.6 hMSC induced increased expression of FoxP3 in purified CD4
+
 T cells.  
CD4
+
 T cells (3 x 10
5
/well) were cultured in the presence or absence of hMSC (1 x 
10
5
/well) in a 24 well plate for 24 h.  After 24 h, purified CD4
+
 T cells were pulled 
by from culture by gentle aspiration and examined for the expression of a house 
keeper, glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) and FoxP3 by (A) 
semi quantitative RT-PCR and (B) Quantitative real time PCR for FoxP3 mRNA. 
(B) CD4
+
 T cells expressed low levels of FoxP3 in the absence of hMSC but the 
level of FoxP3 was significantly increased when CD4
+
 T cells were cocultured with 
hMSC (p<0.02).  Results are representative of three independent experiments with 
qRT-PCR expressed as mean fg/500ng cDNA ± SE each performed in duplicate.  
Statistical analysis was carried out using the student paired t test. 
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Fig 3.7  hMSC induced a T cell population expressing FoxP3 and CD25.  CD4
+
 
T cells (1 x 10
6
/well) were cultured in the presence or absence of hMSC (3 x 
10
5
/well) in a 6 well plate for 72 h.  The expression of FoxP3 and CD25 was 
examined by intracellular flow cytometry.  (A) CD4
+
 T cells alone expressed low 
levels of both FoxP3 and CD25.  (B) Upon coculture with hMSC, both FoxP3 and 
CD25 expression were up regulated on CD4
+
 T cells.   The percentages of double 
positive cells are in the upper right quadrant (%), with the mean fluorescent intensity 
(MFI).  Data are representative of three independent experiments.  (The 
collaboration with Dr. Jennifer Ryan and Dr. Karen English in this experiment is 
gratefully acknowledged). 
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102 
 
3.7 ALLOGENEIC MSC INDUCTION OF FOXP3 AND CD25 EXPRESSION BY 
HUMAN CD4
+
 T CELLS IS IN PART CONTACT DEPENDENT 
Conflicting evidence exists whether cell contact contributes to the 
immunomodulatory function of MSC (Di Nicole, 2002, Djouad, 2003; Krampera, 
2003).  To investigate the role of cell contact in hMSC immune modulation, 
transwell experiments were carried out.  hMSC were cultured in direct cell contact 
with CD4
+
 T cells.  Alternatively, contact was blocked through a transwell system, 
where hMSC were adherent to the bottom of a 24 well tissue culture plate and CD4
+
 
T cells were separated by a 0.4µm membrane transwell insert (contact prohibited).  
After 24 h of culture, CD4
+
 T cells were pulled back from culture by gentle 
aspiration and examined for the expression of FoxP3 by qRT-PCR (Fig 3.8).   When 
hMSC were separated from CD4
+
 T cells in the transwell system, the induction of 
FoxP3 was significantly decreased among CD4
+
 T cell population, when compared 
to CD4
+
 T cells that had direct contact with hMSC (Fig 3.8).  This suggested that cell 
contact between CD4
+
 T cells and hMSC was involved in FoxP3 induction.    
FoxP3 and CD25 protein levels were analysed by combined 
intra/extracellular flow cytometry.  hMSC and CD4
+
 T cells were cocultured with 
cell contact permitted and cell contact prohibited (transwell) for 72 h .  Expression of 
FoxP3 and CD25 was investigated using flow cytometry.  In the transwell system, 
allogeneic hMSC did not induce FoxP3
+
 CD25
+
 expression in purified CD4
+
 T cells 
(2.86% FoxP3 and 0.19% CD25), when compared to cultures where contact was 
permitted (8.54% FoxP3 and 1.3% CD25) (Fig 3.9).  This reiterated the finding by 
qRT-PCR, suggesting that direct cell contact was required for the induction of FoxP3 
expression.   
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Next, the requirement for cell contact in a multi-cell system was examined.  
Unseparated allogeneic whole PBMC were cultured in the presence or absence of 
hMSC in a transwell system similar to above (contact permitted or prohibited).  
After 72 h, PBMC were recovered by gentle aspiration and the expression of FoxP3 
and CD25 were analysed by flow cytometry.  The expression of FoxP3 and CD25 by 
PBMC was increased when cell contact between PBMC and hMSC was permitted 
(1.46% FoxP3 and 1.68% CD25) (direct contact) or prohibited (1.33% FoxP3 and 
2.33% CD25) (transwell) (Fig 3.10).  This indicated that in the presence of other 
immune cells, cell contact was not required for allogeneic hMSC to induce a FoxP3
+
 
CD25
+ 
regulatory-like T cells.  These data give some explanation into the 
contradictory data described by others.  It also suggests that other cells can 
supplement the contact signal derived from hMSC in vitro. 
 
3.8 ALLOGENEIC MSC INDUCE THE SECRETION OF IMMUNOSUPPRESSIVE 
CYTOKINES BY CD4
+
 T CELLS  
The pattern of cytokine secretion contributes to the characterisation of a T reg 
cell population.  One of the key cytokines secreted by T reg cells is transforming 
growth factor beta-1 (TGFβ1).  Therefore, the expression of TGFβ1 was examined 
on CD4
+
 T cells following their coculture with hMSC.  Purified CD4
+
 T cells and 
hMSC were cocultured for 24 h in vitro.  The expression of TGFβ1 on CD4+ T cells 
cultured in the presence or absence of hMSC was examined by qRT-PCR.  TGF-β1 
mRNA expression was significantly higher in CD4
+
 T cells which were previously 
cultured with hMSC (Fig 3.11 A & B).  This was confirmed at a protein level, 
purified CD4
+
 T cells and hMSC were cocultured for 48 h and the production of 
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TGFβ1 by CD4+ T cells was examined by bead array analysis.  The secretion of 
TGFβ1 by CD4+ T cells following their coculture with hMSC was significantly 
higher than that of CD4
+
 T cells alone (Fig 3.11 C).  These data demonstrated that 
hMSC were capable of induced CD4
+
 T cells that secreted immunosuppressive 
cytokines, typical of a regulatory population.   
 
3.9  SOLUBLE FACTORS PLAY NON REDUNDANT ROLES IN MSC INDUCTION OF 
HUMAN CD4
+
 CD25
+
 FOXP3
+
 T REG-LIKE CELLS 
Modulation of allogeneic responses by MSC requires multiple factors.  Cell-
cell contact and the release of soluble factors play non-redundant roles in MSC 
immunomodulation, as demonstrated in Fig 3.8, 3.9 and 3.10.  Previous studies have 
shown that Prostaglandin E2 (PGE2) and TGFβ1 production contribute to the 
induction of FoxP3 T reg cells (Baratelli, 2005; Fu, 2004).   Ryan et al. have shown 
that PGE2 secreted by MSC was required for modulation of alloantigen driven 
proliferation in an MLR, while TGFβ1 was up regulated in MSC licensed by IFN-γ 
(Ryan, 2007). 
The influence of prostaglandins and TGFβ1 on hMSC immunomodulation 
was examined.  The production of prostaglandins was ablated using the 
cyclooxygenase antagonist indomethacin , while TGFβ1 production was neutralised 
through the addition of a human anti-TGFβ1 antibody.  FoxP3 mRNA expression by 
CD4
+
 T cells cocultured with hMSC in the presence or absence of neutralising 
antibody or chemical antagonist was examined by qRT-PCR (Fig 3.12 A), while 
both FoxP3 and CD25 expression was analysed by intra/extracellular flow cytometry 
(Fig 3.12 B).  The presence of indomethacin or anti-TGFβ alone in cocultures 
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resulted in the decreased expression of FoxP3 mRNA on CD4
+
 T cells (Fig 3.12 A).  
While a combination of indomethacin and anti-TGFβ1 led to a further reduction of 
FoxP3 mRNA expression on CD4
+
 T cells to near background levels (Fig 3.12 A).   
Similar to the data seen in figure 3.7, hMSC increased the expression of both 
FoxP3 (6.66%) and CD25 (2.8%) on CD4
+ 
T cells when analysed by flow cytometry.  
However, following the neutralisation of TGFβ1 or antagonism of prostaglandin 
production, the expression of FoxP3 (6.07%) and CD25 (0.89%) was decreased on 
CD4
+
 T cells after coculture with hMSC (Fig 3.12 B).  These data indicated that both 
prostaglandins and TGFβ1 play non-redundant roles in hMSC induction of CD4+ 
CD25
+
 FoxP3
+
 T reg-like cells.  In effect, both cell contact and the subsequent 
release of soluble factors are required for MSC immunomodulation.  The transwell 
system demonstrated that cell contact was required in the absence of other immune 
cells, with soluble factors alone insufficient for the induction CD4
+
 CD25
+
 FoxP3
+
 T 
reg-like population.  The neutralisation or antagonism experiments, where cell 
contact was permitted demonstrated that both prostaglandins and TGFβ1 are the 
soluble effector molecules involved in hMSC induction of CD4
+
 CD25
+
 FoxP3
+
 T 
reg-like cells. 
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Fig 3.8 Direct cell contact is required for the induction FoxP3 in purified CD4
+
 
T cells.  Purified CD4
+
 T cell (3 x 10
5
/well) were cultured in the presence or absence 
of hMSC (1 x 10
5
/well) in a 24 well plate for 24 h.  Cell contact was prohibited using 
a transwell system.  The expression of FoxP3 was determined by qRT-PCR.  The 
induction of FoxP3 was significantly less on purified CD4
+ 
T cells when direct cell 
contact with hMSC was prohibited (transwell) (p<0.05).  This indicated that direct 
cell contact was required for FoxP3 induction on CD4
+
 T cells by hMSC.  Statistical 
analysis was carried out using the student paired t test.  Data are representative of 
three experiments.  (The collaboration with Dr. Jennifer Ryan and Dr. Karen English 
in this experiment is gratefully acknowledged). 
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Fig 3.9 Direct cell contact is required for the induction of FoxP3 and CD25 
expression on purified CD4
+ 
T cells by allogeneic hMSC.   Purified CD4
+
 T cell 
(1 x 10
6
/well) were cultured in the presence or absence of hMSC (3 x 10
5
/well) in a 6 
well plate for 72 h.  Cell contact was prohibited using a transwell system.  
Expression of (A) FoxP3 and (B) CD25 were determined by intra/extracellular flow 
cytometry.  FoxP3
+
 CD25
+
 expression was increased in cultures when CD4
+ 
T cell 
and hMSC cell contact was permitted.  hMSC did not induce FoxP3
+
 CD25
+
 
expression on purified CD4
+
 T cells in cocultures where contact was prohibited 
(transwell).  Cell contact is required for FoxP3
+ 
CD25
+
 T reg-like cell induction by 
allogeneic hMSC.  Data are representative of three experiments.  The percentages of 
double positive cells (%) and the mean fluorescent intensity are represented in the 
quadrant. (The collaboration with Dr. Jennifer Ryan and Dr. Karen English in this 
experiment is gratefully acknowledged). 
  
A 
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Fig 3.10 Cell contact is not required for the induction of FoxP3 and CD25 
expression in a multi-cell system.  PBMC (1 x 10
6
/well) were cultured in the 
presence or absence of MSC (3 x 10
5
/well) in a transwell system for 72 h.  The 
expression of (A) Foxp3 and (B) CD25 were determined by intra/extracellular flow 
cytometry.  FoxP3 and CD25 expression were increased on PBMC that had direct 
cell contact with hMSC.  Unlike purified CD4
+
 T cells (Fig 3.8), when cell contact 
was prohibited between hMSC and PBMC, the expression of FoxP3 and CD25 was 
not decreased.  In the presence of other immune cells, cell contact is not required for 
allogeneic hMSC induction of FoxP3
+
 and CD25
+
 T reg-like cells.  Data are 
representative of three experiments.  The percentages of double positive cells are in 
the upper right quadrant (%).  (The collaboration with Dr. Jennifer Ryan and Dr. 
Karen English in this experiment is gratefully acknowledged). 
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Fig 3.11 Purified CD4
+
 CD25
+
 FoxP3
+
 T cells induced by allogeneic hMSC 
express Transforming growth factor beta 1 (TGFβ1).  CD4+ T cells (1 x 106/ml) 
and hMSC (3 x 10
5
/ml) were coculture for 24 h for mRNA analysis and 48 h for 
cytokine analysis.  (A) RT-PCR detection of TGFβ1 mRNA and (B) TGFβ1 mRNA 
by qRT-PCR on CD4
+
 T cells was examined.  The expression of TGFβ1 was 
significantly higher in CD4
+
 T cells which were previously cultured in the presence 
of hMSC (p<0.001).  (C) The secretion of TGFβ1, an important immunosuppressive 
cytokine was detected by bead array analysis.  Significantly more TGFβ1 was 
secreted when CD4
+
 T cells were cocultured with hMSC (p<0.05).  These data 
indicated the induction of an immunosuppressive phenotype and environment.  
Statistical analysis was carried out using the student paired t test.  Data are 
representative of three experiments, performed in triplicate.  
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Fig 3.12 Prostaglandins and TGFβ1 play non-redundant roles in MSC 
induction of CD4
+ 
CD25
+ 
FoxP3
+
 T cells.  Purified CD4
+
 T cells (1 x10
6
/ml) were 
cultured in the presence or absence of hMSC (3 x10
5
/ml) for (A) 24 h or (B) 72 h.  
The production of prostaglandins was ablated using the cyclooxygenase antagonist 
indomethacin (indo) (40 µM) and TGFβ1 was neutralised with anti-TGFβ1 (4 
µg/ml).  (A) FoxP3 mRNA expression was analysed by qRT-PCR after 24 h, while 
(B) FoxP3 and CD25 protein expression were analysed by intracellular flow 
cytometry after 72 h.  The presence of indomethacin or anti-TGFβ1 in cultures 
resulted in the (A) decreased expression of FoxP3 mRNA and (B) decreased FoxP3 
and CD25 expression by flow cytometry on CD4
+
 T cells following coculture with 
hMSC.  Data are representative of three experiments.  The percentages of double 
positive cells (%) and mean fluorescent intensity (MFI) are represented in the 
quadrant.  Statistical analysis was carried out using the student paired t test.  (The 
collaboration with Dr. Jennifer Ryan and Dr. Karen English in this experiment is 
gratefully acknowledged). 
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3.10  CD4
+
 CD25
+
 T CELLS INDUCED BY ALLOGENEIC MSC ARE 
CONVENTIONAL T REG CELLS 
Purified CD4
+
 CD25
+
 T cells that encountered hMSC secreted TGFβ1, (Fig 
3.10) supporting hypothesis that hMSC-derived signals condition the local tissue 
environment to promote the induction of T reg cells.  The release of 
immunosuppressive cytokines alone or the expression of CD25 and FoxP3, are not 
however sufficient in determining whether the CD4
+
 CD25
+
 T cells induced by 
hMSC are conventional T reg cells.  To investigate whether hMSC generate 
functional T reg cells, CD4
+ 
CD25
+ 
T cells induced by coculture with hMSC were 
repurified and examined for their suppressive activity in an MLR.   
Purified CD4
+
 T cells and allogeneic hMSC were cocultured for 72 h.  After 
72 h, CD4
+
 T cells were repurified (isolated) using a CD25 microbead isolation kit, 
to obtain a CD4
+
 CD25
+
 T cell population.  These repurified CD4
+
 CD25
+
 T cells 
were then cocultured with PBMC from two MHC mismatched donors in an MLR.  
The repurified CD4
+
 CD25
+
 T cells were found to significantly reduce alloantigen 
driven proliferation (Fig 3.13).  This indicated that the T cell populations induced by 
allogeneic hMSC could reasonably be described as conventional T reg cells with a 
functional suppressor function. 
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Fig 3.13 Purified CD4
+
 CD25
+
 FoxP3
+
 T cells induced by allogeneic MSC 
suppress alloresponses.  CD4
+ 
CD25
+ 
T cells induced by coculture with MSC were 
repurified by microbead separation and cocultured with PBMC from two MHC 
mismatched donors in 96 well plates in an MLR.  Repurified CD4
+
 CD25
+
 T cells 
significantly reduced allodriven proliferation in an MLR (p<0.05).  [
3
H]-Thymidine 
incorporation was  expressed as counts per minute (cpm).  Statistical analysis was 
carried out using the student paired t test.  Data represent triplicates repeated three 
times. (The collaboration with Dr. Jennifer Ryan and Dr. Karen English in this 
experiment is gratefully acknowledged). 
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3.11 SUMMARY 
The aim of this chapter was to determine how hMSC suppress innate and 
adaptive immune responses in vitro.  First, the effect of complement activation on 
hMSC survival was analysed.  Second, the role for cell contact and the release of 
soluble factors by hMSC in the induction of a T reg population were investigated.  
Finally, the induction of functional T reg-like cells by hMSC was examined in vitro.  
hMSC were not destroyed by human or murine complement in vitro.  These data 
suggested that, in the case of hMSC therapy in a xenogeneic murine model or in 
allogeneic human clinical studies, the alternative complement pathway activation 
might not confound hMSC action.  These data will be important when considering 
hMSC as a cell therapy, as complement is a vital component of innate immunity and 
involved in hyper-acute transplant rejection.  The induction of a T reg-like cell by 
hMSC was investigated in vitro.  Allogeneic hMSC cocultured with purified CD4
+
 T 
cells resulted in a significant increase in FoxP3.  Direct cell contact and hMSC-
derived soluble factors, such as TGFβ1 and prostaglandins played non-redundant 
roles in the induction of CD4
+
 CD25
+
 FoxP3
+
 T reg-like cell.  These hMSC induced 
CD4
+
 CD25
+
 FoxP3
+
 T reg cells in turn, suppressed alloantigen driven proliferation.   
The experiments described in this chapter have provided novel insight into 
hMSC immunomodulation and identifying the mechanisms used by hMSC in the 
induction of functional T reg cells.  TGFβ1 and prostaglandins production were two 
key soluble factors involved in hMSC mediated modulation.  However, this chapter 
did not identify the possible contact candidates required for the induction of 
regulatory immune cells.  The identification of a contact signal required for 
successful immunomodulation by MSC would be important in contributing to the 
rational use of MSC as an immunomodulatory cell therapy in the future. 
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CHAPTER 4 
IDENTIFYING CONTACT DEPENDENT SIGNALS INVOLVED IN 
MESENCHYMAL STEM CELL MODULATION OF DENDRITIC 
CELL FUNCTIONS 
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4.1  INTRODUCTION 
In Chapter 3, hMSC induction of T reg cells from purified populations of 
CD4
+
 T cells was shown to involve both soluble factors and cell contact dependent 
signals.  Although the identity of the contact signals were not addressed in that 
chapter, possible candidates have been suggested by others (Djouad, 2007; Zhang, 
2009).   Theoretically, MSC might influence CD4
+
 T cells in two ways, through 
direct cell contact or indirectly via contact with DC.  The identity of the direct cell 
contact signal between murine MSC (mMSC) and CD4
+
 T cells was pursued by 
another member of the group and was not explored here.  However, the ability of 
mMSC to interfere with DC maturation, antigen presentation and induction of 
regulatory/ tolerogenic DC was examined in this chapter.  
DC are the most potent antigen presenting cell (APC), involved in antigen 
uptake, and processing for presentation to naïve CD4
+
 T cells (Banchereau, 2000).  
For the purpose of this study, murine bone marrow derived DC were used, as the use 
of human DC was not possible due to limited availability of DC and CD4
+
 T cells 
from the same HLA background.  The aims of this chapter were: 
a)  To determine if mMSC modulate DC function in vitro, by interfering 
with DC maturation, antigen presentation or the release of IL-10 and IL-
12p70.   
b) To investigate and identify the potential cell contact signals contributing 
to mMSC interaction with DC.   
Potential mMSC ligands were analysed for their role in DC maturation and/or 
antigen presentation.  Following this, likely candidates were neutralised or blocked 
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in coculture studies between mMSC and DC and their precise roles in DC maturation 
and/or antigen presentation were determined.  
4.2  CHARACTERISATION OF ADULT MURINE MSC 
 In order to examine the DC MSC interaction it was necessary to switch to 
murine systems.  This was due to the limitations on DC isolation, batch 
size/reproducibility and the need for CD4
+
 T cells from the same donor.  Therefore, 
mMSC were used and required similar characterisation as carried out in Chapter 3.  
mMSC were isolated from the femurs and tibiae of BALB/c or C57 BL/6 female 
mice, using plastic adherence and selective media, as described in section 2.3.1.  At 
each passage, mMSC were examined microscopically for changes in appearance.  A 
homogenous population of mMSC was evident from passage 3 to 8 with fibroblastic, 
spindle-shaped morphology (Fig 4.1).  There was no evidence of spontaneous 
differentiation in these cultures.  Batches of mMSC were characterised by flow 
cytometry after every passage analogous to work in chapter 3.  The expression of 
Sca-1 and CD44 and the lack of expression of CD45 and CD11b were used to 
characterise a population of mMSC (Peister, 2004; Horwitz, 2005).  mMSC isolated 
by other groups typically express variable levels of Sca-1, CD106 and CD44, with 
no expression of CD11b, CD34, CD45, CD48, CD117 or CD135 (Baddoo, 2003).  
Isolated cells at passage 3 expressed MHC class I, Sca-1 and CD44,but not the 
haematopoietic markers CD45, CD11b, CD34, MHC class II or the haematopoietic 
progenitor cell marker CD117 (Fig 4.2).  Subsequent culturing of mMSC to passage 
8 resulted in increased expression of MHC class I, Sca-1, CD44 and CD106.   Cells 
expressing CD45, CD11b, CD34, CD117 or MHC class II were not observed at any 
passage between 3 and 8 (Fig 4.3).   
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Fig 4.1  mMSC have a fibroblastic morphology.  mMSC were isolated from 
BALB/c or C57 BL/6 mice.  mMSC were adherent to plastic and cultured to 80-90% 
confluency.  Morphology was examined using phase contrast microscopy from 
passage 3-8.  Image above represents typical cells from passage 5.  Original 
magnification × 100. 
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Fig 4.2  Surface marker expression by mMSC.  mMSC isolated by adherence to 
plastic from BALB/c or C57 BL/6 mice expressed MHC class I, Sca-1, CD106 and 
CD44, but not MHC II, CD117, CD34, CD11b, CD45 or CD80 at passage 3.  
Cultured MSC were characterised by flow cytometry for expression of a panel of 
markers (open histogram-green) and corresponding isotype controls (closed 
histogram-purple). A minimum of 10,000 events were acquired for each marker. 
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Fig 4.3  mMSC surface marker expression at later passages.  MSC isolated by 
adherence to plastic from BALB/c or C57 BL/6 mice expressed MHC class I, Sca-1, 
CD106 and CD44, but not CD117, CD34, CD11b, CD45 or CD90 at passage 8. 
MSC were characterised by flow cytometry for expression of a panel of markers 
(open histogram-green) and corresponding isotype controls (closed histogram-
purple). A minimum of 10,000 events were acquired for each marker. 
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4.3  MMSC SHOW TRILINEAGE DIFFERENTIATION CAPACITY 
 The capacities of the mMSC used in this study to differentiate to osteoblasts, 
adipocytes or chondrocytes were examined.  mMSC were cultured in the presence or 
absence of differentiation factors as described in Table 2.1.  mMSC were then 
stained with reagents to identify differentiated cells (Section 2.7 & Table 2.2).  
Osteoblasts were detected using Alizarin Red S (Fig 4.4 B), adipocytes by staining 
with Oil Red O (Fig 4.4 D) and chondrocytes were assessed by the expression of 
Aggrecan, a proteoglycan found in the extracellular matrix of cartilage by RT-PCR 
(Fig 4.4 E).  mMSC maintained their tri-lineage differentiation capacity through 
passage 3 to 8 (Fig 4.4).  These data confirmed the multilineage potential associated 
with mMSC.  Together with the data from figure 4.2 and 4.3, this suggested that the 
cells used in this study were typical mMSC according to the ISCT criteria (Horwitz, 
2005).  
4.4  MMSC SUPPRESS ALLOGENEIC PROLIFERATION 
 The ability of MSC to suppress lymphocyte proliferation is important when 
characterising the validity of a population of MSC, according to ISCT regulations.  
Previous members of the Mahon group examined MSC suppression of lymphocyte 
proliferation (Ryan, 2007; English, 2008).  However, it was important to verify this 
characteristic for each new batch of mMSC isolated.  Therefore, the 
immunosuppressive ability of mMSC isolated for the purpose of the studies herein 
was first analysed using mitogen driven proliferation assay.  Splenocytes from 
C57BL/6 (H-2
b
) mice were cultured in the presence or absence of allogeneic 
BALB/c (H-2
d
) mMSC or in the presence of a mitogen concanavalin A (ConA).   As 
expected, mitogen stimulation induced a significant increase in splenocyte 
121 
 
proliferation, whereas the presence of allogeneic mMSC significantly inhibited 
proliferation (p<0.0001) (Fig 4.5 A).  This result indicated that allogeneic mMSC 
were capable of potent immunosuppression of lymphocyte proliferation. 
 mMSC possess the ability to suppress alloreactivity (Djouad, 2003).  To 
verify this, mMSC were included in a two-way mixed lymphocyte reaction (MLR).  
Splenocytes from C57BL/6 (H-2
b
) (D1) and FV/BN (H-2
q
) (D2) mice were 
cocultured in the presence or absence of (third party) allogeneic BALB/c (H-2
d
) 
mMSC (Fig 4.5 B).  Coculture of allogeneic splenocytes resulted in proliferation, 
however, this was significantly suppressed in the presence of mMSC (p<0.0182) 
(Fig 4.5 B).  mMSC are slow growing cells and do not proliferate in the time course 
of this experiment.  These data indicated that the mMSC populations isolated were 
capable of suppressing both mitogen driven and alloantigen driven proliferation.   
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Fig 4.4 mMSC differentiated along the osteogenic, adipogenic and chondrogenic 
lineages.  mMSC were seeded at a density of 1 x 10
3
cells/cm
2
 and cultured in (A & 
C) complete αMEM media, (B) osteogenic induction media or (D) adipogenic 
induction media for 21 days.  (B) Osteogenesis was assessed using Alizarin Red S.  
(D) Adipogenesis was visualised by staining cells with Oil Red O.  Magnification x 
100 using phase contrast microscopy.  (E) Chondrogenic differentiation was 
determined by RT-PCR for the expression of the proteoglycan aggrecan.  mMSC 
expressed Aggrecan following 21 days of culture in differentiation complete αMEM 
media containing TGFβ3.  mMSC did not spontaneously differentiate into 
osteocytes, adipocytes or chondrocytess when cultured for 21 days in complete 
αMEM media without differentiation components.  The above data represent passage 
5.  Collectively, these data are representative of the differentiation capacity of 
mMSC from passage 3 to 8.  
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Fig 4.5 Allogeneic mMSC inhibit mitogen driven and alloantigen driven 
proliferation.  BALB/c (H2
d
) mMSC (passage 5) were examined for their capacity 
to inhibit (A) mitogen driven (ConA) proliferation of C57BL/6 (H2
b
) splenocytes 
and (B) alloantigen driven proliferation of MHC-mismatched donor mice (C57BL/6 
(H2
b
)) (D1) and FV/BN (H2
q
) (D2)) splenocytes.  mMSC (1 x 10
5
/ml) and 
splenocytes (1 x 10
6
/ml) were cocultured for 72 h.  [
3
H]-Thymidine at 0.5 µCi/ml 
was added for the final 6 h of culture.  Cells were harvested using an automated cell 
harvester.  (A) mMSC significantly inhibited  mitogen driven lymphocyte 
proliferation (p<0.0001).  (B) mMSC significantly suppressed allo-driven 
proliferation (p<0.0182).  Statistical analysis was carried out using the student paired 
t test.  Results are representative of three independent experiments for each passage 
of mMSC from 3 to 8.   
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4.5  MURINE MSC PREVENT LPS DRIVEN DC MATURATION 
The transition from immature to mature DC is characterised by a number of 
changes, including the increased secretion of IL-12 and the increased expression of 
MHC class II and costimulatory molecules.  Bone marrow derived DC were 
stimulated with LPS in the presence or absence of allogeneic mMSC for 48 h.  After 
48 h, the expression of MHC class II and the costimulatory molecule CD86 were 
analysed on DC by flow cytometry (Fig 4.6 A).  Supernatants from these cultures 
were collected at 48 h and cytokine secretion was analysed by ELISA (Fig 4.6 B).   
Maturation of DC with LPS for 48 h resulted in an increase in maturation 
marker expression, both MHC class II (3405 MFI) and CD86 (1222 MFI) by flow 
cytometry (Fig 4.6 A).  However, mMSC coculture prevented the increase in MHC 
class II (2636 MFI) and CD86 (815 MFI) expression (Fig 4.6 A).  DC that had been 
stimulated with LPS for 48 h secreted elevated levels of IL-12p70 and lower levels 
of IL-10 (Fig 4.6 B) as has been previously reported (English, 2008).  Following 
coculture with mMSC, DC secreted significantly less IL-12p70 (p<0.0001) and 
significantly more IL-10 (p<0.0001) (Fig 4.6 B).  mMSC did not secrete IL-12p70 
suggesting that this was a direct influence on DC.  However, mMSC secrete low 
levels of IL-10 and this could contribute to the elevated levels of IL-10 present in 
coculture supernatant (Fig 4.6 B).  These data suggested that mMSC disrupt the 
maturation of DC, preventing the upregulation of MHC class II and CD86 
expression, in conjunction with a decrease in IL12-p70 production and an increase in 
IL-10 production.  These data are consistent with a hypothesis suggesting that 
mMSC keep DC in a semi-mature or tolerogenic state. 
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Fig 4.6  mMSC prevent LPS driven DC maturation.  Immature DC (iDC) were 
stimulated with LPS (100 ng/ml) (mDC) and cultured in the presence or absence of 
mMSC for 48 h.  DC were analysed by flow cytometry for the expression of 
maturation markers, (A) MHC class II and CD86 or by ELISA of culture supernatant 
for (B) IL-12p70 or (C) IL-10.   (A) mDC were separated from adherent mMSC by 
gentle aspiration after 48 h for flow cytometry. Percentage positive and mean 
fluorescence intensity (MFI) represented on histogram.  Isotypes are shown as closed 
histograms (purple), while specific marker expressions are represented as open 
histograms (green).  Data are representative of three independent experiments.  
Supernatants were collected after 48 h for cytokine analysis by ELISA.  (B) mMSC 
significantly (p<0.0001) decreased the production of IL-12p70 by DC, while (C) 
significantly (p<0.0001) increasing the production of IL-10.  Statistical analysis was 
carried out using the student paired t test.  Data are representative of three 
experiments each performed in triplicate.  
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4.6  MMSC INDUCE A TOLEROGENIC DC 
 Presentation of antigen in the presence of costimulation by DC is critical for 
the activation of naïve CD4
+
 T cells.  In the event of antigen presentation in the 
absence of costimulation, clonal T cell anergy or apoptosis can occur (Schwartz, 
1989).  Tolerogenic DC are said to be resistant to maturation, with low levels of 
MHC II and costimulatory molecule expression, low production of IL-12p70, high 
production of IL-10, impaired T cell activation and increased ability to generate 
alloantigen specific T reg cells (Morelli, 2007).  To examine this and in a bid to 
strengthen the data above, the effect of mMSC on antigen presentation by DC was 
analysed by flow cytometry, measured by the display of I-Eα peptide.  The YAe 
antibody used recognises the I-Eα peptide but only when displayed by the I-Ab MHC 
class II molecule of C57/BL6 DC.  C57/BL6 DC express I-A
b
 but not I-E and cannot 
constitutively express the I-Eα: I-Ab MHC class II trimeric complex (Murphy, 1992).   
DC isolated from C57BL/6 bone marrow were pulsed with I-Eα peptide for 
48 h.  Antigen displayed by DC was recognised through the addition of fluorescently 
labelled YAe antibody and analysis by flow cytometry (Fig 4.7 A).  DC pulsed with 
the I-Eα peptide were capable of displaying specific I-Eα antigen (90%).  However, 
following coculture with mMSC, DC were unable to display the antigen at high 
levels (42%) (Fig 4.7 A), suggesting that mMSC prevented or impaired the 
presentation of alloantigen by DC.   
mMSC cocultured with DC prevented the increase of maturation markers, 
MHC class II and CD86, keeping the DC in a semi-mature state (Fig 4.6 A).  
However, in order to describe these DC as tolerogenic, they must be less capable of 
supporting T cell proliferation.  It was therefore necessary to demonstrate that DC 
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encounter with mMSC resulted in the induction of a DC population impaired for that 
function.  The approach to demonstrate such a “tolerogenic function” involved a 
two-step design.  First, DC were pulsed with antigen, ovalbumin (OVA), in the 
presence or absence of mMSC.  The DC were then repurified and cocultured with 
OVA antigen specific CD4
+
 T cells isolated from DO11.10 mice.  If the DC 
population were tolerogenic, the hypothesis was that T cell proliferation would be 
impaired.  To examine this hypothesis, C57BL/6 mMSC were cocultured with 
BALB/c DC pulsed with OVA for 48 h.  Then, DC were repurified from adherent 
mMSC by gentle aspiration and placed into fresh culture with DO11.10 isolated 
CD4
+
 T cells, which carry a transgenic T cell receptor specific for OVA peptide 323-
339, for a further 72 h.  As expected, OVA pulsed DC were capable of supporting 
DO11.10 CD4
+
 T cell proliferation (Fig 4.7 B).  However, DC pulsed with OVA in 
the presence of mMSC were subsequently unable to stimulate CD4
+
 T cell 
proliferation (Fig 4.7 B).  This was a striking finding given that each T cell in this 
population was specific for the antigen employed.  A fully functional mMSC was 
required for the induction of a tolerogenic DC, as OVA pulsed DC in presence of 
formalin fixed MSC (fMSC) retained the capacity to support CD4
+
 T cell 
proliferation (Fig 4.7 B).  Thus it is reasonable to conclude that mMSC induced a 
genuinely tolerogenic DC population that was unable to classically support the 
proliferation of antigen specific CD4
+
 T cells in vitro. 
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Fig 4.7 mMSC interfere with antigen presentation by DC, inducing a 
tolerogenic DC.  (A) iDC alone or iDC pulsed with Eα peptide (10 µg/ml) in the 
presence or absence of mMSC were labelled with biotinylated YAe antibody, 
followed by streptavidin-FITC and analysed by flow cytometry.  mMSC reduced the 
presentation of I-Eα peptide by iDC.  (B) iDC that were previously pulsed with OVA 
in the presence or absence of mMSC or formalin fixed mMSC (fMSC) for 48 h were 
repurified and cocultured with OVA specific DO11.10 CD4
+
 T cells for 72 h.  
Proliferation through 
3
H Thymidine incorporation was measured.  DC pulsed with 
OVA supported proliferation of DO11.10 CD4
+ 
T cells (p<0.0001).  DC pulsed with 
OVA in the presence of mMSC significantly reduced (p<0.0001) the proliferation of 
DO11.10 CD4
+
 T cells in vitro.  Fully functional mMSC were required for the 
induction of a tolerogenic DC, as fixed mMSC (fMSC) did not interfere with the 
presentation of antigen by DC.  Statistical analysis was carried out using the student 
paired t test.  Data are representative of three experiments performed in triplicate. 
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4.7 DIRECT CELL: CELL CONTACT BETWEEN MSC AND DC IS REQUIRED FOR 
THE INDUCTION OF A “SEMI-MATURE” DC IN VITRO 
The need for direct cell: cell contact between MSC and immune cells has 
remained unclear to date.  Many groups suggest that MSC require direct cell contact 
with its target cell while others suggest otherwise (Beyth, 2005; Jiang, 2005; Nauta, 
2006; Djouad, 2007).  Therefore, the need for direct cell contact between mMSC and 
DC for maturation inhibition was examined.  A similar approach to that carried out 
in Chapter 3 was employed.  Using a transwell system, the direct cell contact 
between mMSC and DC was prohibited.  Similar to data shown in Figure  4.6 A, 
when direct cell contact between mMSC and DC was permitted, mMSC successfully 
prevented the maturation of DC inducing a semi-mature population, as indicated by 
low levels of MHC class II (1083 MFI) and CD86 (815 MFI) expression (Fig 4.8).  
However, when direct cell contact was prohibited using the transwell system, mMSC 
no longer prevented DC maturation as an increase in maturation marker expression 
was observed(MHC II (1663 MFI )and CD86 (1320 MFI)), indicating successful DC 
maturation (Fig 4.8).  This finding showed that in order for mMSC to induce a semi-
mature DC population direct cell contact between the two cell populations was 
required.  This finding encouraged the investigation into identifying possible cell 
contact molecules involved in this immune modulation by mMSC on DC maturation. 
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Fig 4.8  Direct cell contact between mMSC and DC is required for the induction 
of a semi-mature DC population.  DC (1 x 10
6
/well) matured with LPS (100 
ng/ml) (mDC) displayed increased MHC class II and CD86 expression after 48 h by 
flow cytometry.  DC matured in the presence of mMSC (3 x 10
5
/well) had decreased 
levels of MHC class II and CD86 expression, indicating a semi-mature phenotype.  
When direct cell contact was prohibited in a transwell system, mMSC were unable to 
interfere with the maturation of DC and no longer induced a semi-mature phenotype.  
Percentage of cells and mean fluorescence intensity (MFI) is indicated in each 
histogram.  Data are representative of three experiments. 
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4.8 EXAMINATION OF CANDIDATE CONTACT SIGNALS: CD33-RELATED SIGLEC 
EXPRESSION BY MURINE MSC  
After identifying the need for direct cell contact between mMSC and DC, the 
following sections investigated the roles of possible contact molecules involved in 
mMSC modulation of DC maturation.  Siglecs were the first candidate investigated.  
Siglecs are a family of type-1 sialic-acid binding immunoglobulin-like lectins that 
are involved in immune cell: cell interactions and regulate the function of cells in 
both the innate and adaptive immune systems through glycan recognition (Crocker, 
2007) (Chapter 1.6.1).  CD33-related Siglecs also play a role in the regulation of 
cellular proliferation and differentiation during immune responses (Crocker, 2003).  
Therefore, Siglecs were a credible candidate signal used by mMSC in immune 
modulation. 
To determine if mMSC expressed Siglecs, a semi-quantitative molecular 
approach to measure the CD33-related Siglecs E, F, G and H was followed (Fig 4.9).  
Tissues known to express Siglec E and H (splenocytes), F (bone marrow) or G (bone 
marrow & splenocytes) were used as positive controls to optimise the conditions 
required for RT-PCR.  The optimum annealing temperatures for the detection of 
Siglec expression were Siglec E 62°C; Siglec H, 58°C; Siglec F, 60°C; and Siglec G, 
60°C.  All further RT-PCR analyses were carried out using these optimised 
temperature conditions.  
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Fig 4.9  Optimisation of Siglec primers. Primers for (A) Siglec E, (B) Siglec H, (C) 
Siglec F and (D) Siglec G were optimised for RT-PCR using  temperature gradients 
ranging from 55°C to 64°C. (A) Siglec E optimal temperature was 62°C, (B) Siglec 
H optimal temperature was 58°C, (C) Siglec F optimal temperature was 60°C and 
(D) Siglec G optimal temperature was 60°C. Spleen derived cells were used as a 
positive control for (A) Siglec E, (B) Siglec H and Siglec G (D).  Bone marrow cells 
were used as a positive control for both (C) Siglec F and (D) Siglec G.  
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4.9  CD33-RELATED SIGLECS ARE NOT EXPRESSED BY MURINE MSC 
The expression of CD33-related Siglecs on unstimulated or stimulated 
mMSC was examined.  IFNγ or prolactin were chosen as stimulants as prolactin 
induces (chondrogenic) differentiation of bone marrow derived MSC (Ogueta, 
2002), whereas IFNγ induces increased immunosuppressive activity by MSC both in 
vitro and in vivo (English, 2007; Ryan, 2007; Polchert, 2008).  After stimulation with 
or without prolactin or IFNγ for 24 h, the expression of CD33-related Siglecs on 
mMSC or unstimulated mMSC were analysed by RT-PCR.  mRNA for CD33-
related Siglecs were not detectable on unstimulated or stimulated  mMSC after 24 h 
(Fig 4.10).  Reagents for murine Siglecs are not well developed but the expressions 
of Siglec E and H were also analysed by flow cytometry after stimulation with or 
without prolactin or IFNγ for 24 h.  Stimulated and unstimulated mMSC did not 
express Siglec H or Siglec E by flow cytometry (Fig 4.11).  Thus, mMSC did not 
appear to express the CD33 family of Siglecs, suggesting that mMSC expression of 
Siglecs is not the contact dependent signal. 
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Fig 4.10 CD33-related Siglecs are not expressed by mMSC. Optimised primers 
were used to determine the expression of (A) Siglec E (62°C), (B) Siglec H (58°C), 
(C) Siglec F (60°C) and (D) Siglec G (60°C) on mMSC and mMSC stimulated with 
prolactin (50 ng/ml) or IFNγ (50 ng/ml) after 24 h. RT-PCR analysis showed that 
CD33-related Siglecs are not expressed by MSC. Housekeeper gene expression, (E) 
GAPDH, used as a positive control for cDNA synthesis.  
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Fig 4.11 MSC do not express Siglec E or H. Siglec E and H expression were 
analysed by flow cytometry on (A) mMSC alone or mMSC stimulated with (B) 
prolactin (50 ng/ml) or (C) IFNγ (50 ng/ml) for 24 h.  Unstimulated mMSC and 
stimulated mMSC did not express Siglec E or H.  Isotype controls are represented by 
filled purple histograms, while cell specific markers by open green histograms. Data 
are representative of three experiments. 
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4.10 REGULATORY MOLECULE EXPRESSION BY MMSC AND BONE MARROW 
DERIVED DC 
 As mMSC did not appear to express CD33 related Siglecs, the expression of 
other regulatory molecules were examined.  In the first instance, the B7 family of 
receptors and ligands: CTLA-4, ICOS and PD-1, were examined as these are 
involved in the activation, regulation and inhibition of immune cell responses 
(Amarnath, 2010; Alegre, 2001; Herman, 2004; Latchman, 2001; Nishimura, 2001).  
The expression of B7 family receptors and ligands were examined on both mMSC 
and DC by RT-PCR.   
mMSC were stimulated with prolactin, TNFα or IFNγ for 24 h and the 
expression of CTLA-4, ICOS, LICOS, PD-1 and PDL-1 on mMSC were determined 
by RT-PCR and qRT-PCR (Fig 4.12 A & B).  Unstimulated mMSC did not express 
CTLA-4, ICOS or PD-1 receptors, but appeared to express the ligands LICOS and 
PDL-1 (Fig 4.12 A).  Upon further investigation by qRT-PCR, mMSC did not 
express LICOS or PDL-1 (Fig 4.12 A).  However, stimulation of mMSC with IFNγ 
resulted in the up regulation of PDL-1 expression (Fig 4.12 A & B).   
Bone marrow derived DC were isolated from C57BL/6 mice and matured in 
the presence of LPS for 24 h.  The expression of ICOS, LICOS, PD-1 and PDL-1 
was analysed by qRT-PCR (Fig 4.13 A & B).  Immature DC (iDC) and mature DC 
(mDC) expressed similar levels of LICOS and PDL-1, while ICOS and PD-1 
receptor expression was increased following maturation with LPS (Fig 4.13 B).    
The data herein suggested that the B7 family receptors and ligands were possible 
candidates for cell contact dependent immune cell modulation by mMSC and DC.     
 
138 
 
A 
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Fig 4.12  mMSC express LICOS and PDL-1.  mMSC were stimulated with TNFα 
(50 ng/ml), prolactin (50 ng/ml) or IFNγ (50 ng/ml) for 24 h.  (A) The expression of 
regulatory molecules, CTLA-4, ICOS, LICOS, PD-1 and PDL-1 were analysed by 
RT-PCR.  mMSC did not express CTLA-4, ICOS and PD-1 receptors, but did 
express LICOS and PDL-1.  (B) The expression of LICOS and PDL-1 were analysed 
by qRT-PCR on unstimulated and stimulated mMSC.  IFNγ stimulation increased 
the expression of LICOS and PDL-1 on mMSC. 
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Fig 4.13  DC express ICOS, LICOS, PD-1 and PDL-1. Bone marrow derived DC 
were isolated and matured in the absence (iDC) or presence (mDC) of LPS at 100 
ng/ml for 24 h. The expression of ICOS, LICOS, PD-1 and PDL-1 was analysed by 
(A) RT-PCR and (B) qRT-PCR.  Both immature (iDC) and mature DC (mDC) 
expressed similar levels of LICOS and PDL-1, while maturation increases the 
expression of ICOS and PD-1 receptors. 
285bp 180bp 
149bp 151bp 
500bp 
140 
 
4.11  NOTCH EXPRESSION BY MMSC  
Notch signalling is involved in cell fate decisions during development, stem 
cell maintenance, cell proliferation, differentiation and apoptosis (Radtke, 2004; 
Fiuza, 2007) (Chapter 1.6.2), and Notch-ligand interaction has a role in other 
immune modulatory situations (Fiuza, 2007).  Therefore, the Notch signalling 
pathway was investigated as a possible candidate for the cell contact signal used by 
mMSC.  The expression of Notch receptors, Notch 1 and 2 and the Notch ligand, 
Jagged 1, 2 and Delta-like ligand 1 were analysed on mMSC alone or mMSC 
stimulated with TNFα, prolactin, LPS or IFNγ for 24 h by RT-PCR (Fig 4.14) (Table 
4.1).  Primers were previously optimised in the laboratory, prior to analysis using 
known positive controls for expression.  The expression of Notch 1, Notch 2, Jagged 
1 and Delta-like ligand-1 were observed on mMSC, while Jagged 2 was not 
expressed by mMSC (Fig 4.14 A).  Stimulation of mMSC by prolactin, TNFα or 
LPS decreased the expression of Notch 1 when compared to unstimulated mMSC 
(P<0.05).  Stimulation of mMSC with prolactin, IFNγ or LPS resulted in a decrease 
of Notch 2 expression when compared to mMSC alone.  While IFNγ stimulation of 
mMSC decreased Jagged 1 expression when compared to mMSC alone (Fig 4.14 B). 
The expression of Notch receptors and ligands by unstimulated mMSC was 
characterised at the protein level by flow cytometry (Fig 4.15).  mMSC expressed 
Notch 1, Notch 2, Jagged 1 and Delta-like ligand-1, but not Jagged 2 similar to that 
found by RT-PCR (Fig 4.15).  The expression of both Notch receptors and ligands 
on stimulated or unstimulated mMSC suggested that Notch signalling could possibly 
be the contact dependent signal involved in modulation of immunity by MSC.  
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Fig 4.14  MSC expressed Notch receptors and ligands. mMSC were unstimulated 
or stimulated with TNFα, prolactin, IFNγ or LPS at 50 ng/ml for 24 h. Expression of 
Notch receptors and ligands were analysed by (A) RT-PCR and (B) qRT-pCR.  (A) 
mMSC expressed Notch 1, Notch 2, Jagged 1 and Delta-like ligand 1.  mMSC did 
not express Jagged 2.  (B) Stimulation of mMSC by prolactin, TNFα or LPS 
decreased the expression of Notch 1 (p<0.05).  Stimulation of mMSC with prolactin, 
IFNγ or LPS resulted in a decrease of Notch 2 (p<0.05).  While IFNγ stimulation of 
mMSC decreased Jagged 1 expression (p<0.05).  Statistical analysis was carried out 
using the students paired t test.  
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Table 4.1  Expression of  Notch receptor and ligands by mMSC Summary 
 
 
Treatment of Cells Notch 1 Notch 2 Jagged 1 Jagged 2 Delta-like 
ligand 1 
MSC 
MSC+ TNFα 
MSC+ Prolactin 
MSC+ IFNγ 
MSC + LPS 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
- 
- 
- 
+ 
+ 
+ 
+ 
+ 
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Fig 4.15 Notch expression by MSC.  Expression of Notch 1, Notch 2, Jagged 1, 
Jagged 2 and Delta-like ligand 1 by mMSC alone were analysed by flow cytometry.  
mMSC expressed Notch 1, Notch 2, Jagged 1 and Delta-like ligand 1.  mMSC did 
not express Jagged 2. Isotypes are represented as closed histograms (purple), while 
specific marker expressions are represented as open histograms (green).  
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4.12  EXPRESSION OF NOTCH BY MURINE DC 
The expression of Notch by immature DC (iDC) and LPS matured DC 
(mDC) were analysed by qRT-PCR and flow cytometry.  iDC were generated by 
culturing bone marrow cells with GM-CSF for 8 days and matured with LPS for a 
further 48 h.  The expression of Notch 1, Notch 2, Jagged 1, Jagged 2 and Delta-like 
ligand 1 on iDC and mDC were examined by RT-PCR and followed on a 
quantitative level by qRT-PCR (Fig 4.16 A & B) (Table 4.2).  iDC expressed Notch 
1 and Jagged 2 which decreased upon maturated with LPS (Fig 4.16 A & B).  iDC 
expressed low levels of Notch 2, which increased following LPS maturation (Fig 
4.16 A & B).  The expression of Jagged 1 and Delta-like ligand 1 were increased on 
DC following maturation by LPS (Fig 4.16 A & B).  These data found that DC were 
capable of Notch receptor and ligand expression at an RNA level.  
The expression of Notch receptors and ligands were analysed on DC matured 
in the presence of LPS for 48 h by flow cytometry (Fig 4.17).  Data corresponded to 
mRNA analysis, Notch 1 and Jagged 2 expression on DC was decreased after 
stimulation with LPS (Fig 4.17), while Notch 2, Jagged 1 and Delta-like ligand 1 
expression were increased following maturation with LPS (Fig 4.17).  As the 
expression of specific Notch receptors and ligands were present on both DC and 
mMSC, this suggested that Notch signalling could be a possible candidate for 
mMSC: DC cell-cell interaction.   
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Fig 4.16  Notch expression by dendritic cells.  iDC were matured with 100 ng/ml 
LPS for 24 h.  Expression of Notch receptors, Notch 1, Notch 2 and Notch ligands 
Jagged 1, Jagged 2 and Delta-like ligand 1 were analysed by (A) RT-PCR and (B) 
qRT-PCR.  Maturation by LPS reduced the expression of Notch 1 and Jagged 2 on 
DC.  Notch 2, Jagged 1 and Delta-like ligand 1 expression were increased on DC 
following maturation by LPS.  Data are representative of three independent 
experiments.  
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Fig 4.17  Notch expression on dendritic cells by flow cytometry.  DC were 
matured with LPS (100 ng/ml) for 48 h and the expression of Notch receptors and 
ligands were analysed by flow cytometry.  Notch 1 and Jagged 2 expression was 
decreased on DC following stimulation with LPS.  Notch 2, Jagged 1 and Delta-like 
ligand 1 expression was increased on DC after maturation with LPS for 48 h.  Data 
are representative of three experiments.    
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Table 4.2 Summary of Notch expression by DC 
 
 
 
Cells 
Notch 1 Notch 2 Jagged 1 Jagged 2 Delta-like 
ligand 1 
Immature DC 
(iDC) 
++ + + ++ + 
Mature DC 
(mDC) 
+ ++ ++ + ++ 
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4.13  MMSC CONTACT WITH DC ACTIVATES NOTCH SIGNALLING  
The next step in identifying a possible cell contact signal involved in mMSC 
modulation of DC maturation was to look at the Notch signalling pathway 
functionally.  To investigate whether the Notch signalling pathway was involved in 
mMSC suppression of DC maturation, the activation of Notch target genes, such as 
HES1 was examined.  mMSC cocultured with  LPS stimulated DC (mDC) induced 
the expression of the Notch target gene, HES1 (Fig. 4.18 A).  However, the 
expression of HES1 was reduced when Notch signalling was blocked using a gamma 
secretase inhibitor, GSI (Fig 4.18 A).  These data suggested that Notch signalling 
was involved in mMSC-DC maturation interaction.  Therefore, further studies using 
the Notch inhibitor, GSI, were carried out.   
mDC were cocultured with mMSC in the presence or absence of GSI or 
DMSO (vehicle control).  After coculture, the expression of the maturation markers, 
MHC class II and CD86 were analysed by flow cytometry (Fig 4.18 B & C).  As 
expected, DC showed increased expression of both MHC class II (3405 MFI) and 
CD86 (319 MFI) when matured with LPS.  However, in the presence of mMSC, the 
expression of MHC class II (2636 MFI) and CD86 (285 MFI) were reduced, 
characteristic of a semi-mature DC phenotype (Fig 4.18 B & C).  The addition of 
Notch inhibitor, GSI to the coculture restored the expression of MHC class II (3081 
MFI) and CD86 (319 MFI) to levels similar to mDC.  Vehicle control, DMSO, in 
coculture experiments had no effect (Fig 4.18 B & C).   
mMSC prevented the production of IL-12p70 by mDC but increased IL-10 in 
coculture (Fig 4.6 B).  The effect of blocking Notch signalling (by GSI) on the 
production of IL-12p70 and IL-10 by DC in coculture with mMSC was analysed by 
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ELISA (Fig 4.19).  After 48 h, coculture supernatant was harvested and analysed for 
IL-12p70 and IL-10 production.  Although blocking Notch signalling in vitro in 
coculture experiments restored the maturation of DC, the production of IL-12p70 
was not altered.  However, blocking Notch in cocultures between mMSC and DC 
appeared to increase IL-10 production.  These data suggested that mMSC suppress 
DC maturation through Notch.  However, the modulation of cytokine signalling 
seems to be independent of Notch signalling and may well be through MSC derived 
IL-10.   
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Fig 4.18  Notch signalling is involved in MSC inhibition of DC maturation.  DC 
were matured with LPS (100 ng/ml) in the presence or absence of mMSC for 24 or 
48 h.  Notch signalling was blocked through the addition of GSI (1 µM) to MSC: DC 
cocultures.  After 24 h, (A) DC were analysed for the expression of Notch target 
gene HES1 by RT-PCR.  HES1 expression was down regulated on DC when Notch 
signalling was blocked using GSI.  After 48 h, DC were harvested and analysed for 
the expression of (B) MHC class II and (C) CD86 by flow cytometry.  Blocking 
Notch signalling using GSI inhibited mMSC modulation of DC maturation.  Vehicle 
control for GSI, DMSO, had no effect on DC maturation.  Isotypes are represented 
as closed histograms (purple), while specific marker expressions are represented as 
open histograms (green).  Mean fluorescence intensity (MFI) are represented on 
histogram (upper right).  Data are representative of three independent studies.  
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Fig 4.19 Blocking Notch signalling between MSC and DC had no effect on 
cytokine production.  mMSC and DC were cocultured in the presence of LPS for 
48 h.  Notch signalling was blocked through the addition of GSI.  Supernatants were 
harvested after 48 h of coculture and analysed for the presence of IL-10 and IL-
12p70 by ELISA. mMSC significantly (p<0.05) decreased IL-12p70 production and 
significantly (p<0.05) increased the production of IL-10 by DC.  Blocking Notch 
signalling through the addition of GSI had no effect on cytokine production when 
compared to DC cocultured with mMSC. Statistical analysis was carried out using 
the students paired t test.  Data are representative of three independent experiments 
performed in triplicate.  
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4.14 NOTCH SIGNALLING IS REQUIRED FOR MSC SUPPRESSION OF ANTIGEN 
PRESENTATION BY DC 
 mMSC interfere with the presentation of I-Eα peptide by C57 BL/6 isolated 
DC (Fig 4.7 A).  However, to investigate whether Notch signalling was required for 
antigen presentation by DC, the Notch γ-secretase inhibitor, GSI, was used in 
coculture experiments.  DC isolated from C57/BL6 bone marrow were pulsed with I-
Eα peptide and cocultured with mMSC in the presence or absence of GSI or DMSO 
for 48 h.  In the presence of mMSC, DC pulsed with I-Eα peptide were unable to 
display the antigen (Fig 4.20) (47%), in line with the result shown previously (Fig 
4.7 A).  However, when Notch signalling was blocked using GSI, mMSC could no 
longer prevent DC from displaying I-Eα antigen (Fig 4.20), as the percentage of cells 
presenting I-Eα was similar to that of DC alone pulsed with I-Eα antigen (75%).  
These data confirmed that not only was Notch signalling involved in mMSC 
inhibition of DC maturation, but it was required for the inhibition of antigen 
presentation by DC when mMSC were present.  
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Fig 4.20 Notch is involved in MSC suppression of DC antigen presentation.  DC 
alone or DC pulsed with I-Eα peptide (10 µg/ml) in the presence or absence of MSC, 
GSI or DMSO were cultured for 48 h.  The number of DC presenting the I-Eα 
peptide was measured by YAe expression, by flow cytometry.  (B) DC pulsed with 
I-Eα peptide expressed higher levels of YAe when compared with  (A) DC alone.  
However, (C) when mMSC were present, DC were unable to present antigen.  By 
blocking Notch signalling using GSI, (D) DC antigen presentation was restored, 
indicating that Notch signalling was involved in mMSC interference of DC antigen 
presentation.  (E) GSI vehicle control had no effect on antigen presentation.  
Percentage of cells within the marked region are represented in the histogram. 
Isotype shown in purple YAe expression in green. Data are representative of three  
experiments.  
157 
 
4.15 NOTCH IS REQUIRED FOR MMSC INDUCTION OF TOLEROGENIC DC 
In order to examine the possible role of Notch signalling in the induction of a 
tolerogenic DC by mMSC, the experiment described in section 4.6 (Fig 4.7 B) was 
repeated with GSI present in the cocultures.  DC were pulsed with OVA in the 
presence or absence of mMSC.  DC were the harvested by gentle aspiration from 
adherent mMSC and placed in a proliferation assay with OVA specific DO11.10 
CD4
+
 T cells.  DC pulsed with OVA were capable of supporting DO11.10 CD4
+
 T 
cell proliferation (Fig 4.21).  However, DC pulsed with OVA in the presence of 
mMSC were unable to stimulate CD4
+
 T cell proliferation (Fig 4.21).   
To investigate if Notch signalling was essential for this induction of a 
functional tolerogenic DC by mMSC, GSI or inhibitor vehicle control DMSO were 
also included in coculture experiments.  Following coculture with mMSC and GSI, 
OVA pulsed DC were repurified and placed in coculture with DO11.10 CD4
+
 T 
cells.  Interestingly, by blocking Notch signalling through the addition of GSI, 
mMSC were no longer able to induce a functional tolerogenic DC, as indicated by a 
significant increased in CD4
+ 
T cell proliferation (p<0.0001) (Fig 4.21).  These data 
confirmed that Notch signalling was required for the induction of a functional 
tolerogenic DC population by mMSC in vitro.  
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Fig 4.21  Notch is required for the induction of a functional tolerogenic DC by 
MSC.  DC pulsed with OVA in the presence or absence of mMSC, GSI (1 µM) or 
DMSO for 24 h were harvested and washed twice before further culturing with 
DO11.10 CD4
+
 T cells for 72 h. After 72 h, proliferation through 
3
H Thymidine 
incorporation was measured.  DC pulsed with OVA supported the proliferation of 
DO11.10 CD4
+ 
T cells.  DC that had been cultured in the presence of mMSC were 
significantly less able to support proliferation of DO11.10 CD4
+
 T cells (P<0.05). 
However, DC cultured in the presence of mMSC and GSI did not inhibit the 
proliferation of DO11.10 CD4
+ 
T cells, as indicated by a significant increase on 
CD4
+
 T cell proliferation (p<0.0001).  This indicated a requirement for Notch 
signalling in the induction of a tolerogenic DC by mMSC.  Statistical analysis was 
carried out using the students paired t test.  
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4.16 ATTEMPTS TO EXPLORE JAGGED 1 IN DC MATURATION 
mMSC express the Notch ligand Jagged 1.  Recently, Cheng et al. found that 
Notch ligand Jagged 1 stimulated the accumulation of DC precursors, while 
preventing their transition to terminally differentiated DC (Cheng, 2007).  These data 
suggested that Jagged 1 ligand could be the possible ligand involved in cell contact 
between mMSC and DC.  The neutralisation of Jagged 1 expression by mMSC was 
examined. 
DC were matured with LPS in the presence of absence of mMSC.  In some 
treatment groups, the neutralisation of Jagged 1 was carried out through the addition 
of anti-mouse Jagged 1 antibody.  The expression of maturation marker, MHC class 
II and costimulatory marker, CD86 were analysed by flow cytometry (Fig 4.22 A & 
B respectively).  DC cocultured with mMSC had reduced levels of maturation 
marker expression a semi-mature DC phenotype.  Following the neutralisation of 
Jagged 1 (5 μg/ml) in coculture between mMSC and DC, the levels of maturation 
marker expression on DC increased marginally to similar levels seen by mature DC, 
suggesting that the ligand Jagged 1 could possibly be involved in DC: MSC 
interactions (Fig 4.22 A & B).  However, on closer inspection, the control antibody 
for anti-Jagged 1 was found to have an effect on DC maturation marker expression.  
These data suggested that this antibody was not sufficient in the neutralisation of 
Jagged 1 and that a more specific technique was required for knock down of Jagged 
1 expression on mMSC.  Therefore, the idea of silencing Jagged 1 expression by 
siRNA was investigated. 
 Expression of murine Jagged 1 RNA was silenced using a pre-designed 
siRNA pre-select kit.  mMSC were cultured in 24 well plates to about 60% 
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confluency.  Different amounts of siRNA in the presence of Lipofectamine 2000, a 
transfection reagent, were added to wells in duplicate for 24 or 48 h.  siRNA ranging 
from 10 nmol to 25 nmol were used.  After siRNA/mMSC culture for 24 h and 48 h, 
Jagged 1 expression was analysed on mMSC by RT-PCR (Fig 4.22 C & D).  Jagged 
1 siRNA at 15 nmol was optimal for complete Jagged 1 knockdown after 24 h (Fig 
4.22 C).  However, after 48 h, the expression of Jagged 1 had returned to normal 
expression on mMSC (Fig 4.22 D).  To identify if Jagged 1 is the ligand involved in 
mMSC modulation of DC maturation or inhibition of antigen presentation, Jagged 1 
expression would require complete knock down for a minimum of 48 h for coculture 
experiments.  These data found that both the neutralisation and silencing of Jagged 1 
expression by mMSC were insufficient tools for identifying the ligand as a specific 
contact candidate.  In order to investigate a role for Jagged 1 on mMSC as a possible 
contact candidate, a more specific knock down technique would need to be 
employed.  
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Fig 4.22 Neutralising Jagged 1 in coculture studies did not affect DC 
maturation.  DC were matured with LPS in the presence or absence of mMSC for 
48 h. Murine Jagged 1 was neutralised using an anti-mouse Jagged 1 antibody or 
corresponding control (8 µg/ml or 5 µg/ml).  The expression of DC maturation 
markers (A) MHC class II and (B) CD86 were examined by flow cytometry after 48 
h.  Jagged 1 was not involved in mMSC: DC maturation.   siRNA in the presence of 
Lipofectamine 2000, a transfection reagent, were added to mMSC at 60% 
confluency in duplicate.  siRNA ranging from 15 nmol to 25 nmol were used for (C) 
24 or (D) 48 h, then  the expression of Jagged 1 was analysed by RT-PCR. (C) 
siRNA at 15 nmol  silenced  Jagged 1 expression for 24 h. After 48 h, (D) the 
expression of Jagged 1 had returned to that of MSC alone.  Housekeeper gene 
expression, (D) GAPDH, used as a positive control for cDNA synthesis. 
C 
D 
(154bp) 
(154bp) 
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4.17  SUMMARY 
The aims of the experiments described in this chapter were to identify the 
contact dependent signal required for MSC mediated immunosuppression.  In this 
Chapter, mMSC were found to suppress DC maturation and DC antigen 
presentation.  mMSC induced a semi-mature/tolerogenic DC.  This was shown when 
OVA pulsed DC cocultured in the presence of mMSC were unable to induce the 
proliferation of D011.10 CD4
+
 T cells. 
To identify possible contact signals between mMSC and DC, a number of 
possible candidates were analysed.  Siglecs are known to regulate the function of 
cells in both the innate and adaptive immune systems through glycan recognition 
(Crocker, 2007).  This encouraged the investigation of CD33-related Siglec 
expression by mMSC.  However, after CD33-related Siglecs were shown not to be 
expressed by mMSC.  Therefore, further investigation into Siglecs, as a contact 
signal between MSC and DC was discontinued. 
The B7 family of molecules provide signals that are critical for both 
stimulating and inhibiting T cell activation (McAdam, 1998).  The expression of 
specific B7 family receptors and ligands were analysed on mMSC and DC by qRT-
PCR.  mMSC did not express ICOSor PD-1 receptors or ligands.  While, DC 
expressed both ICOS and PD-1 receptors and ligands.  This suggested that the B7 
family of receptors were not involved in the cell contact between mMSC and DC. 
Previous work identified Notch signalling to be involved in DC maturation 
(Cheng, 2003).  Therefore, a role for the Notch signalling pathway in mMSC 
modulation of DC maturation and antigen presentation was investigated.  mMSC and 
DC expressed Notch receptors and ligands as analysed by qRT-PCR and flow 
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cytometry.  mMSC prevented the upregulation of maturation marker expression by 
DC, increasing the secretion of IL-10 and decreasing the production of IL-12p70.  
mMSC inhibited the presentation of antigen by DC, inducing a tolerogenic DC in 
vitro.  Using a γ-secretase inhibitor (GSI) to block Notch signalling, mMSC were no 
longer able to interfere with DC maturation, antigen presentation or the induction of 
a function tolerogenic DC.  These data highlighted a role for Notch signalling 
between mMSC and DC. 
Identifying a role for a specific Notch ligand was difficult, as there are only a 
limited number of neutralisation reagents available for Notch signalling.  An anti 
mouse Jagged 1 neutralising antibody was not adequate to deliver convincing data 
regarding the identity of the Notch ligand and although mMSC were successfully 
silenced for Jagged 1, knock down in expression was not durable.  By 48 h, the 
expression of Jagged 1 on mMSC had returned to normal.  A more permanent knock 
down of Jagged 1 on MSC is required.  Taken together, these data showed that 
mMSC induce tolerogenic DC and provided evidence for a role of Notch signalling 
in the contact dependent component of MSC mediated immune modulation of DC 
function.   
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CHAPTER 5 
DEVELOPMENT OF A HUMANISED MOUSE MODEL OF ACUTE 
GRAFT VERSUS HOST DISEASE 
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5.1   INTRODUCTION 
The ability of MSC to suppress immune responses in vitro and some of the 
associated mechanisms through which this occurs, were identified in Chapters 3 and 
4.   However, the relevance of MSC immune modulation requires an examination of 
in vivo efficacy.  Furthermore, the in vivo efficacy of MSC therapy needs 
demonstration in systems appropriate and relevant to human disease.  Allogeneic 
HSC transplantation (HSCT) is the therapy of choice for high-risk haematological 
malignant and certain non-malignant or autoimmune disorders (Chapter 1.8.1).  The 
major confounding complication following HSCT is the development of GvHD 
The rationale for the use of MSC as a cell-based therapy for aGvHD is based 
on the poor success rates with steroid therapy and observations that MSC have 
immunosuppressive qualities (Le Blanc, 2004; Polchert, 2008; English, 2010).  In 
2004, Le Blanc et al. described the successful treatment of a patient with steroid 
resistant grade IV aGvHD using allogeneic MSC (Le Blanc, 2004).  However, the 
mechanism by which MSC therapy was beneficial was unclear.  More recently, 
Osiris Therapeutics reported that Prochymal (an MSC like product) was successful 
in treating 76% of patients with steroid refractory liver GvHD in a phase III trial; 
however, no beneficial effects were seen for the topical manifestations of GvHD and 
overall the therapy did not achieve the efficacy endpoints required (Martin, 2010).  
These data show that next generation modified MSC may be a future therapy, but 
also highlight that there is little understanding of how MSC mediate their beneficial 
effects in a clinical setting.   The development of more appropriate animal models to 
understand how MSC modulate GvHD would contribute greatly in developing novel 
MSC and second generation MSC based therapies, which would allow questions of 
dose and timing to be resolved and even allow standardisation of human products. 
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The objectives of this chapter were: a) to establish a consistent and 
reproducible humanised mouse model of aGvHD and b) to determine if human MSC 
therapy could alleviate or prevent disease progression in this model.  The strategy 
adopted was to use a xenogeneic human in mouse model, where human PBMC were 
delivered to immunodeficient mice to provoke aGvHD, combined with the use of 
human MSC as a therapy.  These objectives were broken down into a number of 
specific approaches:   
1) Optimisation of a humanised mouse model to provide a consistent aGvHD 
like disease.  
2) Determination if allogeneic human MSC were effective as a therapy for 
aGvHD treatment/prevention.  This included study of the timing of MSC treatment 
for a beneficial effect.   
3) An in vitro and in vivo examination of the “licensing” effect found by our 
group and Polchert et al., whereby MSC “licensed” with IFNγ prior to administration 
proved to be more beneficial as a therapy (Ryan, 2007; Polchert, 2008). 
5.2  DEVELOPMENT OF A HUMANISED MOUSE MODEL OF ACUTE GRAFT 
VERSUS HOST DISEASE  
Humanised mice are promising models in which to study human 
hematopoiesis and immunity.  Recently, new murine models suitable for HSC 
engraftment have been developed (Chapter 1.11).  Among the more promising are 
the so-called humanised models that include the NOD-Scid IL2 receptor gamma null 
mice (NOD-Scid IL2rγnull) (NSG) created by Pearson et al. (Pearson, 2008).  One 
benefit of the NSG mouse is that human PBMC delivered by intravenous injection 
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(i.v.) allows for the study of human immune function, as the transferred lymphocytes 
are functionally mature and go directly into circulation (Pearson, 2008).   
Using the protocol created by Pearson et al. as a guideline and starting point, 
a humanised mouse model of aGvHD was developed (Fig 5.1).  After conditioning 
by low dose total body irradiation of 2.4 Gray (Gy), 2 x 10
7
 human PBMC were 
administered via the tail vein and the development of aGVHD examined.  As 
suggested by Pearson et al. and the recommendation of the local ethics committee, 
the development of aGvHD was defined as total body weight loss greater than 15% 
of original starting weight with a series of clinical manifestations including posture 
(hunching), reduced activity, fur texture (ruffling) and diarrhoea.  These parameters 
were amalgamated into a pathological score (Chapter 2.11.2) and mice that scored 
2.0 for each parameter mentioned above (a cumulative score of 8.0) or had an excess 
of 15% weight loss were considered to have severe aGvHD and were sacrificed 
humanely.   
Optimisation studies were carried out using small numbers of NSG mice.  
Whilst this was far from ideal, it was dictated by small litter sizes and was necessary 
to conserve valuable mice for more informative studies.  Preliminary experiments 
using the above protocol found that NSG mice (n=3) that received human PBMC (2 
x 10
7
) all developed aGvHD like symptoms, including >15% weight loss (Fig 5.2 
A), hunched posture, reduced activity and ruffled fur (Fig 5.2 C).  NSG mice that 
received PBS (vehicle control) displayed no aGvHD symptoms and remained 
healthy (Fig 5.2).  However, further preliminary studies found that the development 
of pathology was inconsistent at this PBMC dose.  This inconsistency was evident 
when comparing data from repeat experiments (Fig 5.2 & Fig 5.3).  In the latter 
studies, PBMC administration did not lead to aGVHD development, as NSG mice 
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(n=3) that received PBMC had no significant weight loss (Fig 5.3 A), developed 
little or no signs of aGvHD (Fig 5.3 C), with the majority of mice surviving for more 
than 28 days (Fig 5.3 B).  These inconsistencies suggested that further optimisation 
was required and that the model described by Pearson et al. would require 
refinement.  
 
 
Fig 5.1 Development of a humanised mouse model of acute graft versus host 
disease.  NOD-Scid IL2rγnull (NSG) mice were irradiated receiving 2.4 Gy, after 4 h, 
freshly isolated PBMC (2 x 10
7/mouse) were administered intravenously in 200 μl 
(i.v.) via the tail vein.  In later experiments, hMSC were given i.v. on day 0, 7 or 14, 
with prestimulated hMSC given i.v. on day 0.  aGvHD development was monitored 
daily by recording weight loss, fur texture, posture, activity and diarrhoea.  
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Fig 5.2 aGvHD development in a humanised mouse model.  Human PBMC at 2 x 
10
7
 were given i.v. via the tail vein to low dose irradiated NSG mice.  aGvHD 
development measured daily by  (A) weight loss, (B) Survival or (C) Pathological 
Score (hunched posture, ruffled fur, reduced activity or diarrhoea).  aGvHD 
development occurred between day 10 and 15 (n=3). 
A 
B 
C 
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Fig 5.3 aGvHD development was not consistent between experiments.  Human 
PBMC at 2 x 10
7
 were given i.v. via the tail vein of low dose irradiated NSG mice.  
aGvHD development, measured by (A) weight loss (B) Survival or (C) Pathological 
Score (including hunched posture, ruffled fur, reduced activity and diarrhoea) were 
measured daily.  However, PBMC administration at 2 x 10
7
 per mouse  did not 
consistently lead to  aGvHD development between day 10 and 15, as after 20 days 
(B) 66% of mice had survived (n=3).   
A 
B 
C 
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5.3  HUMAN PBMC READILY ENGRAFT IN NOD-SCID IL2RγNULL MICE 
 To further understand the model, it was important to determine if freshly 
isolated human PBMC could engraft in NSG mice.  Using the protocol described in 
section 5.2 and in section 2.11.1, PBMC (2 x 10
7
/mouse) were administered to low 
dose irradiated mice, and at day 12 NSG
 
mice were sacrificed and spleens were 
harvested.  Splenocytes were examined for the expression of mouse and human CD4, 
CD8 or CD45 by flow cytometry.  As NSG
 
mice lack mature lymphocytes, it was 
not surprising that splenocytes isolated from NSG mice that received PBS did not 
possess detectable cells that expressed any mouse or human T cell markers (Fig 5.4 
A & B respectively).  This indicated that the NSG
 mouse model was not “leaky” 
with rare occurrence of murine lymphocytes and that human reagents did not cross 
react with non-target mouse cells.   Following human PBMC transfusion, cells 
expressing human CD4, CD8 or CD45 were detected (Fig 5.4 C).  The key finding 
of this experiment was that human cells engrafted in the model and were not 
eliminated.  Human PBMC remained detectable for at least 12 days post transfusion, 
a period when aGvHD pathology was developing. 
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Fig 5.4 Human PBMC engraftment in NOD-Scid IL2rγnull mice.  Using flow 
cytometry, NSG mice that received PBS or human PBMC were examined for murine 
and human T cell markers on day 12 post transfusion.  Murine CD4
+
, CD8
+
 or 
CD45
+
 cells were not detected in the spleen of PBS or PBMC treated mice.  Human 
CD4
+
, CD8
+ 
and CD45
+
 cells were detected among the splenocytes of NSG mice
 
that 
received human PBMC.  Data are representative of three spleens per treat group.  
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5.4  THE  DOSE OF PBMC IS CRITICAL FOR CONSISTENT AGVHD 
DEVELOPMENT 
Pearson et al. suggested 2 x 10
7
 PBMC were required for consistent aGvHD 
development in a humanised mouse model (Pearson, 2008).  However, using the 
above protocol (Fig 5.1), PBMC at 2 x 10
7
 per mouse yielded inconsistent aGvHD 
development (Fig. 5.2 & 5.3).  Therefore, the number of PBMC required for 
consistent development of aGvHD was examined.  PBMC isolated from buffy coat 
preparations (Chapter 2.3.6) were administered i.v. at varying doses per mouse (Fig 
5.5 & 5.6).  PBMC (2 x 10
5
, 2 x 10
6
, 2 x 10
7
, 3 x 10
7
 or 4 x 10
7
 per mouse) were 
administered following low dose total body irradiation of 2.4 Gy.  The percentage 
weight loss (Fig 5.5 A & 5.6 A), percentage survival (Fig 5.5 B & 5.6 B) and 
pathological parameters (Fig 5.5 C & 5.6 C) were recorded daily.  PBMC at 2 x 10
7
 
per mouse induced aGvHD development in 40% of mice by day 15 (n=5), with 60% 
of mice surviving for more than 30 days (Fig 5.5 B).  PBMC administered at 2 x 10
5
 
or 2 x 10
6 
(n=5) did not induce aGvHD development, with 100% mice surviving for 
more than 30 days (Fig 5.5 B). This suggested that, although Pearson et al. 
recommended 2 x 10
7
 PBMC for aGvHD development in this model, a higher dose 
of PBMC was required for consistent aGvHD pathology.  Lower doses of PBMC 
were not successful in inducing aGvHD.  
Upon increasing the dose of PBMC per mouse, a more consistent outcome 
was observed (Fig 5.6).  PBMC given i.v. at 2 or 3 x 10
7
 per mouse (n=3) induced 
aGvHD by day 15 (Fig 5.6).  Interestingly, only 2 of 3 mice given PBMC at 4 x 10
7
 
developed aGvHD by day 15 (n=3).  This was difficult to explain and no 
experimental observation was noted indicating a reason.  It may be that the sample 
size was too low; however, it may be that at high doses, physiological effects of 
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large cell numbers may lead to deletion or PBMC apoptosis.  Alternatively, PBMC 
cell clumping may impair the ability of PBMC to function in vivo.   It should be 
noted that in these dose-ranging studies, small numbers of mice were used without 
repetition.  This limitation was to preserve the numbers of valuable experimental 
animals and these studies were not used to test a hypothesis but rather to optimise a 
protocol.  
The above data indicated the need for a higher dose of PBMC for more 
consistent aGvHD development in this model.  However, protocols with more 
consistency were still required as some repeat experiments using 3 x 10
7
 PBMC per 
mouse did not result in aGvHD development or resulted in aGvHD development by 
day 10, which was too severe to treat using MSC as a cell therapy (data not shown).  
Differences in PBMC delivery rate, source, T-cell dose and initial mouse weight 
were unavoidable in our experimental set up.  Some of these differences were 
potentially involved in the development of aGvHD.  Therefore, attempts were made 
to limit variation in set up and in further studies PBMC were isolated freshly from 
whole blood sampled on the day of administration and the source of PBMC were 
confined to a panel of four selected healthy donors.   
The optimal dose of PBMC required for aGvHD pathology was now 
determined by taking into account the initial starting weight of NSG mice.  Using the 
initial starting weight and the number of PBMC administered, the amount of freshly 
isolated PBMC required for aGvHD pathology was calculated per gram of mouse 
body weight.  By reanalysing earlier data, it was calculated that 6.3 x 10
5
 PBMC g
-1
 
(23 g mouse) were required for aGvHD development by day 12-15 post i.v. 
injection.  This protocol was found to be reproducible and consistent in additional 
experiments, as all NSG
 
mice (n=5) that were given 6.3 x 10
5
 PBMC g
-1
 developed 
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aGvHD had more than 15% weight loss, displayed pathological symptoms of 
aGvHD and were sacrificed by day 14 (Fig 5.7).  This protocol was therefore 
adopted as the optimised aGvHD model for subsequent studies.   
5.5  INITIAL MSC EFFICACY STUDIES AGAINST AGVHD IN A HUMANISED 
MOUSE MODEL 
Human MSC (hMSC) used as a therapy were characterised as described in 
chapter 3, section 3.2 to 3.5.  hMSC expressed typical surface markers, MHC class I, 
Sca-1 and CD90, retained tri-lineage differentiation capacity into osteocytes, 
adipocytes and chondrocytes and were capable of suppressing both allogeneic and 
mitogen driven proliferation in vitro.  Prior to optimisation of the humanised mouse 
aGvHD model, initial studies were performed with hMSC as a therapy when given 
on day 7.  In this case, PBMC at 2 x 10
7
 and varying doses of hMSC at 2 x 10
6
, 0.4 x 
10
6 
or 0.08 x 10
6
 were given per mouse.  The percentage weight loss, survival and 
aGvHD pathological scoring are represented in Fig 5.8.  In some instances, hMSC 
appeared to influence aGvHD development, as NSG mice that received hMSC (2 x 
10
6
, 0.4 x 10
6
) as a therapy on day 7 developed the signs of aGvHD, weight loss, 
ruffled fur, reduced activity and hunched posture (Fig 5.8 A & C).  However, NSG 
mice that received PBMC did not develop any significant signs of aGvHD and all 
mice survived (Fig 5.8 A, B & C).  As the humanised model was highly variable at 
this point, no firm conclusions were made, but it did inform the choice in 
determining the exact number of PBMC (6.3 x 10
5
 g
-1
) and hMSC (4.4 x 10
4
 g
-1
) per 
gram of body weight in later studies. 
Following the optimisation of the humanised model (Fig 5.7), hMSC as a cell 
therapy was examined again.  However, previous work from our lab (Kavanagh, 
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2011) and other groups (Li, 2008) were taken into consideration when deciding on a 
dose for hMSC treatment.  We found that hMSC therapy of between 0.5 x 10
6
 and 2 
x 10
6
 cells per mouse proved beneficial in reducing pathology in many mouse 
inflammatory models, including aGvHD and allergen driven asthma (Li, 2008; 
Kavanagh, 2011).  Therefore, hMSC given at 1 x 10
6
 cells per mouse (23g mouse) or 
more precisely the equivalent of 4.4 x 10
4
 cells per gram (as calculated in section 
5.4) on day 7 were used here.  hMSC therapy was found to have a beneficial 
influence on aGvHD development, as by day 12 NSG mice that received PBMC 
alone developed aGvHD, while NSG mice treated with hMSC showed little or no 
signs of aGvHD (Fig 5.9).  This hMSC dose was therefore selected for all future 
studies.  
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Fig 5.5 Optimisation of PBMC dose-initial studies.  NSG mice received 2.4 Gy 
irradiation.  After 4 h, PBMC at 2 x 10
7
, 2 x 10
6
 or 2 x 10
5
/mouse were injected i.v. 
into the tail vein. Mice were monitored daily for the development of aGvHD.  (A) 
Percentage weight loss (B) percentage survival and (C) pathological signs of aGvHD 
development were recorded.  PBMC at 2 x 10
7
 per mouse did not induce consistent 
aGvHD development (n = 5 mice per group).    
 
A 
B 
C 
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Fig 5.6 Optimisation of PBMC dose-follow on studies.  NSG mice received 2.4 
Gy irradiation.  After 4 h, PBMC at 2 x 10
7
, 3 x 10
7
 or 4 x 10
7
/mouse were i.v. 
injected into the tail vein.  Mice were monitored daily for the development of 
aGvHD.  (A) Percentage weight loss, (B) survival and (C) pathological signs of 
aGvHD development were recorded.  3 x 10
7
 and 2 x 10
7
 PBMC/mouse induced 
aGvHD development in 100% of mice by day 12 and 15 respectively (n = 3 mice per 
group).    
 
A 
B 
C 
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Fig 5.7 Optimisation of PBMC dose-optimised model.  NSG mice received 2.4 Gy 
gamma irradiation.  After 4 h, PBMC at 6.3 x 10
5
 g
-1
 were i.v. injected into the tail 
vein. NSG mice were monitored daily for the development of aGvHD.  aGvHD 
development indicative of (A) >15% weight loss, recorded by day 14. (B) 
Percentage survival and (C) pathological signs of aGvHD development reached a 
cumulative score of eight by day 14.  6.3 x 10
5
 g
-1
 PBMC induced consistent aGvHD 
development (100%) by day 14. (n = 5 mice per group).    
  
A 
B 
C 
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Fig 5.8 Optimisation of MSC dose response-1.  NSG mice received 2.4 Gy 
irradiation.  After 4 h, PBMC at 2 x 10
7
/mouse were i.v. injected into the tail vein. 
hMSC were given on day 7 at varying concentrations, 2 x 10
6
, 0.4 x 10
6
 or 0.08 x 
10
6
/mouse. (A) Weight loss, (B) survival and (C) aGvHD pathological scores were 
monitored daily for signs of aGvHD development. hMSC at 2 x 10
6
 or 0.4 x 10
6
 
seemed to contribute to aGvHD development. However, PBMC at 2 x 10
7
 proved 
inconsistent for aGvHD pathology (n = 3 mice per group). 
  
A 
B 
C 
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Fig 5.9 Optimisation of MSC dose response-2.  NSG mice received 2.4 Gy 
irradiation.  After 4 h, PBMC at 6.3 x 10
5
 g
-1
 were i.v. injected into the tail vein.  
hMSC were given on day 7 at 4.4 x 10
4 
g
-1
. (A) Percentage weight loss, (B) 
percentage survival and (C) aGvHD pathological scores were monitored daily for 
signs of aGvHD development.  PBMC at 6.3 x 10
5
 g
-1
 induced consistent signs of 
aGvHD (A & C) by day 12.  hMSC therapy dampened the signs of aGvHD 
pathology and prolonged the survival of NSG mice when compared to PBMC alone 
mice on day 12 (n = 2 mice per group). 
A 
B 
C 
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5.6  THE EFFICACY OF MSC THERAPY IS DEPENDENT ON TIME OF 
ADMINISTRATION 
The time of administration of cell therapy may be a critical parameter in 
determining efficacy and clinical application.  This was amenable to study in our 
system.  Using the newly optimised protocol for aGvHD development in a 
humanised mouse model (Fig 5.7), NSG mice were given low dose total body 
irradiation of 2.4 Gy and freshly isolated PBMC (6.3 x 10
5
 g
-1
) from healthy donors.  
hMSC (4.4 x 10
4
 g
-1
) were given as a therapy on day 0, 7 or 14 (Fig 5.10).  
Irradiation alone did not induce pathology or affect the wellbeing of the mice, as 
NSG mice that received PBS alone did not develop aGvHD and had no observed 
effect from irradiation.  However, mice that were irradiated and received PBMC (6.3 
x 10
5
 g
-1
) on day 0, developed significant weight loss, had signs of ruffled fur, 
reduced activity and hunched posture leading to 100% of mice developing aGvHD 
by day 15 (Fig 5.10).  hMSC therapy delivered concurrent with PBMC had no 
beneficial effect, as 66% of mice had significant weight loss and developed 
pathological signs of aGvHD (n=3) (Fig 5.10 C) by day 25 and were sacrificed.  
However, hMSC given as a treatment on day 7 or day 14, significantly prolonged the 
survival of mice (p<0.0001) (100%) for more than 28 days and mice did not develop 
any significant pathological signs of aGvHD, when compared to hMSC treatment at 
day 0 (Fig 5.10 B & C).  These data suggested that the timing of hMSC therapy was 
important for the successful treatment of aGvHD, with hMSC therapy on day 7 post 
PBMC administration proving to be beneficial.  However, due to limited numbers of 
mice and to preserve animals for further studies on the protective mechanism 
involved, the numbers of mice used here for this study were limited (n=3).   
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Fig 5.10 MSC cell therapy is time dependent.  NSG mice received 2.4 Gy 
irradiation, 4 h later, PBMC at 6.3 x 10
5 
g
-1
 were i.v. injected into the tail vein.  
hMSC were administered at 4.4 x 10
4 
g
-1
 on day 0, concurrent with PBMC or on day 
7 or 14 after PBMC treatment.  (A) Percentage weight loss (B) Survival and (C) 
aGvHD pathological symptoms were recorded daily.  hMSC administered on day 0 
had no significant beneficial effect in preventing (A) weight loss, (B) prolonging 
survival or (C) reducing aGvHD-like symptoms. However, hMSC administered on 
day 7 or 14 significantly (p<0.0001) increased aGvHD related (B) survival and (C) 
reduced aGvHD like pathological symptoms (n = 3 mice per group). 
A 
B 
C 
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5.7  HUMAN MSC PROLONGED THE SURVIVAL OF NSG MICE WITH AGVHD 
The series of experiments above meant that it was possible to perform a 
larger, more informative experiment to determine if hMSC therapy had a beneficial 
effect on aGvHD development.  Freshly isolated PBMC from healthy donors were 
administered i.v. on day 0 at 6.3 x 10
5
g
-1
 to NSG mice after low dose body 
irradiation.  On day 7, hMSC (4.4 x 10
4
 g
-1
) were given i.v. as a cell therapy.  NSG 
mice that received irradiation and PBS alone (n=5) did not develop any signs of 
aGvHD, such as  excessive weight loss, hunched posture, reduced activity or ruffled 
fur (Fig 5.11).  NSG mice that received PBMC on day 0 (n=5), all consistently 
developed aGvHD (100%) by day 12, indicated by >15% weight loss and 
development of aGvHD pathology (Fig 5.11 A & C).  hMSC treatment on day 7, 
significantly prolonged the survival (p<0.0008) of NSG
 
mice with aGvHD with 20% 
of mice surviving for more than 30 days (Fig 5.11 B).  These data demonstrated that 
the timing of hMSC administration was important in the use of hMSC as a therapy in 
aGvHD and that hMSC could significantly reduce the development of aGvHD in this 
model.  
5.8  IFNγ STIMULATION ENHANCED THE IMMUNOSUPPRESSIVE CAPACITY OF 
MSC IN  VITRO, BUT TNFα STIMULATION  DID NOT 
For clinical use, hMSC must remain immunosuppressive in an inflammatory 
environment.  Therefore, the effects of IFNγ and TNFα stimulation on the expression 
of immunosuppressive properties by hMSC were studied to improve understanding 
of how hMSC work in vivo in the treatment of aGvHD.  IFNγ and TNFα are two key 
proinflammatory cytokines involved in aGvHD pathology.  Ryan et al. found that 
IFNγ stimulation on MSC promoted the immunosuppressive capacity of hMSC 
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(Ryan, 2007).  While Polchert et al. showed that IFNγ stimulated mMSC were five-
fold more beneficial in treating aGvHD in a mouse model, compared to unstimulated 
mMSC (Polchert, 2008).  TNFα on the other hand, can have multiple effects on MSC 
growth factor secretion, proliferation and survival depending on which TNF receptor 
is activated (Miettinen, 2011).  hMSC were stimulated in vitro with IFNγ or TNFα 
for 48 h and the expression of MHC class I and II were analysed by flow cytometry.  
Unstimulated hMSC expressed MHC class I and not MHC class II (Fig 5.12 A).  
However, IFNγ (MSCγ) induced the expression of MHC class II on hMSC (Fig 
5.12), whereas, TNFα (MSCα) stimulation did not (Fig 5.12).   
The ability of stimulated hMSC to inhibit the proliferation of mitogen driven 
lymphocytes was analysed.  Here, hMSC or hMSC pre-stimulated with IFNγ or 
TNFα for 48 h, were placed in a proliferation assay in the presence of donor 
lymphocytes stimulated using the mitogen ConA.  As shown in chapter 3.5, hMSC 
significantly inhibited the proliferation of allogeneic lymphocytes in vitro.  Pre-
stimulation of hMSC with IFNγ or TNFα, did not interfere with the ability of hMSC 
to suppress lymphocyte proliferation (Fig 5.12 B).  These data suggested that in the 
presence of inflammatory cytokines, hMSC were still capable of 
immunosuppression.  These findings were similar to that found by Polchert et al., 
therefore, the in vivo influence of stimulation by IFNγ on MSC was examined 
further. 
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Fig 5.11  MSC cell therapy on day 7 prolonged the survival of NOD Scid IL-
2rγnull mice with aGvHD.  NSG mice received 2.4 Gy irradiation.  After 4 h, PBMC 
at 6.3 x 10
5
g
-1
 were i.v. injected into the tail vein.  hMSC were administered at 4.4 x 
10
4
 g
-1
 on day 7 post PBMC transfusion.  (A) Percentage weight loss, (B) percentage 
survival and (C) pathological signs of aGvHD were recorded daily.  hMSC 
significantly prolonged the survival (p<0.0008) of NSG mice with aGvHD, slowing 
down the rate of weight loss and reducing the clinical signs of aGvHD development 
(n=5 mice per group).  Statistical analysis was carried out using Kaplan Meier 
survival curves. 
A 
B 
C 
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Fig 5.12 IFNγ and TNFα stimulation did not interfere with the 
immunosuppressive capacity of hMSC.  (A) IFNγ stimulation for 48 h upregulated 
the expression of MSC class II on hMSC, whereas TNFα licensing had no effect on 
MHC class II expression on hMSC as shown by flow cytometry.  (B) hMSC, IFNγ 
(MSCγ) or TNFα (MSCα) stimulated hMSC were cocultured with PBMC in a 
mitogen driven proliferation assay.  IFNγ or TNFα stimulation did not ablate hMSC 
inhibition of proliferation (n = 3).  Statistical analysis was carried out using the 
students paired t test. 
A 
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5.9  IFNγ STIMULATED MSC PROLONGED THE SURVIVAL OF NOD SCID IL-
2RγNULL MICE WITH AGVHD WHEN COMPARED TO UNSTIMULATED MSC  
 The data above suggested a mechanism where hMSC stimulated with IFN  
prior to administration, become activated and somehow are better able to suppress 
aGvHD.  hMSC stimulated by IFNγ showed an increased ability to inhibit 
proliferation in vitro (Fig 5.11).  These data suggested the investigation of IFNγ 
prestimulated hMSC in the treatment of aGvHD in the optimised humanised NSG 
murine model.  The approach here was to prestimulate hMSC with IFNγ (MSCγ) for 
48 h prior to their administration to NSG mice on day 0 in conjunction with PBMC.  
As usual, all mice were irradiated with 2.4 Gy on day 0 and allowed to rest for 4 h 
before PBMC infusion.  Prestimulated MSC (MSCγ) were given concurrent with 
PBMC on day 0.  The symptoms of aGvHD developed by 15, when 100% of mice 
receiving PBMC alone showed signs of aGvHD (n=5) (Fig 5.13).  Treatment with 
hMSCγ on day 0 significantly prolonged survival (p<0.0057) of mice when 
compared to mice that had not received any hMSC therapy.   
These data showed that hMSC prestimulated with IFNγ administered 
concurrent with PBMC had a beneficial effect on the development of aGvHD.    
Comparing data from Fig 5.13 with Fig. 5.11, hMSCγ and MSC were equally 
successful in dampening aGvHD pathology.  These data were similar to the findings 
of Polchert et al., whereby murine MSCγ therapy was found to prevent aGvHD 
development.  However in the model herein, prestimulated hMSC as a therapy 
prolonged the survival of mice with aGvHD, but did not prevent aGvHD 
development completely, which was a finding closer to the Osiris Therapeutics phase 
III clinical trial (Martin, 2010).   
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Fig 5.13 Prestimulated MSC significantly prolonged the survival of NOD Scid 
IL-2rγnull mice with aGvHD.  NSG mice received 2.4 Gy irradiation.  After 4 h, 
PBMC at 6.3 x 10
5
 g
-1
 were i.v. injected into the tail.  IFN  stimulated MSC (MSCγ) 
were administered at 4.4 x 10
4
 g
-1
 in conjunction with PBMC on day 0.  (A) 
Percentage weight loss, (B) percentage survival and (C) pathology of aGvHD 
development were recorded daily. MSCγ as a therapy significantly (p<0.0057) 
prolonged the (B) survival of NSG mice with aGvHD, (C) reducing aGvHD 
symptoms (n = 5 mice per group).  Statistical analysis was carried out using Kaplan 
Meier survival curves. 
A 
B 
C 
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5.10  HUMAN MSC THERAPY SIGNIFICANTLY REDUCED AGVHD PATHOLOGY  
The main target organs involved in aGvHD pathology include the lung, liver 
and gut.  Joo et al. found that MSC improved the histological aGvHD score of target 
organs after transplantation (Joo, 2010).  Therefore, in this study histological 
analysis was carried out on aGvHD target organs after the transplantation of hMSC 
as a cell therapy.   As in the previous experiment, NSG mice were irradiated and 
received PBMC (6.3 x 10
5
 g
-1
) on day 0.  Unstimulated hMSC (4.4 x 10
4 
g
-1
) were 
given on day 7, whereas IFNγ stimulated hMSC were given in conjunction with 
PBMC on day 0.  On the day of significant aGvHD pathology (approximately day 
12), the lung, liver and gut were harvested and placed in formalin for histological 
analysis.  
Tissue sections were stained by H&E and the histological aGvHD score was 
evaluated for each treatment group according to the criteria described in section 
2.12.2 and 2.12.3 (Hill, 1997; Grass, 1999; Polchert, 2008).  As expected, the livers 
of NSG mice that received PBS as a control, appeared normal, with no cell 
infiltration, tissue fibrosis or endothelialitis (Fig 5.14 A) and the histological scoring 
presented as normal (score of 0) (Fig 5.14 B).  After aGvHD development in mice 
receiving PBMC alone, there was a significant increase in mononuclear cell 
infiltration and endothelialitis (p<0.0001), especially around the hepatic ducts of the 
liver, when compared to control PBS mice (Fig 5.14 A & B).  hMSC treatment on 
day 7 post PBMC transfusion significantly reduced liver pathology (p<0.0086), with 
a decrease in cell infiltration and reduction in the number of hepatic ducts displaying 
endothelialitis (Fig 5.14 A & B) on day 12.  Therapy with IFNγ stimulated hMSC on 
day 0, significantly reduced aGvHD pathology of the liver also (p<0.0163), with a 
decrease in cell infiltration and endothelialitis around hepatic ducts (Fig 5.13 A & 
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B).  There was no significant difference in pathology between the hMSC and hMSCγ 
treated groups (Fig 5.14 B), as both therapies worked equally as well.  
Histological analysis of tissue sections taken from the small intestine of the 
gut found that PBS treated mice appeared normal, with no sloughing of villi or no 
accumulation of infiltrating cells into the laminar propria.  However, NSG mice that 
received PBMC on day 0 had significant blunting of villi and cell infiltration in the 
lamina propria of the gut when compared to NSG mice that received the PBS control 
(Fig 5.15 A & B, p<0.0001).  NSG mice that received IFNγ prestimulated hMSC 
(p<0.0142) or unstimulated hMSC (p<0.0249) had significantly less tissue damage 
to villi and a decrease in mononuclear cell infiltration (Fig 5.15 A & B).  As seen in 
the liver, there was no significant difference between hMSC treated groups, as both 
groups equally dampened the pathology of aGvHD in the gut (Fig 5.15 B).  
Histological analysis of PBS treated NSG mouse lungs appeared normal, comprised 
of regular air spaces and little or no mononuclear cell infiltration (Fig 5.16 A).  
However, after PBMC delivery, significant pathology of the lung developed with 
extensive mononuclear cell infiltration into the lung alveolar spaces compared to the 
PBS control mice (Fig 5.16, p<0.0002).  Following treatment with unstimulated 
hMSC on day 7 or IFNγ prestimulated hMSC on day 0, the lung pathology of mice 
did not improve when compared to aGvHD mice that received PBMC on day 0 (Fig 
5.16 A).  MSC treatment did not reduce mononuclear cell infiltration into the lungs, 
which resulted in no change in aGvHD histological scoring in NSG mice with 
aGvHD (Fig 5.16 B).  These data suggested that while hMSC therapy significantly 
reduced the PBMC mediated damage of the liver and gut, it had no effect on mouse 
lung.   
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Fig 5.14 Human MSC therapy significantly reduced aGvHD pathology in the 
liver. NSG mice were given PBMC by i.v. injection on day 0. Mice were treated 
with unstimulated hMSC on day 7 and IFNγ prestimulated MSC day 0. Following 
aGvHD development on day 12, livers were harvested from each treatment group 
and tissue sections were analysed by (A) H&E staining. (B) A well defined aGvHD 
histological scoring system was used to determine the level of aGvHD development 
between the groups. (A) Mice that received PBMC on day 0 showed increased 
mononuclear infiltration (denoted with arrow and letter a) and increased 
endothelialitis around hepatic ducts (denoted with arrow and letter b). Both 
unstimulated MSC (p<0.0086) and IFNγ prestimulated MSC (p<0.0163) 
significantly improved aGvHD pathology by (A) reducing the collection of 
mononuclear cells in the hepatic tissue (denoted with arrow and letter a) and 
reducing the number of vessels displaying endothelialitis (denoted with arrow and 
letter b). MSC therapy resulted in a reduction in the (B) aGvHD histological score of 
mice with aGvHD (n = 4 per group).  Statistical analysis was carried out using the 
students paired t test. 
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Fig 5.15 Human MSC therapy significantly reduced aGvHD pathology in the 
gut. NSG mice were given PBMC by i.v. injection on day 0. Mice were treated with 
unstimulated MSC on day 7 or IFNγ prestimulated MSC day 0. Following aGvHD 
development on day 12, sections of the gut were harvested from each treatment 
group and tissue sections were analysed by (A) H&E staining. (B) A well defined 
aGvHD histological scoring system was used to determine the level of aGvHD 
development between the groups.  (A) Mice that received PBMC on day 0 showed 
signs of increased cell infiltration (denoted with arrow and letter a) and increased 
blunting of the villi (denoted with arrow and letter b), indicating a (B) sigificant 
increase in aGvHD pathology (p<0.0001). Both unstimulated MSC (p<0.0249) and 
IFNγ prestimulated MSC (p<0.0142) significantly improved aGvHD pathology by 
(A) reducing cell infiltration (denoted with arrow and letter a) and damage to 
villi/crypts in lamina propria (denoted with arrow and letter b) and (B) improving the 
aGvHD histological score of mice with aGvHD (n = 4 per group).  Statistical 
analysis was carried out using the students paired t test. 
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Fig 5.16 Human MSC therapy had no effect on aGvHD pathology in the lung. 
NSG mice were given PBMC by i.v. injection on day 0. Mice were treated with 
unstimulated hMSC on day 7 or prestimulated hMSC day 0. Following aGvHD 
development on day 12, lungs were harvested from each treatment group and tissue 
sections were analysed by (A) H&E staining. (B) A well-defined aGvHD 
histological scoring system was used to determine the level of aGvHD development 
between the groups. (A) Mice that received PBMC on day 0 displayed increased 
mononuclear infiltration into the alveolar spaces (denoted by arrow and letter a) 
leading to a (B) significant increase in aGvHD pathology (p<0.0002). (A) hMSC 
therapy did not improve aGvHD pathology as there was no reduction in cell 
infiltration (denoted by arrow and letter a) following MSC therapy.  (B) There was 
no improvement in aGvHD histological score of mice with aGvHD. (n = 4 per 
group).  Statistical analysis was carried out using the students paired t test. 
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5.11 IFNγ STIMULATED MSC SIGNIFICANTLY REDUCED TNF-α PRESENT IN 
THE SERUM OF NOD SCID IL-2RγNULL MICE WITH AGVHD 
 One of the key characteristics of aGvHD is the production of inflammatory 
cytokines such as IFNγ and TNFα (Ferrara, 2009).  In this study, the effect of hMSC 
cell therapy on the production of IFNγ and TNFα in a humanised model of aGvHD 
was analysed.  Using the optimised protocol for aGvHD development (Fig 5.11 & 
5.13), IFNγ prestimulated hMSC were given on day 0 concurrent with PBMC, while 
unstimulated hMSC were given on day 7 post PBMC injection.  On the day of 
aGvHD development, day 12, serum was taken from all NSG mice (n=6) and 
analysed for the presence of human TNFα and IFNγ by bead array.  
 As expected, NSG mice that received PBMC on day 0 had significantly more 
human TNFα  present in the serum after 12 days when compared to NSG mice that 
received PBS as a control (Fig 5.17 A, p<0.0027).  Following hMSC cell therapy, 
NSG mice had significantly less human TNFα present in the serum, as seen  after 
treatment with IFNγ prestimulated MSC (MSCγ) when compared to NSG mice 
given PBMC alone on day 0  (Fig 5.17 A, p<0.0197).  Unstimulated MSC given on 
day 7 had no significant effect on the presence of human TNFα in NSG mice on day 
12 (Fig 5.17 A).  The presence of human IFNγ in the serum of NSG mice with 
aGvHD following PBMC administration was significantly more than PBS control 
NSG mice when compared on day 12 post transfusion (Fig 5.17 B, p<0.05).  hMSC 
cell therapy had no significant effect on the presence of human IFNγ in the serum of 
NSG mice on day 12 (Fig 5.17 B).  The data herein suggested that hMSC cell 
therapy could suppress the production of inflammatory signals involved in the 
development of aGvHD, in particular TNFα. 
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Fig 5.17 MSC cell therapy reduced the production of human TNFα in the serum 
of NOD scid IL2rγnull mice with aGvHD.  NSG mice were given PBMC (6.3 x 105 
g
-1
) by i.v injection on day 0.  IFNγ prestimulated hMSC (4.4 x 104 g-1) were given 
on day 0 concurrent with PBMC.  Unstimulated hMSC (4.4 x 10
4
 g
-1
) were 
administered on day 7 post PBMC injection.  On day 12, the day of aGvHD 
pathology, serum was taken from NSG mice and analysed for the presence of (A) 
human TNFα and (B) human IFNγ by bead array.  IFNγ prestimulated MSC 
significantly reduced the production of (A) human TNFα (p<0.0197) in the serum of 
NSG mice with aGvHD.  hMSC therapy had no significant effect on (B) human 
IFNγ production (n=6).  Statistical analysis was carried out using the students paired 
t test. 
201 
 
5.12  SUMMARY 
The goals of this chapter were to 1) optimise a humanised mouse model of 
aGvHD, 2) determine if hMSC were effective as a therapy for aGvHD 
treatment/prevention and 3) test the hypothesis that MSC require prestimulation for 
their immunosuppressive abilities to prove beneficial in the setting of aGvHD 
pathology.  Pearson et al. designed a protocol for the development of a humanised 
mouse model of aGvHD in 2008, using the NOD Scid IL-2rγnull mouse (Pearson, 
2008).  Using this protocol as a guideline and starting point, a more optimised and 
consistent humanised model of aGvHD was designed in this chapter.   
Using an optimised and consistent aGvHD humanised mouse model, hMSC 
given as a therapy on day 7 post PBMC transplant proved beneficial in prolonging 
the survival of mice with aGvHD.  While IFNγ prestimulated hMSC significantly 
prolonged the survival of mice with a GvHD when administered concurrent with 
PBMC on day 0. Following histological analysis of target aGvHD organs, hMSC 
treatment reduced the pathology of aGvHD in NSG mice.  Both unstimulated and 
stimulated hMSC reduced aGvHD pathology of the liver and the gut.  However, in 
contrast, hMSC treatment had no significant effect in reducing aGvHD pathology in 
the lung.  Following treatment of NSG mice with IFNγ prestimulated MSC, the 
production of human TNFα was significantly reduced in the serum of NSG mice 
with aGvHD.  Taken together, these data demonstrated a beneficial effect of MSC 
therapy on aGvHD treatment in a humanised murine model.  The next step was to 
determine how MSC exerted their beneficial role in vivo.  Identifying the exact 
mechanisms used by MSC to induce such positive results in vivo would allow better 
design of therapies and clinical studies.  
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CHAPTER 6 
MECHANISMS INVOLVED IN MSC MODULATION OF ACUTE 
GRAFT VERSUS HOST DISEASE 
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6.1  INTRODUCTION 
The development of a humanised aGvHD model was described in Chapter 5 
based on the NOD-Scid IL2rγnull (NSG) mouse. This model provides a very powerful 
tool for discovering the therapeutic mechanisms exerted by hMSC in a realistic 
environment.  The key observation in Chapter 5 was that hMSC therapy prolonged 
the survival of NSG mice by delaying the onset of aGvHD.  This effect was 
enhanced when hMSC were pre-stimulated with IFNγ.   
In steroid resistant aGvHD, patients are refractory to treatment for the 
alleviation of symptoms and an alternative treatment modality is required.  In some 
studies, MSC therapy has a beneficial effect (Le Blanc, 2008; Kurtzberg, 2009) 
however, the exact mechanism of MSC action in these situations remains unclear (Le 
Blanc, 2004; Augello, 2007).  In this Chapter using the optimised humanised mouse 
model of aGvHD developed in Chapter 5, the beneficial mechanisms evoked by 
hMSC in vivo were investigated.   
The aim of the experimental work described herein was to identify possible 
mechanisms used by hMSC in prolonging the survival of mice with aGvHD.  Four 
possible mechanisms were considered.  These included the 1) induction of graft T 
cell apoptosis by hMSC; 2) induction of graft T cell anergy, as a form of peripheral 
tolerance in vivo, 3) induction of graft T reg cells, similar to those identified in vitro 
or 4) direct inhibition of donor T cell proliferation in vivo, which might involve the 
release of soluble factors by hMSC, such as prostaglandins.  These mechanisms were 
examined using a reductionist approach in the humanised model to determine a how 
hMSC are of benefit in aGvHD.    
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6.2  HMSC DID NOT INDUCE APOPTOSIS OF PBMC IN VITRO OR IN VIVO 
 One hypothesis for the beneficial effect seen in Chapter 5 could be stated as 
“hMSC induce apoptosis of donor PBMC” in the aGvHD NSG model.  There has 
been conflicting evidence for MSC induction of T cell apoptosis with Plumas et al. 
suggesting it occurs, whereas Zappia et al. put forward the opposite opinion (Plumas, 
2005; Zappia, 2005).  Therefore, the ability of MSC to induce apoptosis of T cells 
was investigated, both in vitro and in vivo. 
 First, using the hMSC/PBMC coculture model, the induction of PBMC 
apoptosis in vitro by hMSC was examined.  A known inducer of PBMC apoptosis, 
cisplatin (positive control), caused significant apoptosis of PBMC (Fig 6.1 A) as 
detected by flow cytometry for Annexin V/ Propidium iodide (PI) staining, 
indicating that apoptosis could be detected using this in vitro system.  Following this, 
PBMC were cocultured with or without hMSC for 24 h.  PBMC were pulled back 
from adherent hMSC and the number of apoptotic cells were measured using the 
flow cytometry method mentioned above.  hMSC did not induce apoptosis of PBMC 
(Fig 6.1 A), but rather hMSC appeared to significantly (p<0.0002) protect PBMC 
from apoptosis.  This result is in line with the known supportive role of MSC in 
lymphopoiesis (Chen, 2006).  These data suggested that hMSC were not involved in 
the induction of PBMC apoptosis in vitro.  Nevertheless, the capacity for hMSC to 
induce apoptosis was investigated in vivo.  As in vitro data were not supportive, and 
as NSG mice were an expensive and scarce resource, this was tested on a small 
scale.  If evidence of enhanced apoptosis was seen in vivo, a larger scale experiment 
would be justified and carried out.  However, if no evidence was found for hMSC 
apoptosis of donor PBMC, then this approach would not be pursued.   
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Prior to performing this work, it was necessary to validate that in vivo 
apoptosis could be detected ex vivo.  Therefore, BALB/c mice were lethally 
irradiated (12 Gy).  After 24 h, these mice were injected i.v. with a green fluorescent 
dye, FLIVO, which binds to activated caspases within apoptotic cells.  This 
technique has been used in other studies to detect apoptosis in vivo (Cursio, 2008).  
The FLIVO dye was allowed to circulate for 1 h, after which the lung, liver and 
spleen were harvested and the level of FLIVO staining was measured by flow 
cytometry (Fig 6.1 B).  Apoptotic cells were detected in the liver after lethal 
irradiation, but not found in the lung or spleen (Fig 6.1 B).  These data are in line 
with previous studies suggesting the liver is the main organ responsible for deletion 
of apoptotic T cells (Reviewed in Park et al., 2002) and showed that the in vivo 
detection of apoptotic cells was possible using this technique.   
To investigate whether hMSC therapy functioned through the induction of 
apoptosis of donor CD4
+
 T cells in vivo, the model above was adapted.  NSG mice 
were sub-lethally irradiated with 2.4 Gy, a conditioning dose as opposed to the 
positive control dose used above.  NSG mice received PBS or PBMC i.v after 4 h.  
Unstimulated hMSC were given on day 7 post PBMC injection, while IFNγ 
stimulated hMSC (MSCγ) were given concurrent with PBMC treatment on day 0 
(Fig 6.2 B & D).  Following the development of aGvHD pathology on day 12, the 
FLIVO reagent was administered i.v. and allowed to circulate for 1 h.  After 1 h, the 
lung (Fig 6.2 B) and liver (Fig 6.2 D) were harvested and analysed for FLIVO/CD4 
by two-colour flow cytometry.  No increase in apoptotic CD4
+
 T cells were detected 
in the lung or liver following the treatment of aGvHD with hMSC (Fig 6.2 B & D).  
These data suggested that hMSC did not induce apoptosis of CD4
+
 T cells in vivo 
and that this was unlikely to be the mechanism involved in the beneficial effect 
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mediated by hMSC in this model.  However, it is always difficult to validate a 
negative result and it might be argued that apoptotic cells were present at an earlier 
time point, before day 12.  This might be the case for MSC  delivered on day 0, but 
more difficult to envisage for hMSC delivered on day 7.  MSC would need to a) 
encounter sufficient PBMC to limit pathology, b) induce significant T cell apoptosis 
(again at a scale sufficient to limit pathology), c) for these apoptotic cells to be 
trapped in the liver (the site of lymphocyte deletion) and d) then be completely 
removed within five days.  Nevertheless, a small scale in vivo study was carried out.  
In this case, NSG mice were treated with PBS, PBMC or PBMC and MSCγ therapy 
on day 0.  FLIVO dye was administered i.v. 24 h later (Day 1) and allowed to 
circulate for 1 h, after which the lung and liver were harvested (Fig 6.2 A & C).  As 
expected, no apoptotic CD4
+
 T cells were detected in the lung (Fig 6.2 A) or liver 
(Fig 6.2 C) following hMSC therapy.  Taken together with the in vitro data and the 
previous in vivo study, these data indicated that the induction of apoptosis could not 
reasonably account for the beneficial effects seen in Chapter 5. 
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Fig 6.1 hMSC do not induce detectable apoptosis of PBMC in vitro.  (A) PBMC 
were cultured in the presence of cisplatin or hMSC for 24 h.  PBMC alone or with 
cisplatin at 250 µg/ml were cultured as controls.  The presence of hMSC 
significantly inhibited apoptosis of PBMC in vitro (p<0.0002).  The percentage of 
positive cells within the marked region are represented in the upper right quadrant.  
Data are representative of two studies.  (B) Female BALB/c mice were lethally 
irradiated with 12 Gy to induce apoptosis in vivo. After 24 h, FLIVO green dye (8 
µg/mouse) was given i.v. via the tail vein and allowed to circulate for 1 h. The lung, 
liver and spleens of mice were harvested and analysed for FLIVO staining by flow 
cytometry.  Apoptotic cells were detected in the liver of BALB/c mice after lethal 
irradiation, but not in the lung or spleen. Data are representative of three mice per 
sample group (n=3). The percentage of positive cells within the marked region and 
the mean fluorescence intensity (MFI) of those cells are represented in each 
histogram.   
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A  Lung Day 1 
 
B  Lung Day 12 
 
 
C Liver Day 1 
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D Liver Day 12 
 
 
Fig 6.2 hMSC did not induce detectable apoptosis in PBMC in vivo.  Irradiated 
NSG mice received PBS or PBMC (6.3 x 10
5
 g
-1) on day 0.  IFNγ stimulated hMSC 
(MSCγ) (4.4 x 104 g-1) were given on day 0 or unstimulated hMSC (4.4 x 104 g-1) 
were given on day 7.  On day 1 or 12, FLIVO green dye (8 μg/mouse) was injected 
i.v and left to circulate for 1 h.  The (A & B) lungs and (C & D) liver were harvested 
from each mouse and analysed for FLIVO staining and human CD4 PE.  hMSC cell 
therapy did not induce CD4 T cell apoptosis in vivo.  Data are representative of two 
mice per group (n=2).  
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6.3  HMSC DID NOT INDUCE T CELL ANERGY IN VITRO 
An alternative hypothesis for the beneficial effect seen in Chapter 5 could be 
formulated around the induction of T cell anergy by hMSC in the aGvHD NSG 
model.  Krampera et al. and Glennie et al. have found that murine MSC inhibit T 
cell proliferation, which appeared to be reversible (Krampera, 2003; Glennie, 2005).  
These data were similar to that shown by Zappia et al., whereby mMSC cocultured 
with T cells induced a state of anergy, which was partially reversible through the 
addition of IL-2 (Zappia, 2005).  Combined, these data suggested that MSC were 
capable of inducing T cell anergy. 
The ability of hMSC to induce T cell anergy in vitro was examined in this 
model.  To closely mimic in vivo circumstances, an in vitro two-step proliferation 
assay was designed.  Previous studies found that murine DC alone were insufficient 
for the stimulation of human CD4
+
 T cells in an xenogeneic setting in vitro.  These 
findings suggested that murine DC required an additional stimulus in order to 
activate the proliferation of human CD4
+
 T cells.  This led to the design of a two-
step proliferation assay.  Firstly, murine DC isolated from bone marrow of BALB/c 
mice were stimulated with polyIC and cocultured with human CD4
+
 T cells isolated 
from PBMC for 5 days.  To investigate the induction of human CD4
+
 T cell anergy 
by MSC, hMSC were added to some coculture treatment groups.  Following 5 days 
of coculture, the proliferation of human CD4
+
 T cells was analysed through the 
addition of [3H]-thymidine.  Human CD4
+
 T cells cultured with polyIC stimulated 
murine DC induced significant T cell proliferation (p<0.0001).  However, if hMSC 
were present in the coculture, the induction of T cell proliferation was significantly 
reduced (p<0.05) (Fig 6.3 A).  These data showed that hMSC were capable of 
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inhibiting T cell proliferation in a xenogeneic setting, a setting similar to that found 
in the aGvHD NSG model.    
To examine if the reduction in T cell proliferation by hMSC was due to the 
induction of T cell anergy, a second proliferation assay was performed.  In this case, 
following coculture with murine DC, polyIC and/or hMSC for 5 days, human CD4
+
 
T cells were repurified from cultures by magnetic bead isolation.  CD4
+
 T cells were 
allowed to rest overnight after which, these human CD4
+
 T cells were cultured for a 
second time with irradiated xenogeneic BALB/c DC stimulated with or without 
polyIC (Fig 6.3 B).  The hypothesis here was that upon restimulation, “anergic” 
human CD4
+
 T cells that had previously been cultured in the presence of hMSC 
would not proliferate and this inhibition would be reversible through the addition of 
IL-2.  However, this was not the case.  Following, the second coculture of human 
CD4
+
 T cells with irradiated DC and polyIC, an increase in T cell proliferation was 
observed (Fig 6.3 B).  The proliferation of CD4
+
 T cells that had previously been 
cultured in the presence of hMSC was similar, suggesting that hMSC did not induce 
T cell anergy in vitro (Fig 6.3 B).  The addition of IL-2 did not affect the 
proliferation of human CD4
+
 T cells (Fig 6.3 C).  These data suggested that although 
hMSC were capable of inhibiting T cell proliferation in vitro, this inhibition of T cell 
proliferation was not due to induction of T cell anergy.  These data are in contrast 
with Glennie et al. and Zappia et al., although one key point to note is that human T 
cell induced anergy was examined here, whereas others explored MSC induced 
anergy in a completely murine setting (Glennie, 2005; Zappia, 2005). 
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Fig 6.3 hMSC did not induce T cell anergy in vitro.  (A) Human CD4
+
 T cells (1 x 
10
6
/ml) were cocultured in the presence or absence of BALB/c bone marrow derived 
DC (muDC) (1 x 10
5/ml), polyIC (20 μg/ml) or hMSC (1 x 105/ml) in a 96 well plate 
for 5 days.  After 5 days, [
3
H]-thymidine was added to the well for 6 h and T cell 
proliferation was analysed.  Murine DC stimulated with polyIC induced significant 
human CD4
+
 T cell proliferation (p<0.0001).  In the presence of hMSC, the 
proliferation of CD4
+
 T cell proliferation was significantly reduced (p<0.05).  (B) 
Following coculture with murine DC, polyIC and/or hMSC, CD4
+
 T cells were 
repurified and cocultured with irradiated DC (irrDC) and polyIC for 72 h.  After 72 
h, T cell proliferation was analysed by [
3
H]-thymidine incorporation.  CD4
+
 T cells 
previously cocultured with hMSC proliferated upon restimulation with polyIC.  (C) 
The addition of IL-2 had no effect on T cell proliferation.  
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 6.4  HMSC INDUCED REGULATORY-LIKE T CELLS EXPRESSING FOXP3 IN 
VITRO; BUT FAILED TO INDUCE SIMILAR POPULATIONS IN VIVO 
 In Chapter 3, it was clearly shown that hMSC were capable of inducing 
functional regulatory T cells (T reg) in vitro (English, 2009).  Other studies of cell 
therapy by the Mahon group have shown that mMSC-induced T reg cells are 
required for beneficial affects in vivo (Kavanagh, 2011).  This is supported by work 
in other models such as Crohn’s disease (Ciccocioppo, 2011) and even aGvHD, 
whereby Cao et al. found that ex vivo expanded human T reg cells significantly 
enhanced the survival of NOD-scid mice with aGvHD (Cao, 2009).  Therefore, the 
induction of T reg like cells by hMSC as a possible mechanism involved in the 
effective treatment of aGvHD in NSG humanised model was examined. 
 Firstly, hMSC were examined for their ability to induce  FoxP3 expressing T 
reg cells in vitro from a population of PBMC isolated from one of the four healthy 
donors used for the induction of aGvHD in vivo (Fig 6.4 A & B).  After coculture 
with hMSC for 72 h in vitro, PBMC were harvested by gentle aspiration from 
adherent hMSC and analysed for the coexpression of CD4, CD25 and intracellular 
FoxP3 by flow cytometry.  hMSC induced a CD4
+
 T reg like cell population 
expressing FoxP3 and CD25 in vitro (Fig 6.4 A). These data were in line with the 
findings in Chapter 3.  However, hMSC did not to induce a CD8
+
 FoxP3
+
 population 
in vitro (Fig 6.4 B) suggesting that unconventional CD8
+
 T reg like cells were not 
induced by hMSC.   
IFNγ and TNFα are two key cytokines involved in aGvHD pathology.  hMSC 
are likely to encounter high levels of these two cytokines in vivo.  In Chapter 5, it 
was shown that hMSC prestimulation had an enhanced beneficial therapeutic effect. 
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Therefore, the above experiment was repeated where hMSC were pre-stimulated 
with IFNγ or TNFα for 48 h prior to coculture with PBMC in vitro.  The expression 
of the regulatory markers FoxP3 and CD25 was examined on CD4
+
 T cells by flow 
cytometry.  Stimulation of hMSC with inflammatory mediators did not further 
increase the number of cells expressing CD25 or FoxP3 on CD4
+
 or CD8
+
 T cells in 
vitro (Fig 6.4 A & B).  These data implied that although MSC induced  CD4
+
 T reg 
like cells in vitro, pre-stimulation of hMSC with proinflammatory cytokines did not 
increase the number of regulatory like cells.  
The induction of a T reg-like population in vitro from PBMC suggested that 
this could be a potential therapeutic mechanism utilised by hMSC in vivo.  
Therefore, the possibility of T reg induction by MSC in the in vivo model of aGvHD 
was explored.  NSG
 
mice were irradiated with 2.4 Gy and received PBS or PBMC 
after 4 h.  MSC treated groups received hMSC on day 7 post PBMC administration 
or IFNγ stimulated hMSC on day 0 concurrent with PBMC.  On day 12, the typical 
onset day of aGvHD pathology, the lung, liver and spleen were harvested and 
analysed for the expression of human CD4, CD8, CD25 and Foxp3 by flow 
cytometry (Fig 6.5) (n=6).  Whilst hMSC induction of a T reg population was clearly 
seen in vitro (Fig 6.4 A) and previously detectable in vivo in other models used in the 
Mahon lab (Kavanagh, 2011), there was no evidence of induction or expansion of 
CD4
+
 CD25
+
 FoxP3
+
 or CD8
+
 CD25
+
 FoxP3
+
 T reg like cell populations in vivo 
(Fig. 6.5).  This was the case following treatment with either hMSC on day 7 or 
IFNγ stimulated hMSC on day 0.  No such populations were observed in the lung 
(Fig 6.5 A), liver (Fig 6.5 B) or spleen (Fig 6.5 C).  These data suggested that the 
hMSC induction of CD4
+
 or CD8
+
 CD25
+
 FoxP3 expressing T reg like cells was 
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unlikely to be the mechanism involved in hMSC induced prolonged survival of NSG 
mice with aGvHD. 
It is important to be cautious in the interpretation of the above data. The 
induction/expansion of human CD4
+ 
or CD8
+
 FoxP3
+
 T reg cell was analysed here.  
Firstly, there may be human stromal or third party factors that are absent in this 
humanised mouse model that prevent human T reg cell expansion, however that does 
little to explain the therapeutic benefit that had been observed (Chapter 5).  
Secondly, there are many other recently described T reg populations that do not 
express FoxP3, CD4, CD8 or CD25, which may be induced in vivo but not explored 
in this study.  In addition, T reg cells may have had an effect early and disappeared 
or be present in non-sampled organs.  Once again, it is highly unlikely that T reg 
cells could have an effect and not be present in the organs sampled, especially when 
these are the target organs involved in GvHD pathology and displaying improvement 
with cell therapy.  In summary, hMSC did not induce a detectable CD4
+
 CD25
+
 
FoxP3
+
 or CD8
+
 CD25
+
 FoxP3
+
 T reg cell population in vivo in this model.  
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Fig 6.4 hMSC induced CD4
+
 but not CD8
+
 T cells expressing FoxP3 and CD25 
in vitro.  PBMC (1 x 10
6
/well) were isolated from fresh healthy donor blood and 
cocultured with hMSC (3 x 10
5
/well) or pre-stimulated MSC (MSCγ) (IFNγ (50 
ng/ml) or (MSCα) TNFα (50 ng/ml) for 72 h in a 6 well plate.  PBMC were 
examined for the co-expression of (A) CD4 or (B) CD8 with the regulatory markers 
FoxP3 and CD25 by flow cytometry.  The percentage of double positive cells are 
given in the upper quadrant. Data are representative of three independent 
experiments. 
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Fig 6.5 hMSC did not induce  FoxP3 expressing T regulatory like population in 
vivo. NSG mice received PBS or PBMC (6.3 x 10
5
 g
-1) on day 0.  IFNγ stimulated 
(MSCγ) or unstimulated MSC (4.4 x 104 g-1) were given i.v. on day 0 or 7 
respectively. On day 12, the (A) lung, (B) liver and (C) spleen were harvested and 
analysed for the expression of human CD4, CD8, CD25 and FoxP3 by flow 
cytometry. CD4
+ 
FoxP3
+
 or CD8
+
 FoxP3
+
 T reg-like cells were not detected in vivo 
following hMSC therapy. Data are representative of six mice per group (n=6).  
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6.5  HMSC INHIBITED THE PROLIFERATION OF PBMC IN VITRO AND IN VIVO  
 It was demonstrated in Chapters 3 and 4 that both human and mouse MSC 
can inhibit T cell proliferation induced in an MLR by allogeneic cells or in 
proliferation assays driven by non-specific mitogens.  It was therefore possible that 
the beneficial influence of hMSC therapy on aGvHD development was a direct anti-
proliferative effect on donor T cells.  This hypothesis was examined in vitro and in 
vivo.  First, the hMSC used here were examined to verify the in vitro suppression of 
proliferation of the donor PBMC used for the induction of aGvHD in vivo.  Donor 
PBMC were stimulated in vitro by either MHC mismatched PBMC (Fig 6.6 A) or a 
mitogen (PHA) (Fig 6.6 B) for 72 h.  hMSC significantly inhibited the proliferation 
of alloantigen driven and mitogen driven proliferation of donor PBMC (Fig 6.6 A & 
B) (p<0.0001).  This inhibition of alloantigen driven proliferation of PBMC by 
hMSC was associated with a significant decrease in both IFNγ (Fig 6.6 C) 
(p<0.0001) and TNFα (Fig 6.6 E) (p<0.0201) present in culture supernatants, as 
analysed by ELISA.  hMSC inhibition of mitogen driven proliferation of PBMC, 
was associated with a significant decrease in IFN-γ (Fig 6.6 D) (p<0.0001) and TNF-
α (Fig 6.6 F) (p<0.0001) production.  This decrease in lymphocyte proliferation 
attributable to hMSC suggested that hMSC might have a similar effect in vivo, 
mediating the development of aGvHD pathology. 
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Fig 6.6 hMSC inhibit  PBMC proliferation and decrease IFNγ and TNFα 
production in vitro. (A) PBMC (number) from two MHC mismatched donors (D1 
or D2) were cultured in the presence or absence of number MSC in  MLR. (A) MSC 
significantly inhibited alloantigen proliferation (p<0.0001) and (B) mitogen driven 
proliferation (p<0.0001) in vitro.  This inhibition of proliferation correlated with a 
significant decrease in the production of (C & D) IFNγ (p<0.0001) and (E & F) 
TNFα (p<0.0201, p<0.0001 respectively) as analysed by ELISA. Statistical analysis 
was carried out using the students paired t test.  Data are representative of three 
experiments, each performed in triplicate. 
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In order to investigate whether hMSC inhibited the proliferation of donor 
PBMC in vivo, the optimisation of an in vivo measure of lymphocyte proliferation 
was required.  Carboxyfluorescein succinimidyl ester (CFSE) is a fluorescent dye, 
which is progressively and consistently diluted following each consecutive cell 
division (Lyons, 1994).  CFSE was used to label donor PBMC in vitro and to look 
for the proliferation of PBMC in response to rhIL-2 and a mitogen, PHA (Fig 6.7).  
A number of attempts were made to obtain meaningful data from CFSE experiments, 
eventually the protocol described in section 2.11.6 was used, representing the 
approach that yielded interpretable data consistent with other workers.  PBMC were 
labelled with 2.5 µM, 5 µM or 10 µM CFSE and cultured on anti-human CD3 coated 
tissue culture plates in vitro.  Cultures were stimulated with rhIL-2 and PHA (Fig 
6.7) for 5 days.  After 5 days, CFSE labelled PBMC were counter labelled with anti 
human CD4 and proliferation was analysed using flow cytometry.  A decrease in 
CFSE fluorescence (MFI) was indicative of CD4 T cell division (Fig 6.7).  
Following the stimulation of CFSE labelled PBMC with rhIL-2 and PHA, the 
distribution of CD4
+
 T cell peak fluorescence was altered (Fig 6.7).  Each peak 
corresponded to a successive cell division, approximately half the fluorescence 
(MFI) of the previous peak.  CD4
+
 T cells labelled with various concentrations of 
CFSE showed proliferation.  Peaks representing three or more rounds of proliferation 
were clearly seen when CD4
+
 T cells were labelled with 5 or 10 µM CFSE, 
compared with PBMC labelled with 2.5 µM CFSE (Fig 6.7), a CFSE concentration 
of 10 µM was chosen for further experiments.  These data showed that the 
proliferation of CD4
+
 T cells in vitro could be successfully detected using CFSE 
staining.   
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Fig 6.7  CFSE labelled CD4
+
 T cells proliferate in vitro.  PBMC were labelled 
with CFSE at 2.5 µM, 5 µM or 10 µM. CFSE PBMC were cultured on anti-human 
CD3 (2 μg/ml) coated tissue stimulated with rhIL-2 (100 U/ml) and PHA (10 µg/ml) 
for 5 days. CFSE PBMC were counterstained with anti-human CD4 and proliferation 
analysed by flow cytometry.  Proliferation of CD4
+
 T cell was undetectable on cells 
labelled with 2.5 µM CFSE. CD4
+
 T cells labelled with 5 µM or 10 µM underwent 
proliferation. Data representative of two independent studies.  
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Next, the possibility that hMSC had an effect on the PBMC division in vitro 
was examined.  Using a technique derived from the in vitro approach above, PBMC 
were labelled with 10 µM CFSE, but in this case, cocultured in the presence of 
hMSC and stimulated with rhIL-2 and PHA for 5 days.  After 5 days, PBMC were 
pulled back from coculture by gentle aspiration from adherent hMSC, counter 
labelled with anti-human CD4 and analysed by flow cytometry (Fig 6.8).  
Unstimulated CD4
+
 T cells only had 35 % of cells progress into division, (65 % of 
CD4
+
 T cells undergoing no divisions) (Fig 6.8).  Upon stimulation with rhIL-2 and 
PHA, CD4
+
 T cells in the presence or absence of hMSC underwent division.  
However, in the presence of hMSC CD4
+
 T cells underwent fewer divisions (36 % 
progressing to a second division), when compared to CD4
+
 T cells in the absence of 
hMSC (46 %).  These findings showed that hMSC inhibited the proliferation of 
CD4
+
 T cells in vitro, as indicated by CFSE expression.  
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Fig 6.8  hMSC reduced the proliferation of CD4
+
 T cells in vitro.  PBMC (1 x 
10
6
/ml) were labelled with 10 μM CFSE and stimulated with rhIL-2 (100 U/ml) and 
PHA (10 μg/ml) in the presence or absence of MSC (1 x 105/ml) for 5 days.  After 5 
days, CFSE stained PBMC were labelled with anti-CD4 and cell proliferation was 
analysed by flow cytometry.  CD4
+
 T cells underwent proliferation in response to 
rhIL-2/PHA by day 5.  In the presence of hMSC, CD4
+
 T cells displayed reduced 
proliferation, with the majority of cell proliferations prohibited after one division.  
Percentage of cells in each division are represented on the histogram.  Data are 
representative of two independent studies.  
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The hypothesis was therefore formulated that, hMSC therapy directly 
inhibited PBMC proliferation in the aGvHD humanised mouse model.  To test this, 
an in vivo model of the CFSE technique was required.  Again, a number of 
preliminary experiments were performed to permit detection of CFSE labelled 
PBMC in vivo.  Ultimately, a concentration of 10 µM was used for labelling.  Higher 
concentrations were found to have a toxic effect on PBMC but lower levels were not 
detectable ex vivo.  This was supported by a protocol from Lyons et al. (Lyons, 
2004).  
The in vivo approach initially involved labelling PBMC with 10 µM CFSE 
on day 0, prior to i.v. injection into a sub-lethally irradiated NSG mouse.  Like 
previous studies, IFNγ stimulated MSC were given concurrently on day 0, while 
unstimulated MSC were given on day 7 post transfusion of PBMC.  When NSG 
mice developed aGvHD on day 12 the lung, liver and spleen were harvested.  The 
level of CFSE staining by CD4
+
 T cells in these organs was analysed by flow 
cytometry.  However, no CFSE was detected at day 12 in any of the target organs, 
lung, liver or spleen (Data not shown).  Therefore, the protocol was refined and the 
readout was shifted to day 5 post transfusion of CFSE labelled PBMC.  The shift to 
an earlier time point was not compatible with use of hMSC alone, as in Chapter 5 it 
was found that hMSC were only effective with delayed administration, primarily 
given on day 7.  Therefore, only IFNγ stimulated hMSC were used for the purpose of 
this experiment. 
 Sub-lethally irradiated NSG
 
mice received CFSE labelled PBMC on day 0 
and MSCγ treatment was given concurrently.  Mice were left for 5 days before 
analysing the effect of MSCγ treatment on PBMC proliferation.  On day 5, the lung, 
liver and spleen were harvested and the fluorescence of CFSE
+
 CD4
+
 labelled T cells 
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were analysed by flow cytometry (Fig 6.9).   CFSE labelled PBMC were detected in 
the lung of NSG
 
on day 5.  MSCγ treated mice had significantly fewer CD4+ T cells 
progressing to division (p<0.0041) when compared to mice that received PBMC 
alone on day 0 (Fig 6.9 A & B).  There was also a significant reduction in the 
number of human CD4
+
 T cells divisions when NSG mice were treated with 
allogeneic MSCγ therapy (P<0.0037) (Fig 6.9 A & B).  Typically, mice receiving 
MSCγ had significantly fewer CD4+ T cells that had undergone  subsequent 
divisions.  Thus in aGvHD mice not treated with hMSC, 66% of CD4
+
 T cells had 
undergone 2 or more divisions whereas in the presence of MSCγ therapy, most 
(52%) of CD4
+
 T cells underwent only one or fewer divisions (Fig 6.9).   These 
data also revealed that aGvHD development in this humanised mouse model was 
primarily a CD4
+
 T cell driven disease  as PBMC not expressing CD4 did not 
undergo proliferation in vivo (Fig 6.9).  CFSE labelled PBMC were not detected in 
the liver or spleen of NSG mice 5 days post transfusion.  These data suggested that 
the majority of PBMC are located in the lung 5 days post administration and this is 
consistent with the lung pathology evident in this model (Fig 5.16).  
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Fig 6.9 MSC reduced the proliferation of CD4 T cells in vivo.  PBMC labelled 
with 10 µM CFSE were administered to NOD-Scid IL2rγnull mice that were 
irradiated with 2.4 Gy with or without MSCγ on day 0. After 5 days, the lung, liver 
and spleen were harvested.  (A) The level of CFSE on CD4
+ 
T cells was analysed by 
flow cytometry. MSC reduced the proliferation of CD4
+
 T cells in the lung only after 
5 days.  CD4
+
 T cells were not detected in the liver or spleen after 5 days. (B) 
Percentage of CD4
+
 cells present in the lung at each division from CFSE labelled 
PBMC after 5 days in vivo.  Data are representative of 5 mice per group (n=5). 
231 
 
6.6 PROSTAGLANDIN PRODUCTION BY HMSC IS NOT ESSENTIAL FOR 
PREVENTING CD4
+
 T CELL DIVISION IN VIVO 
MSC immune modulation is multifactorial requiring both cell: cell contact 
and the release of soluble factors for different aspects of suppression.  To investigate 
if hMSC production of prostaglandins was involved in the inhibition of T cell 
proliferation, in vitro and in vivo studies were carried out.  Firstly, the production of 
PGE2 by hMSC in coculture with PBMC was analysed in vitro.  PBMC were 
cocultured with hMSC for 48 h and the production of PGE2 was analysed by ELISA.  
Prostaglandin production was also blocked in coculture studies through the addition 
of indomethacin (Fig 6.10).  PBMC alone did not produce PGE2, however, in the 
presence of hMSC, the production of PGE2 was significantly increased (p<0.0001) 
(Fig 6.10) consistent with hMSC production of prostaglandins shown earlier 
(Chapter 3).  Following the addition of indomethacin, the production of PGE2 by 
hMSC in the presence of PBMC was significantly reduced (p<0.0001) (Fig 6.10 A).  
The vehicle control for indomethacin (ethanol diluted in medium) had no effect on 
the production of PGE2 by hMSC in vitro.  To investigate if the production of 
prostaglandins by hMSC were essential for the inhibition of PBMC proliferation in 
vitro, proliferation assays were performed.  PBMC were stimulated with a mitogen 
(PHA) in the presence or absence of hMSC for 72 h.  Prostaglandin production was 
blocked using indomethacin.  PBMC stimulated with PHA proliferated significantly 
more that PBMC alone (Fig 6.10 B).  In the presence of hMSC, the proliferation of 
PBMC was significantly reduced.  However, when prostaglandin production was 
blocked through the addition of indomethacin, hMSC could no longer inhibit the 
proliferation of PBMC (Fig 6.10 B).  These data demonstrated that the hMSC used 
in this study were capable of PGE2 production and that PGE2 was essential for 
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hMSC inhibition of PBMC proliferation.  These data also suggested a possible 
mechanism by which hMSC reduce T cell proliferation in vivo, prolonging the 
survival of mice with aGvHD.  
The possibility that the production of prostaglandins by hMSC was the 
mechanism by which hMSC prolonged the survival of NSG mice with aGvHD in 
vivo was examined.  Indomethacin significantly reduced the production of PGE2 by 
MSC and was essential for hMSC inhibition of PBMC proliferation in vitro (Fig 
6.10).  The concentration of indomethacin used in vivo was similar to that used by 
other groups for the blocking of prostaglandin production in vivo (Kulkarni, 1981; 
Bordet, 2000; Cooper, 2010).  Irradiated NSG mice received PBS or PBMC on day 0 
by i.v injection.  Unstimulated hMSC were given on day 7 or prestimulated hMSC 
(MSCγ) were given on day 0.  Mice that received PBMC on day 0 developed 
aGvHD by day 13, indicated by significant weight loss (Fig 6.11 A) and 
development of aGvHD pathological signs (ruffled fur, reduced activity, hunched 
posture and diarrhoea) (Fig 6.11 C).  However, mice that received hMSCγ therapy 
on day 0 or hMSC therapy on day 7 did not develop any significant signs of aGvHD 
(Fig 6.11 C) and survived, similar to those observed in Chapter 5.   
Next, prostaglandin production was blocked in vivo through the 
administration of indomethacin (6 mg/kg) via intraperitoneal (i.p) injection on day 0 
and every 3 days thereafter.  Blocking prostaglandin production had no effect on the 
development of aGvHD, as mice that received PBMC along with indomethacin i.p 
on day 0 has significant weight loss (Fig 6.12 A) and developed pathological signs of 
aGvHD by day 13 (Fig 6.12 C).  Mice that received hMSCγ therapy on day 0 along 
with indomethacin (i.p) every 3 days did not develop any significant signs of aGvHD 
development (Fig 6.12 C), when compared to mice that received hMSC  therapy 
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without indomethacin (Fig 6.11 C).  These data suggested that prostaglandin 
production by hMSCγ was not essential for the prevention of aGvHD in this model.  
The role for prostaglandin production via unstimulated MSC was 
investigated in vivo.  In this case, indomethacin therapy did not commence until 
hMSC administration on day 7.  Mice were irradiated on day 0 and received PBS or 
PBMC by i.v injection.  Following hMSC therapy on day 7, indomethacin was given 
i.p to all groups, including PBS, PBMC and hMSC treated groups on day 7 and 
every 3 days thereafter (Fig 6.13).  Blocking prostaglandin production from day 7 
had no effect on the development of aGvHD by day 16 (Fig 6.13).  Mice that 
received MSC therapy on day 7, along with indomethacin did not develop any signs 
of aGvHD.  These data suggested that prostaglandin production by hMSC was not 
essential for the prevention of aGvHD in this model.   
The production of PGE2 was analysed in the serum of NSG mice with 
aGvHD following hMSC cell therapy by ELISA (Fig 6.14 A).  Low dose irradiated 
NSG mice that received PBS on day 0 had significantly higher levels of PGE2 
present in the serum on day 13, when compared to NSG mice that received PBMC 
(Fig 6.14.A).  hMSC cell therapy administered on day 7 or IFNγ stimulated MSC 
administered on day 0 did not result in an increase in PGE2 in the serum of NSG 
mice with aGvHD when compared to NSG mice that received PBMC alone on day 0 
(Fig 6.14 A).  These data supported the findings shown in figure 6.12 and 6.13, 
which suggested that the production of PGE2 was not involved in the prolonged 
survival of NSG mice with aGvHD.  The analysis of serum following the 
administration of indomethacin also confirmed that the addition of indomethacin via 
intraperitoneal injection (i.p.) every three days was sufficient for a consistent 
decrease in PGE2 production in vivo (Fig 6.14 B & C).  It is important to note that 
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indomethacin treatment was not specific for MSC produced prostaglandins in this 
case.  However, these data clearly show that prostaglandin production, whether 
already present in vivo or through the presence of MSC therapy was not essential for 
suppression of aGvHD in this model.  
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Fig 6.10 Prostaglandins are essential for MSC inhibition of PBMC proliferation 
in vitro.  (A) hMSC (3 x 10
5
/well) were coculture with PBMC (1 x 10
6
/well) in a 6 
well plate for 48 h and the production of PGE2 was analysed by ELISA.  PGE2 
production was blocked through the addition of indomethacin (indo) (20 µM).  
Vehicle control (crtl) (ethanol) for indomethacin was added to control wells.  hMSC 
produced PGE2 in vitro in the presence of CD4
+
 T cells. (B) hMSC (4 x 10
5
/ml) were 
cocultured with PBMC (4 x 10
6
/ml) in a 96 well plate for 72 h in the presence of 
indomethacin.  [3H]-Thymidine at 0.5 μCi was added for the final 6 h of culture.   
hMSC significantly reduced (p<0.0001) the proliferation of PBMC in vitro through 
the secretion of PGE2.  Blocking prostaglandin production through the addition of 
indomethacin significantly increased (p<0.05) the proliferation of PBMC in the 
presence of hMSC.  Indomethacin successfully blocked PGE2 production by hMSC. 
Statistical analysis was carried out using the students paired t test.  Data are 
representative of three experiments. 
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Fig 6.11 MSC cell therapy prolonged the survival of mice with aGvHD.  
Irradiated mice received PBS or PBMC on day 0.  Unstimulated MSC were given on 
day 7 or prestimulated MSC (MSC ) were given on day 0. MSC therapy (A) reduced 
weight loss, (B) increased survival and (C) reduced the development of aGvHD 
symptoms.  Data are representative of 4 mice per group (n=4).  
 
B 
C 
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Fig 6.12 Production of prostaglandins by MSCγ were not essential in the 
beneficial effect seen in vivo. Irradiated mice received PBS or PBMC on day 0.  
Prestimulated MSC (MSC ) were given concurrent with PBMC on day 0.  
Indomethacin (6mg/kg) was administered intraperitoneal (i.p) on day 0 and every 3 
days thereafter.  Blocking prostaglandin production did not interfere with the ability 
of MSC  prolonging the survival of mice with aGvHD.  Indomethacin treatment did 
not (A) increase weight loss, (B) decrease survival or (C) increase the symptoms of 
aGvHD development in mice.  Data are representative of 4 mice per group (n=4). 
 
A 
B 
C 
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Fig 6.13  Prostaglandins by hMSC were not essential for the beneficial effect 
seen in vivo.  Irradiated mice received PBS or PBMC on day 0.  Unstimulated MSC 
were given on day 7.  Treatment of mice with indomethacin via i.p injection 
commenced on day 7 and was given every 3 days thereafter.  Blocking prostaglandin 
production did not interfere with the ability of MSC prolonging the survival of mice 
with aGvHD.  Indomethacin treatment did not (A) increase weight loss, (B) decrease 
survival or (C) increase the symptoms of aGvHD development in mice.  Data are 
representative of 4 mice per group (n=4). 
  
A 
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Fig 6.14  hMSC did not increase prostaglandin production in NSG mice with 
aGvHD.  (A) Low dose irradiated NSG mice received PBS or PBMC on day 0.  
hMSC cell therpay was given on day 7, while IFNγ stimulated MSC (MSCγ) therapy 
was given concurrent with PBMC on day 0.  Following the evelopment of aGvHD 
on day 13, serum was taken from each mouse and analysed for the production of 
PGE2 by ELISA.  hMSC cell therapy did not increase the production of PGE2 in 
NSG mice with aGvHD.  Indomethacin (indo) at 6 mg/kg was adminitered by 
intraperitoneal injection (i.p.) on (B) day 7 with hMSC therapy or on (C) day 3 with 
hMSCγ therapy and every three days thereafter.  Serum was taken from each NSG 
mouse on day 13 following aGvHD development.  The production of PGE2 was 
analysed by ELISA.  Indomethacin consistently reduced the amount of PGE2 present 
in the serum of NSG mice. Data are representative of 4 mice per group (n=4). 
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6.7  SUMMARY 
The aim of this Chapter was to determine the mechanism involved in hMSC 
modulation of aGvHD development in a humanised mouse model as found in 
Chapter 5.  The literature suggested four possible mechanisms by which MSC cell 
therapy might be mediating a beneficial effect in vivo.  These mechanisms included 
the induction of lymphocyte apoptosis, induction of T cell anergy, the induction of 
regulatory T cells or the direct inhibition of T cell proliferation.  
In vitro and in vivo analysis suggested that hMSC did not induce PBMC 
apoptosis.   Although there is contradictory published data, the data presented herein 
clearly suggested that hMSC did not induce apoptosis and this was not the 
mechanism used by hMSC in prolonging the survival of mice with aGvHD.  hMSC 
were found not to be involved in the induction of T cell anergy, following in vitro 
analysis.  The induction or expansion of T reg populations were suggested to be 
involved in the regulation and prevention of aGvHD in other models.  Although, 
hMSC induced a T reg-like population in vitro, this did not translate to the situation 
in vivo as hMSC did not induce a detectable T reg-like population in NSG mice with 
aGvHD.  Therefore, the therapeutic benefit was unlikely to depend on this 
mechanism.   
hMSC can suppress immune responses through the direct inhibition of T cell 
proliferation in vitro.  Following hMSC therapy in vivo, donor lymphocytes 
displayed reduced proliferation in the lung of NSG mice with aGvHD.  Possible 
roles for hMSC derived prostaglandins were examined using the antagonist 
indomethacin to block the secretion of prostaglandin, PGE2, by MSC in vitro and in 
vivo.  However, blocking PGE2 production had no effect on the ability of hMSC to 
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prolong the survival of mice with aGvHD.  This suggested that, although MSC 
secrete PGE2, the mechanism involved in the reduced proliferation of donor T cells 
in vivo by MSC did not require PGE2 production.  This Chapter developed both in 
vitro and in vivo models to address the four key hypotheses by which MSC cell 
therapy could be beneficial in treating aGvHD.  These findings contribute to on 
going research in this area.  
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CHAPTER 7 
DISCUSSION 
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The induction of tolerance is an important mechanism involved in the 
regulation of immune responses against self antigens (“self tolerance”) or innocuous 
non-self antigens (“induced tolerance”).  Tolerance supports successful organ and 
hematopoietic stem cell transplantation.  The primary utility for MSC therapy was 
originally thought to be in repair and regeneration of damaged tissues (Caplan, 
1991).  However, it has since become apparent that MSC can play a therapeutic role 
in immune modulation.  Haynesworth and Caplan first proposed the contribution of 
MSC derived trophic factors to therapeutic efficacy (Haynesworth, 1996).  These 
findings paved the way for using MSC as cell based modulators of immune mediated 
diseases rather than purely regeneration-based therapies.  MSC have a unique if 
partial, privilege from allogeneic rejection, meaning that in the absence of complete 
immune suppression, MSC are not rapidly rejected by an allogeneic host (Bruder, 
1998; Le Blanc, 2004; Ryan, 2005).  This finding put MSC in a spotlight, where 
their use as a unique allogeneic cell therapy becomes plausible.  Autologous MSC 
therapy had proved successful (Koc, 2000), however, allogeneic MSC allows for a 
more “off the shelf” multi-recipient therapy with comparable efficacy to autologous 
cells.  The aims of this thesis were to investigate the ability of MSC to induced 
regulatory DC and T cell populations in vitro, to determine the exact mechanisms of 
suppression and to extend this to define the regulatory mechanisms used by MSC in 
the treatment of aGvHD using a humanised mouse model.  
In chapter 3, the effect of allogeneic hMSC on human CD4
+
 T cells was 
examined in vitro.  Firstly, the effect of a validated homogenous population of 
hMSC on whole PBMC proliferation was examined and proliferation shown to be 
significantly reduced in the presence of hMSC (Fig 3.4).  These data were similar to 
other groups, where MSC exhibited potent anti-inflammatory properties associated 
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with an inhibitory effect on T cell activation and proliferation (Di Nicola, 2002; 
English, 2007; Ryan, 2007; Benvenuto, 2007; Ramasamy, 2008; Park, 2011).  
Following hMSC coculture, the expression of the regulatory markers, FoxP3 and 
CD25 were increased in purified CD4
+
 T cells, suggestive of a T reg cell population 
(Fig 3.6 & 3.7).  CD4
+ 
CD25
+ 
FoxP3
+
 T cells induced by hMSC had suppressive 
characteristics.  Repurifying T cells induced by coculture with hMSC and placing 
them in a two way MLR demonstrated that such T reg cells were capable of 
inhibiting allogeneic PBMC responses even after removal of MSC (Fig 3.13).  T reg 
cells have important roles in the induction and maintenance of specific 
immunological unresponsiveness to foreign alloantigens in vivo (reviewed by Wood, 
2011).  The fact that hMSC were capable of inducing a population of T cells with a 
regulatory phenotype suggested that MSC might prove beneficial as a cell based 
therapy for solid organ transplantation, GvHD or autoimmunity.   
Through a series of neutralisation studies, the roles of soluble factors, 
prostaglandins and TGFβ1 production by hMSC were examined in relation to the 
induction of T reg cells in vitro.  hMSC constitutively secreted PGE2 and TGFβ1, 
key soluble factors involved in mediating MSC immune modulation of T cells 
(English, 2007; Ryan, 2007).  The demonstration of non-redundant roles for soluble 
factors was similar to data from other groups (Baratelli, 2005; Fu, 2004; Ghannam, 
2010; Park, 2011).  PGE2 enhances the in vitro inhibitory function of human 
CD4
+
CD25
+
 T reg cells and significantly up regulates FoxP3 promoter activity, 
increasing FoxP3 expression (Baratelli, 2005; Ghannam, 2010).  While TGFβ 
signalling is involved in the initiation and maintenance of FoxP3 expression and 
regulatory function (Fu, 2004).  Complimenting the data herein and the work by 
others, Park et al. recently confirmed a role for TGFβ in the induction of CD4+ 
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FoxP3
+
 T reg cells by mMSC (Park, 2011).  The data here and elsewhere identify 
important roles for both PGE2 and TGFβ in MSC mediated immune modulation 
(Baratelli, 2005; Fu, 2004; Ghannam, 2010; Park, 2011).  However, these findings 
were contradicted by Prevosto et al. who suggested a role for GITR
+
/CTLA-4 and 
CD25
+
 in the induction of T cells with suppressor activity by MSC, but found no 
roles for TGFβ1, PGE2 or IL-10 (Prevosto, 2007).  While Selmani et al. showed that 
soluble HLA-G5, secreted by hMSC, was required for the suppression of T 
lymphocytes present in whole PBMC (Selmani, 2008).  The conflicting data relating 
to the release of various soluble factors by MSC (TGFβ1 vs PGE2 vs HLA-G5) 
between studies might be explained by experimental design.  The use of a purified 
CD4
+
 T cell population here compared to a heterogenous unpurified system by 
Prevosto and Selmani could be the explanation.  This would suggest that in a multi-
cell system, the role of individual mediators could possibly be masked by the 
presence of other cells, as multiple independent pathways can modulate different 
aspects of MSC mediated suppression (English, 2007; English, 2008).  This was 
supported by the findings here when hMSC were cocultured with unseparated whole 
PMBC.  Under these conditions, cell contact was not required for hMSC induction of 
FoxP3 expression whereas direct cell contact was required when purified CD4
+
 T 
cell populations were used (Fig 3.10).  This suggested that cell contact signals were 
substituted by other factors present in a whole population of PBMC that are not 
present in a purified two-cell system.  The exact cell contact molecule/molecules 
involved in MSC generation of T reg cells are the subject of study by other members 
of the Mahon group.  Chapter 3 found that hMSC induced a FoxP3
+ 
T reg cell 
population in vitro, which required an unidentified direct cell contact signal between 
246 
 
hMSC and CD4
+
 T cells and the subsequent release of soluble factors, PGE2 and 
TGFβ1.   
The induction of T reg cells in vitro by hMSC, suggested the involvement of 
hMSC in the induction of immune tolerance through the generation of regulatory 
cells.  This is a key finding in relation to the induction of tolerance in transplantation, 
as CD4
+ 
CD25
+ 
FoxP3
+
 T reg cells have a beneficial role in aGvHD and the 
maintenance of GvL and GvT in vivo (Cohen, 2002; Hoffmann, 2002; Cao, 2009).  
Interestingly, DC can generate T reg cells in patients with different types of cancers 
(Steinman, 2008; Hubert, 2007), as the induction of semi-mature/tolerogenic DC are 
capable of driving the differentiation and proliferation of FoxP3
+
 T reg cells 
(Mahnke, 2003; Mahnke, 2007; Wakkach, 2003).  Therefore, in chapter 4, the ability 
of murine bone marrow derived MSC induction of semi-mature/tolerogenic DC was 
examined in vitro.   
For the purpose of the work carried out in chapter 4, a switch from human to 
murine cells was made, as there were limitations regarding the use of human derived 
DC and the isolation of DC and T cells from the same HLA background was difficult 
to achieve.  Therefore, murine bone marrow derived MSC and DC were used.  
mMSC modulated three aspects of DC function: maturation, cytokine secretion and 
antigen presentation (Fig 4.6 & 4.7).  mMSC coculture prevented the LPS driven  
increase of DC MHC class II and CD86 expression, which coincided with a 
significant decrease in the production of IL-12p70 and significant increase in IL-10.  
To examine if mMSC interfered with antigen presentation by DC, an antigen specific 
display system was employed exploiting YAe antibody recognition of the I-Eα 
peptide bound to I-A
b
 MHC class II (Rudensky, 1991).  This approach yielded data 
suggesting that mMSC reduced the antigen presentation ability of DC.  These 
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findings were similar to that found by Jiang et al., where hMSC interfered with DC 
differentiation from monocytes, decreased IL-12 production and hampered antigen 
presentation (Jiang, 2005).  Collectively, these data suggested that by preventing 
maturation of DC, mMSC were keeping DC in a “semi-mature” or tolerogenic 
phenotype.  Allowing DC to become more regulatory might contribute to the 
immunosuppressive capacity carried out by MSC (Lutz, 2002; Jiang, 2005; 
Aggarwal, 2005; English, 2007).  To investigate if the semi-mature DC population 
induced by mMSC had a functional effect, a well-defined antigen specific T cell 
proliferation system was used.  DC pulsed with OVA peptide supported DO11.10 
CD4
+
 T cell proliferation.   In the presence of mMSC, OVA pulsed DC were 
significantly less able to stimulate DO11.10 T cell proliferation.  These data 
suggested that mMSC induced a semi-mature/tolerogenic DC population, interfered 
with the antigen presentation of DC, induced a “regulatory” DC, and prevented the 
proliferation of antigen specific T cells, findings recently confirmed by Chiesa et al. 
(Chiesa, 2011).  These data supported the hypothesis proposed in chapter 3, that 
MSC induction of immune tolerance was due to the generation of regulatory immune 
cells, including CD4
+
 T reg cells and tolerogenic DC. 
mMSC modulation of DC function involved both soluble and cell contact 
factors (Beyth, 2005; Jiang, 2005; Nauta, 2006; Djouad, 2007; Li, 2008; Zhang, 
2009).  Previous work by the Mahon group confirmed the work of Jiang et al. (Jiang, 
2005) identifying a role for IL-6 in mMSC modulation of DC maturation, with no 
role identified for TGFβ or HGF (English, personal communication).  Through 
neutralisation studies, the secretion of VEGF and M-CSF by MSC were found to be 
involved in DC differentiation from precursor cells (Nauta, 2006; Djouad, 2007).  
Collectively, these data identified a role for MSC derived IL-6, IL-10, VEGF and M-
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CSF in the DC differentiation, subsequent maturation and ultimate shaping of T cell 
function.  
 At the commencement of this work, published data supported a role for 
soluble factors in MSC immune modulation of DC, but the need for direct cell 
contact between MSC and DC was unclear.  Using a transwell system, similar to that 
used in chapter 3, the presence of mMSC had no effect on LPS driven DC 
maturation if contact was prohibited.  These data implied that direct cell contact was 
required between mMSC and DC in order for MSC to have a modulatory effect on 
DC maturation and suggested that contact was an upstream event to IL-6 secretion.  
This work was similar to that published by others whereby cell contact played an 
important role in MSC: DC modulation (Beyth, 2005; Djouad, 2007; Zhang, 2004).   
In chapter 4, a number of possible cell contact candidates were analysed for 
their involvement in mMSC immune modulation of DC function.  The first candidate 
for analyses were the sialic-acid binding immunoglobulin-like lectins, Siglecs.  
Siglecs are involved in immune cell: cell interactions.  The maturation of DC results 
in an increase of glycan expression, which allows for increased Siglecs and galactin 
binding (Bax, 2007).  Mature cells of the innate immune system, such as monocytes 
and dendritic cells express CD33-related Siglecs (Crocker, 2007).  CD33 related 
Siglecs modulate leukocyte behaviour, including the inhibition of cellular 
proliferation (Vitale, 1999; Balaian, 2003) and cytokine production (Lajanias, 2005).  
These findings encouraged the investigation of CD33-related Siglec expression by 
mMSC and drove the hypothesis that mMSC could prevent DC maturation through 
Siglec: glycan recognition, which would relay an inhibitory signal.  However, 
following mRNA and protein analysis of CD33-related Siglecs expression on mMSC 
alone or prestimulated mMSC could not be demonstrated (Fig 4.10).  There is no 
249 
 
data published to suggest the expression of Siglecs by mMSC.  Therefore, a role for 
CD33-related Siglecs in mMSC modulation of DC maturation was considered 
improbable.  However, the possibility of CD33-related Siglec expression by DC and 
glycan expression by mMSC was not explored.  In this case, the recognition of 
specific Siglecs on DC may occur through the expression of various glycans by 
mMSC.  However, the differential glycan expression on mMSC following various 
stimulations was not profiled during this thesis.   
The B7 family of ligands play important roles in the regulation of T cell 
activation and immune tolerance (Greenwald, 2005).  The B7 receptors (CD28, 
CTLA4, ICOS, PD-1) and ligands (LICOS, PDL-1, PDL-2, CD80, CD86) are 
involved in the activation, regulation and inhibition of T cell responses (Alegre, 
2001; Herman, 2004; Latchman, 2001; Nishimura, 2001) with the balance between 
stimulatory and inhibitory signalling important for the maintenance of tolerance.  As 
MSC were capable of inducing regulatory cell populations the expression of CTLA-
4 (CD152), ICOS (CD278), LICOS (CD275), PD-1 (CD279) and PDL-1 (CD274) 
were analysed on mMSC and DC.  mMSC did not express the B7 ligands, LICOS 
and PDL-1 or the receptors, CTLA-4, ICOS or PD-1.  DC expressed receptors, ICOS 
and PD-1 and ligands, LICOS and PDL-1.  However, the binding of ICOS: LICOS 
stimulates T cell activation, while the binding of PD-1: PDL-1 inhibits T cell 
activation (Greenwald, 2005).  ICOS and PD-1 are expressed on activated T cells 
and their respective ligands on DC.    T reg cells can develop with support through 
the ICOS: LICOS pathway, for the expression of regulatory molecules, such as IL-
10, (Akbari, 2002).  PD-1 ligation results in the decrease of DC maturation marker 
expression and an increase in IL-10 production, inducing a suppressive DC 
phenotype (Kuipers, 2006).  Although the ICOS and PD-1 signalling pathways were 
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not identified as key cell contact factors between MSC and DC in vitro, ICOS and 
PD-1 signalling pathways are involved in the generation of regulatory cells and the 
balance of tolerance and immunity (Salomon, 2001; Aramaki, 2004).  ICOS 
signalling between DC and naïve CD4
+
 T cells is involved in the upregulation of IL-
10 and the induction of suppressor T cells (Tuettenberg, 2009; Levings, 2002).  
ICOS deficient CD4
+
 T cells are insensitive to the tolerogenic effects of DC, 
inhibiting the induction of T reg cells and anergic T cells in vitro (Tuettenberg, 
2009).  In relation to PD-1 signalling, there is a feedback loop whereby, T reg cells 
induce PDL-1 expression on DC, inducing a suppressor phenotype.  In turn, these 
regulatory DC are capable of inducing T reg cells involved in promoting immune 
suppression (Sharma, 2007; Amarnath, 2010).  Although there was no significant 
role found here for ICOS or PD-1 signalling in mMSC induction of tolerogenic DC, 
there are published roles for both ICOS and PD-1 signalling between CD4
+
 T cells: 
DC and the induction of tolerance.  Therefore, it is possible that the induction of 
tolerogenic DC via MSC could occur through different pathways, not involving 
ICOS or PD-1 signalling.  However, the induction T reg cells via MSC could 
possibly involve the ICOS or PD-1 pathways, which could indirectly influence the 
induction of tolerogenic DC by MSC.  This hypothesis highlights a multi-
relationship system whereby numerous contact signals might be involved in the 
modulation of immune tolerance, some of which are independent of MSC.  This 
concept is represented in Figure 7.1.  
Another candidate for contact dependent suppression was the Notch 
signalling pathway.  Interactions between Notch receptors and ligands play a crucial 
role in the cross talk between cells of the immune system and their surrounding 
microenvironment (Radtke, 2004).  The expression of Notch receptors and ligands 
251 
 
are important in stem cell maintenance, cell proliferation, differentiation, apoptosis 
and induction of peripheral tolerance (Hoyne, 2000; Radtke, 2004; Fiuza, 2007).  
Notch signalling is involved in the regulation of T cell activation (Yvon, 2003; 
Beyth, 2005; Liotta, 2008) and DC maturation (Weijzen, 2002; Cheng, 2003; 
Amsen, 2004; Cheng, 2007; Li, 2008; Zhang, 2009).    The expression of Notch 
receptors, Notch 1 & 2, and Notch ligands, Jagged 1 & 2 and Delta like ligand 1, by 
mMSC and DC were analysed.  mMSC expressed both Notch 1 and 2 receptors and 
the ligands Jagged 1 and Delta like ligand 1.  mMSC did not express the ligand 
Jagged 2.  DC on the other hand expressed receptors, Notch 1 and 2 and the ligands, 
Jagged 1, 2 and Delta like ligand 1.  When Notch signalling was blocked in coculture 
experiments, the induction of a semi-mature DC by mMSC was inhibited.  This 
suggested that when the Notch signalling pathway was blocked, mMSC did not 
interfere with DC maturation and highlighted the Notch signalling pathway as a 
required contact signal between mMSC and DC in vitro.  Therefore, the Notch 
signalling pathway was examined in more detail.  In the presence of GSI, mMSC 
were unable to interfere with DC antigen presentation and maturation and blocking 
Notch signalling interfered with the induction of a tolerogenic DC (Fig 4.22).  These 
findings identified a required role for Notch signalling in the induction of a 
functional tolerogenic DC by mMSC.  Unfortunately, the exact Notch receptors or 
ligands involved were not identified in this study.   
Li et al. found that Notch signalling was involved in hMSC induction of DC 
that expressed high levels of IL-10, low levels IL-12, and inhibited T cell 
proliferation.  These hMSC-induced tolerogenic DC also induced a population of T 
reg cells (Li, 2008).  Recently Zhang et al. identified a novel Jagged 2 dependent 
regulatory DC that was generated through cell: cell contact with MSC (Zhang, 
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2009).  These novel Jagged 2 dependent tolerogenic DC secreted high levels of 
TGFβ and were capable of inhibiting mitogen driven lymphocyte proliferation, while 
reducing the production of both IFNγ and IL-2 in culture supernatants (Zhang, 
2009).  Cheng et al. demonstrated that the main Notch ligands, Jagged 1 and Delta 
like ligand 1 had the opposite effects on DC differentiation (Cheng, 2007).  Notch 
signalling through Delta like ligand 1 promoted the generation of fully differentiated 
DC.  However, similar to the hypothesis herein whereby the silencing of Jagged 1 on 
mMSC was attempted, Cheng et al. found that Notch signalling through Jagged 1 
resulted in the accumulation of DC precursors, which prevented the full 
differentiation of DC in vitro (Cheng, 2007).  This finding was similar to that 
demonstrated in Chapter 4.  Therefore, additional measures are currently underway 
within the Mahon Lab to development a cell line of bone marrow isolated mMSC 
that are completely silenced for Jagged 1 (mMSC
Jag-/-
) expression by short hairpin 
RNA (shRNA).  Once developed, the need for Jagged 1 expression by mMSC will 
be analysed for its role in the induction of a tolerogenic DC and regulatory T cell 
populations, identifying its significance in the induction of immune tolerance.  If the 
contact signal between MSC and DC involves members of the Notch signalling 
pathway, this re-emphasises how the modulation of immune tolerance by MSC 
involves many pathways.  
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Fig 7.1 A proposed model of the contact signals required for MSC induction of 
regulatory cells.  MSC mediate their immunomodulatory effects by influencing DC 
and T cell fate.  MSC induce tolerogenic DC through direct cell contact involving 
the Notch signalling pathway and the secretion of IL-6.  While the secretion PGE2, 
and TGFβ subsequent to direct cell contact via Notch are required for the induction 
of T reg cells.  DC mediation of T cell fate can involve multiple signalling pathways 
including Notch, ICOS or PD-1 signalling.   
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Chapter 3 and 4 identified MSC signals capable of influencing immune 
tolerance, through the induction of both innate and adaptive regulatory cells.  This 
suggested that MSC could act therapeutically to prevent T cell mediated diseases, 
where the induction of tolerance could be beneficial.  Therefore, a model system was 
chosen to examine the potential of hMSC to be used therapeutically.  Allogeneic 
bone marrow transplantation is used to treat life-threatening haematological, 
oncological and immunological disorders.  The induction of donor specific tolerance 
following allogeneic bone marrow transplantation is very important for the survival 
of the allograft (Shlomchik, 2007; Ezzelarab, 2011).  In transplantation, T cell 
mediated immune regulation is involved in the induction of antigen-specific 
tolerance to deliberately introduced foreign antigens present in the allograft (Wood, 
2003; Chinen, 2010).  Tolerogenic DC are important in transplantation as they are 
capable of presenting antigen to antigen specific T cells, which results in the 
inhibition of T cell activation or proliferation through T cell deletion, 
unresponsiveness (anergy) or  induction of T reg cells (Morelli, 2007).    Graft versus 
Host Disease (GvHD) was chosen as a model disease as it is a donor T cell mediated 
disease, causing extensive host organ damage.  Both regulatory DC and T cells are 
involved in the prevention of GvHD (Duffner, 2004; Taylor, 2002).  Therefore, a 
humanised mouse model of acute GvHD (aGvHD) was developed and used to 
examine the effect of hMSC cell therapy on aGvHD development within the model. 
Successful MSC cell therapy was first reported in 2004, when Le Blanc et al. 
found that ex vivo expanded haplo-identical human MSC were beneficial for 
treatment of steroid refractory aGvHD of the gut and liver in paediatric patients (Le 
Blanc, 2004).   A follow up non-randomised study for the treatment of steroid 
refractory aGvHD was carried out in 2008, where both paediatric and adult patients 
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were successfully treated with haplo-identical or third party (mismatched) hMSC (Le 
Blanc, 2008).  These studies were the first to identify that immunosuppressive 
characteristics of MSC that were found in vitro were in fact beneficial in vivo also.  
However, the exact mechanisms used by MSC in vivo still remain unclear.  The use 
of murine models are very important tools to help analyse the role of specific 
mechanisms used by MSC and allow research groups to gain insight into how MSC 
exert their beneficial effects in vivo.  
There are many mouse models of aGvHD (reviewed in Chapter 1.11).  
However a humanised mouse model generated from the NOD-Scid IL2rγnull mouse 
(NSG), which readily engrafted human hematolymphoid cells and displayed 
enhanced function of these human lymphocytes in vivo was used here (Shultz, 2007).  
Previously, the NSG humanised model was used to study human type 1 diabetes and 
more recently human derived GvHD (Shultz, 2007; King, 2009; Pino, 2010).  Using 
the NSG model, this thesis set out to optimise a humanised model of aGvHD and 
examine the role of human MSC as a cell therapy for the treatment or prevention of 
aGvHD in vivo.  Pearson et al. published a protocol for the creation of a humanised 
mouse GvHD model using the NSG mice first described by Shultz et al. (Shultz, 
2007; Pearson, 2008).  This original protocol suggested that human PBMC isolated 
from whole buffy coat pack blood at a concentration of 2 x 10
7
 per NSG mouse was 
sufficient for the induction of aGvHD between 10 to 20 days post i.v injection.  
Although PBMC engrafted into the NSG model and were detected in the spleen 12-
16 days post transfusion, initial experiments using PBMC at 2 x 10
7
 per mouse 
proved inconsistent for aGvHD development.  Upon further analysis, the realisation 
of obtaining high numbers of NSG mice, all at the same age and weight proved 
unrealistic for additional studies.  Therefore, taking into consideration previous 
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preliminary studies, an apparent relationship between disease symptoms, PBMC 
dose, PBMC source and initial body weight of each NSG mouse began to emerge.  
From this point on, the dose of PBMC required for consistent aGvHD development 
in this model was optimised with reference to the initial weight of each NSG
 
mouse, 
6.3 x 10
5
 PBMC g
-1 
(2 x 10
7
 PBMC/30g mouse) were required for a more consistent 
aGvHD model (Fig 5.7).  The variation between the protocol created by Pearson et 
al. and the newly optimised protocol in Chapter 5 may have been due to differences 
in radiation dose, delivery rate and source of PBMC between labs.  A switch from 
buffy coat pack isolated PBMC to freshly isolated PBMC from healthy donors on the 
day of delivery also aided the development of a more consistent humanised model.  
Consequently, the source of PBMC remained consistent, with four healthy donors 
chosen for further studies using the humanised mouse model developed herein.   
Using the optimised humanised mouse model of aGvHD, the ability of 
hMSC to prevent, ameliorate or treat aGvHD was examined.  MSC were 
administered on day 0, 7 or 14 post PBMC transfusion (Fig 5.10).  MSC therapy on 
day 0 had no beneficial effect on the survival of NSG mice with aGvHD.  However, 
hMSC given as a therapy on day 7 or 14 significantly prolonged the survival of NSG 
mice with aGvHD, reducing pathological signs of aGvHD.  Subsequent larger 
studies found that hMSC given as a cell therapy on day 7 post PBMC transfusion 
prolonged the survival of NSG mice for more than 30 days, reducing pathology (Fig 
5.11).  These data suggested that the timing of MSC therapy was important in the 
treatment of aGvHD.  These results were similar to that found by other groups in 
diverse systems (Polchert, 2008; Joo, 2010; Christensen, 2010).  Polchert et al. found 
no significant improvement in GvHD related mortality when murine MSC were 
given as a therapy on day 0, but treatment with MSC on day 2 or 20 post bone 
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marrow transplantation prolonged the survival of mice with aGvHD (Polchert, 
2008).  Collectively, these data indicated that for untreated MSC therapy to be 
successful, clinical cell therapy should not be concurrent with HSC delivery.  
In contrast to the data here, others have found no beneficial role for MSC as a 
therapy for GvHD (Sudres, 2006; Jeon, 2009).  Sudres et al. showed that mMSC 
suppressed alloantigen driven T cell proliferation in vitro in a dose dependent 
manner.  However, using a model where C57BL/6 bone marrow cells were injected 
into lethally irradiated BALB/c mice, mMSC therapy had no beneficial effect on 
survival (Sudres, 2006).  This result was not surprising as Sudres administered 
mMSC at the same time as bone marrow transplantation.  Jeon et al. found that 
hMSC were unable to prevent GvHD development in the same murine model used 
by Sudres et al..  Following hMSC administration on day 0 or at a later time point, 
day 7, the survival rate of mice with GvHD did not improve, nor were symptoms of 
GvHD alleviated.  In this case, human MSC were unable to suppress xenogenic T 
cell activation in vitro and cytokine mismatch may explain why no beneficial effects 
against GvHD development were observed following hMSC therapy in vivo.  Unlike 
the model used by Jeon et al., the humanised model in this thesis used human donor 
PBMC for the development of GvHD.  This would avoid the problems experience by 
Jeon et al., as in Chapter 6, hMSC significantly inhibited human PBMC 
proliferation, both in vitro and in vivo.  
The failure of unstimulated MSC to treat aGvHD when delivered 
concurrently with T cells is interesting.  Donor T cells produce high levels of 
inflammatory cytokines in response to antigen recognition, such as IFNγ.  Normally 
IFNγ enhances allogenicity (Ryan, 2007) however; MSC stimulated with IFNγ show 
enhanced immunosuppressive ability, largely a result of increased production of the 
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enzyme IDO (Meisel, 2004; Ryan, 2007; English, 2007).  These data suggested that 
MSC could be activated or “licensed” to display more potent immunosuppressive 
abilities and/or greater efficacy (Polchert, 2008).  Therefore, this aspect of MSC 
biology was examined.  IFNγ stimulated MSC administered with PBMC effectively 
delayed the development of aGvHD (Fig 5.13).  These data suggested that if MSC 
were administered concurrent with bone marrow transplantation, prior stimulation by 
IFNγ would improve efficacy.  One explanation for this might be that the systemic 
inflammation in GvHD mice increases after day 0.  On day 0, there is little or no 
IFNγ available for the activation of hMSC.  However, as GvHD develops, the levels 
of IFNγ increase and by day 2 to 7, there are sufficient levels of IFNγ present within 
the NSG mouse for the activation of hMSC.  Therefore, hMSC administered after the 
development of a proinflammatory environment in vivo, are more successful in 
prolonging the survival of mice with GvHD.  These data clearly state the importance 
of cell manipulation as well as timing in MSC therapy.  
Having identified a significant beneficial role of hMSC therapy for the 
improved survival of NSG mice with aGvHD, the effect of hMSC therapy on 
aGvHD target organs and inflammatory cytokines involved in aGvHD development 
were examined.  Both unstimulated and IFNγ stimulated MSC therapy significantly 
reduced the severity of aGvHD pathology detectable in the small intestine and liver 
of NSG mice after 12 days (Fig 5.14 & 5.15).  hMSC therapy reduced villous 
blunting and lymphocyte infiltration into the lamina propria of the small intestine, 
while reducing vascular endothelialitis and lymphocyte infiltration into the 
parenchyma of the liver.  These data were similar to that found by Polchert et al. and 
Joo et al., where mMSC therapy significantly improved the histological score of the 
intestine and liver of mice with GvHD (Polchert, 2008; Joo, 2010).  Unlike Polchert 
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et al., MSC therapy did not improve the histological analysis of the lung in NSG 
mice with aGvHD, as there was a significant mononuclear cell infiltration in all 
treatment groups (Fig 5.16).  Importantly, the histological results herein mirrored 
those of a Phase III clinical trial carried out by Osiris Therapeutics™ (Martin, 2010).  
This trial set out to examine the effects of a human MSC-like product, Prochymal® 
in the treatment of patients with steroid refractory aGvHD.  In a Phase II trial, 
Prochymal cell therapy was well tolerated in patients with no adverse effects 
(Kebriaei, 2009).  However, in the Phase III trial, patients who received the placebo 
treatment fared better than those that received the Prochymal cell therapy.  This 
Phase III clinical trial was therefore deemed unsuccessful.  Nevertheless, upon 
further analysis of the data collected in the trial, patients who had presented with 
aGvHD manifesting in the liver and the gut, showed significant improvement 
following treatment with Prochymal.  Treatment with Prochymal cell therapy had no 
beneficial effect on skin manifestations or patient survival.  Although histological 
analysis of the skin was not examined in the humanised model in Chapter 5, these 
findings suggested that the beneficial effect of MSC-based cell therapies for aGvHD 
could in fact be target organ dependent.  One way to investigate this hypothesis 
could be to examine the expression of migratory/chemokine receptors on MSC and 
determine if the absence of key skin related chemokine receptors could be one of the 
reasons why MSC based-cell therapy are not beneficial for the treatment of aGvHD 
of the skin.  However, overall, the data presented in Chapter 5 suggested that hMSC 
therapy was involved in reducing the pathology in target GvHD organs, which in 
turn was contributing to the survival of NSG mice with GvHD.  
The inflammatory cytokines, IFNγ and TNFα play important roles in 
determining the severity of GvHD development (Ferrara, 2009).  Therefore, the 
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analysis of cytokines present in the serum following MSC therapy was carried out.  
IFNγ stimulated MSC significantly reduced the levels of human TNFα detected in 
the serum of NSG mice with aGvHD (Fig 5.17 A).  Interestingly, these findings were 
similar to results published by King et al. (King, 2009).    By blocking TNFα 
production through the addition of Etanercept (Enbrel®-a soluble TNFα decoy 
receptor), the pathology of aGvHD was significantly reduced and the survival of 
NSG mice was significantly increased (King, 2009).  Analysis of IFNγ levels in the 
serum of NSG mice following MSC therapy found that the levels of human IFNγ 
were not affected by treatment with MSC (Fig 5.17 B).  Nonetheless, MSC therapy 
proved beneficial in prolonging the survival of NSG mice with aGvHD, reducing 
aGvHD pathology in the liver and gut, while decreasing the amount of TNFα present 
in the serum suggesting that IFNγ is more a result rather than a cause of pathology.  
It is not known how MSC prevent TNFα production but this is highly likely to 
involve suppression of monocytes and possibly DC.  Such an influence may have 
profound influence in the NSG model (Fig 7.3) 
The key to improving current cell therapies for aGvHD is an understanding 
of the mechanisms of cell action.  The model developed in Chapter 5 proved a 
unique tool to test human cell therapies and their mechanisms of action.  In 
particular, the influences of hMSC cell therapy on T cell responses in aGvHD were 
amenable to study.  A number of possible mechanisms were analysed in vivo using 
the NSG aGvHD model.  The induction of immune tolerance involves a precise 
balance between activation and inhibition of T cell responses.  Therefore, in vivo 
studies were carried out to determine the precise mechanism of efficacy.  
Specifically, four hypotheses were tested: 1) that hMSC cell therapy was effective 
through deletion of  donor T cells through apoptosis, 2) that hMSC rendered donor T 
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cells anergic; 3) that hMSC induced a suppressive T reg cell population or 4) hMSC  
directly  inhibited donor  T cell proliferation.   
Several studies have given contradictory evidence in relation to the induction 
of T cell apoptosis by MSC (Plumas, 2005; Zappia, 2005).  In this study, hMSC did 
not induce apoptosis of PBMC in vitro (Fig 6.1).  In fact, hMSC appeared to protect 
PBMC from apoptosis, which is in line with the known supportive role for MSC in 
lymphopoiesis (Chen, 2009). Nevertheless a small-scale experiment was carried out 
to investigate the role for MSC induced T cell apoptosis in vivo.  Following hMSC 
therapy in NSG mice with aGvHD, no apoptotic cells were detected in vivo after 24 
h or 5 days (Fig 6.2).  Contradicting the data herein, Plumas et al. found that hMSC 
inhibited both mitogen and antigen specific driven T cell proliferation in vitro 
through induction of apoptosis of activated T cells, involving the production of IDO 
(Plumas, 2005).  Meisel at al identified a role for IDO expression by hMSC in the 
inhibition of T cell proliferation.  In this case, MSC did not induce apoptosis and T 
cell proliferation was reversible through the addition of IL-2 (Meisel, 2004).  The 
functional effect of IDO is to convert Tryptophan to Kynurenine; the Mahon group 
clarified the study carried out by Meisel et al. and showed that Kynurenine was the 
suppressive agent (Ryan, 2005).  Kynurenine is however toxic in vitro at high 
concentration (Darcy, 2011) and it may well be that the finding of Plumas et al. are 
artefacts of culture systems used (Plumas, 2005).  In direct contrast, many other 
groups have reported that MSC play no role in the induction of T cell apoptosis (Di 
Nicola, 2002; Zappia, 2005; Corcione, 2006; Krampera, 2006).  In spite of the 
contradictory literature, the data here indicated that the induction of T cell apoptosis 
by hMSC was unlikely to be the mechanism by which MSC prolonged the survival 
of NSG mice with aGvHD.   
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The concept that MSC induce T cell anergy has been controversial (Zappia, 
2005; Glennie, 2005).  The findings here suggested that hMSC did not induce CD4
+
 
T cell anergy in vitro.  Although hMSC inhibited the proliferation of human CD4
+
 T 
cells following xenogeneic stimulation with murine DC, upon restimulation of the 
repurified CD4
+
 T cells with irradiated murine DC in the absence of IL-2 
stimulation, antigen specific T cell proliferation occurred (Fig 6.3).  This suggested 
that hMSC did not induce an antigen specific anergic T cell population in vitro.  
These data are contradictory to those found by Glennie et al. and Zappia et al..  In 
these studies, bone marrow derived murine MSC inhibited antigen specific T cell 
proliferation and reduced the production of IFNγ.  However, following the removal 
of mMSC, T cells did not regain their ability to proliferate in response to the cognate 
antigen, but this was reversible by addition of IL-2 suggesting the induction of T cell 
anergy (Zappia, 2005; Glennie, 2005).    Interestingly, the production of IFNγ was 
restored purely upon mMSC removal.  This suggested that mMSC induced a 
phenomenon known as split anergy (Zappia, 2005; Glennie, 2005).  In other murine 
and human studies, it was demonstrated that T cell unresponsiveness was transient 
and completely reversed once MSC were removed from cultures (Krampera, 2003; 
Di Nicola, 2002).  Variations between groups may be due to the use of different 
stimuli in each study design and differences between the uses of murine or human 
MSC.  The transient T cell unresponsiveness seen by others is possibly not due to the 
direct action by MSC, but rather due to the effect of anti-inflammatory factors 
released by MSC into the culture system.       
As it was unlikely that hMSC were inducing T cell apoptosis or anergy, the 
next mechanism to be explored was the hypothesis that MSC were inducing T cell 
tolerance through the induction of T reg cells.  Naturally occurring CD4
+ 
CD25
+ 
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FoxP3
+
 T reg cells play a role in the induction and maintenance of immune tolerance 
(Roncarolo, 2007).  The induction and ex vivo expansion of T reg cells have had 
limited success in the prevention of aGvHD.  Many murine studies have identified a 
correlation between T reg cells and the induction, acceleration and 
treatment/prevention of aGvHD (Cohen, 2002; Edinger, 2003; Cao, 2009).  Chapter 
3 identified the induction of FoxP3 expressing T reg cells by MSC from a purified 
population of CD4
+
 T cells in vitro.  Knowing that MSC are capable of inducing T 
cells with a regulatory phenotype and that T reg cells play a role in preventing 
aGvHD development, the induction of a FoxP3 expressing T reg cell population as a 
possible mechanism by which hMSC prolong the survival of NSG mice with aGvHD 
was examined.  Following unstimulated or IFNγ stimulated MSC cell therapy, no 
increase in FoxP3 expressing T reg cells were detected in the lung, liver or spleen of 
NSG mice with aGvHD.  The absence of a FoxP3 expressing T reg cell population 
was not due to an insufficient ex vivo detection technique as the technique for 
accurate FoxP3 expression was previously utilised by another member of the Mahon 
group (Kavanagh, 2010).  In this case, Kavanagh et al. found that murine MSC 
prevented allergic airway inflammation, through the induction of a FoxP3 expressing 
T reg cells, detected through intracellular staining for FoxP3 expression by flow 
cytometry (Kavanagh, 2010).   
Other research groups have suggested a role for T reg cells in aGvHD 
development and treatment.  The deletion of CD4
+
 CD25
+
 T reg from the bone 
marrow graft prior to transplantation dramatically accelerated aGvHD development 
in other murine models (Cohen, 2002; Taylor, 2002; Cohen, 2006).  Additionally, 
the infusion of ex vivo expanded CD4
+
CD25
+
FoxP3
+
 T reg cells prevents aGvHD 
development, while preserving graft versus leukaemia (GvL) activity (Taylor, 2002; 
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Hoffmann, 2002; Edinger, 2003; Trenado, 2003; Cao, 2009).  This inverse 
correlation between T reg cells and aGvHD has also been found in patients with 
aGvHD (Cao, 2009).  Patients presenting with grade II to IV aGvHD displayed 
reduced numbers of T reg cells when compared to normal healthy individuals or 
patients with mild grade I aGvHD (Cao, 2009).  Li et al. identified a correlation not 
only between the number of T reg cells present in patients with aGvHD, but also in 
the production of TNFα (Li, 2010).  Patients with reduced T reg cells had increased 
levels of TNFα.  This environment would be very characteristic of aGvHD, with 
excessive TNFα resulting from tissue damage and immune cell activation (Li, 2010).   
Recently, the induction of FoxP3 by MSC in a mouse model of aGvHD was 
documented.  Following murine MSC therapy on day 1 in a C3H donor cells into 
irradiated BALB/c mouse model of aGvHD, Joo et al. found an increase in FoxP3 
mRNA in the mesenteric lymph nodes of mice with aGvHD after 9 days, when 
compared to mice that did not receive mMSC therapy (Joo, 2010).  However, mRNA 
expression does not always equate to protein levels, it might be the discrepancies 
between Joo et al. and the data here may be attributed to the fact that FoxP3 
expression was analysed on an mRNA level (Joo, 2010).  However that seems 
unlikely.   The data may reflect a more fundamental issue with NSG mice and a 
limitation of our model.  In NSG mice (even with aGvHD), lymph nodes are 
vestigial.  Therefore, FoxP3 expression in the lymph nodes could not be explored.   
The difference above deserves further consideration.  The use of a mouse in 
mouse model by Joo et al. and human in mouse model here may also contribute to 
the differences in T reg cell detection.  Using a murine model of GvHD (C57BL/6 
donor into BALB/c), Hao et al. found that hMSC isolated from umbilical cord blood 
(hUCBDSC), elevated the numbers of murine FoxP3
+ 
CD4
+
 splenocytes (Hao, 
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2011).  The absence of T reg cell induction by hMSC in this model might be 
explained by the absence of third party (stromal) factors preventing the expansion of 
human T reg cells in the NSG mouse model of aGvHD or that other T reg 
populations are involved that do not express the transcription factor FoxP3.  Of 
course it may be that the numbers of CD4
+
 CD25
+
 FoxP3
+
 T cells present in the 
donor PBMC were too low for their expansion following MSC transfusion in vivo.  
Finally, hMSC therapy prolonged the survival of NSG mice with aGvHD but did not 
prevent aGvHD development, which would suggest that hMSC therapy had more of 
a transient effect on aGvHD development, rather than a permanent tolerogenic 
preventative effect in this model.     
In this model, MSC cell therapy did not induce the expansion of conventional 
T reg cells in vivo. Therefore, the ability of MSC to directly inhibit T cell 
proliferation in vivo was examined.  MSC inhibition of T cell proliferation in vitro is 
well documented (Glennie, 2005; DiNicola, 2005; Zappia, 2005; English, 2009) but 
there are contradictory data available for the inhibition of T cell proliferation by 
MSC in vivo (Sudres, 2006; Zappia, 2005).  Therefore, an in vivo method for the 
detection of T cell proliferation was applied to the NSG model of aGvHD.  IFNγ 
stimulated MSC therapy resulted in the reduction of CD4
+
 T cell proliferation in the 
lungs of NSG mice after 5 days.  These data showed that not only are MSC capable 
of inhibiting T cell proliferation in vitro, but this characteristic of MSC immune 
suppression was also found in vivo.  Interestingly, only CD4
+
 T cells proliferated 
within the NSG aGvHD model as no proliferation of CD8
+
 T cells were detected in 
vivo.  These data highlighted the possibility that MSC cell therapy could prolong the 
survival of NSG mice with aGvHD through the direct inhibition of human donor T 
cells.  In contrast to the data herein, Sudres et al. found that although murine MSC 
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inhibited the proliferation of T cells in vitro, murine MSC therapy administered atthe 
same time as bone marrow transplant to treat GvHD had no effect on the 
proliferation of CFSE labelled T cells in vivo (Sudres, 2006).  However, Christensen 
et al. showed that murine MSC only delayed aGvHD onset but did not prevent 
aGvHD development; finding that although murine MSC could inhibit T cell 
proliferation in vitro, MSC did not prevent T cell proliferation in vivo (Christensen, 
2010), given the difficulty we encountered in detecting in vivo proliferation and its 
timing, this was not surprising. 
If direct inhibition of T cell proliferation is the mechanism of hMSC efficacy 
then the mechanism underlying this effect needed to be explored.  hMSC derived 
soluble factors play a role in the ability of MSC to inhibit T cell proliferation 
(Chapter 6).  Prostaglandins secreted by MSC, are known regulators of T cell 
proliferation.  In chapter 6, it was shown that the release of prostaglandin, PGE2, by 
hMSC was important for the induction of T reg cells in vitro and in Chapter 6 PGE2 
was shown to be required for the cells used in vivo.  Collectively, these data 
highlighted the importance of MSC derived prostaglandins in the mediation of T cell 
mediated responses in vitro.  It was therefore plausible that the direct T cell 
inhibition seen in vivo was due to hMSC production of prostaglandins.  To 
investigate this, indomethacin was administered to aGvHD mice in conjunction with 
hMSC therapy.  Although indomethacin reduced the production of prostaglandins in 
each treatment group (Fig 6.14), this decrease did not affect the survival or 
pathological score of NSG mice with aGvHD.  There was no significant difference 
between hMSC treated mice or hMSC/indomethacin treated mice.  This suggested 
that the production of prostaglandins by hMSC in vivo were not involved in the 
beneficial effect seen following hMSC therapy.  There are other possible soluble 
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factors secreted by MSC that may play a role in the reduction of T cell proliferation 
in vivo, such as IDO, HGF or TGFβ, which were not analysed here.   
 This thesis explored many aspects of MSC immune modulation both in vitro 
and in vivo (Fig 7.2).  The use of mouse models has allowed for the progression of 
research tools and therapies over the past decade.    By using the novel model here, 
the effect of hMSC therapy on aGvHD development was assessed and the exact 
mechanisms employed were explored.  One benefit of the NSG model was that the 
development of aGvHD was due to the infusion of human cells (PBMC) and the 
treatment of the disease was carried out using hMSC.  This allowed for the research 
of human aGvHD pathology and how human cell therapies might be deployed.  One 
drawback with this humanised model, which was identified in this thesis was, due to 
the lack of a functional lymphoid system, the detection of key lymphoid organs such 
as the lymph nodes or thymus were extremely difficult.   
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Fig 7.2 A schematic representation of the mechanisms involved in MSC 
induction of tolerance in vitro and in vivo.  Tolerance induction by MSC involves 
the generation of tolerogenic DC and T reg cells in vivo. MSC therapy can directly 
reduce donor CD4
+ 
T cell expansion.  MSC can also inhibit DC maturation, 
indirectly interfering with CD4
+
 T cell proliferation.  In aGvHD, donor CD4
+
 T cells 
drive pathology leading to destruction of target cells, tissues and organs.  This is 
supported by mature activated DC.  MSC prevent CD4
+
 T cell proliferation.  This 
might be via tolerogenic DC induction as in Chapter 4.  In other aGvHD models, 
MSC induced T reg cells are likely to play a role but this may be less prevalent in the 
NSG model. 
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  It is therefore appropriate to synthesise the conclusions so far and propose a 
model of how MSC are beneficial in aGvHD.  It is an irony that this thesis focused 
on adaptive immunity (T reg) and DC, whereas one of the most important aspects 
was an observation from the animal model on innate responses.  Following hMSC 
cell therapy in vivo, the production of human TNFα in the serum of aGvHD mice 
was significantly reduced.  TNFα is the key cytokine involved in the manifestation 
of aGvHD both in murine models and in patients.  The main cells involved in the 
production of TNFα in the NSG model are donor monocytes, macrophages, DC or 
the few remaining antigen presenting cells within the NSG mouse.  Excessive TNFα 
can directly or indirectly (Fas/Fas ligand) induce apoptosis of donor and host cells; 
activate donor DC inducing maturation and enhanced alloantigen presentation; 
activate donor CD4
+ 
T cells through TNFR 1 or 2; induce target organ damage 
through the activation of CD8
+
 CTL and NK cells; and increase the permeability of 
the endothelium, allowing for the infiltration of donor cells into target organs, 
resulting in extensive tissue damage.  In the NSG model, little CD8
+
 T cell 
expansion was seen, however endothelialitis was observed in diseased but not treated 
mice (Fig 5.14-5.16).  It is tempting to speculate that a key aspect of MSC protection 
here was the prevention of vascular permeability through suppression of monocyte 
derived TNFα (Fig 7.3).  Nevertheless, key aspects of innate and adaptive immunity 
were shown to be influenced in vitro and in vivo in this work (Fig 7.2).  T reg cell 
induction was expected to be the key feature of protection, but this was not 
demonstrated in vivo for reasons described above.  It is likely that T reg cells have a  
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Fig 7.3  The role of MSC in limiting aGvHD pathology.  MSC can work in a 
number of ways; through limiting TNFα production.  Donor monocytes, 
macrophages and DC secrete high levels of TNFα in the humanised aGvHD NSG 
model.  MSC cell therapy significantly reduces TNFα in the serum of NSG mice 
with aGvHD.  Excess TNFα can directly induce host tissue apoptosis or indirectly 
through the activation of donor cytotoxic T lymphocytes (CTL) and natural killer 
(NK) cells.  TNFα can drive the activation of donor DC and CD4+ T cells increasing 
donor lymphocyte proliferation.  As a stimulator of the acute phase reaction, TNFα 
can increase the permeability of the endothelium, allowing the infiltration of donor 
lymphocytes and other effector molecules into target organs.  
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role in other models and indeed in human disease/therapy and the absence of this 
here is a reflection of the model.  Nevertheless, allogeneic MSC do suppress 
(xenoantigen driven) CD4
+
 T cell proliferation in vivo; as aGvHD pathology is 
driven by T cell expansion.  This is a significant finding.  However, the mechanism 
does not involve anergy or apoptosis induction of donor T cells, but rather a more 
direct suppression.  PGE2 was speculated to be the mediator involved (from data in 
Chapter 3), but this did not appear to be the case.  In chapter 4, a role for MSC 
induced DC suppression was explored, which highlighted this as a future area for in 
vivo study.  Recently mMSC were shown to affect the ability of DC to prime T cells 
in vivo; (Chiesa, 2011).  It might be that the reduction of donor T cell proliferation 
observed in vivo following hMSC therapy could be due to MSC-induced tolerogenic 
DC (Fig 7.2 & 7.3) consistent with the in vitro data from chapter 4.  
To conclude, the use of autologous MSC are beneficial in treating 
autoimmune diseases and pathologies, but are limited by the time it takes to isolate, 
standardise, regulate, quality assure  and expand these MSC prior to patient 
treatment.  The cost model for bespoke therapy is also prohibitive.  Therefore, the 
concept of using standardised, regulatory compliant, allogeneic MSC as a beneficial 
cell therapy is very exciting.  Knowing the exact mechanisms by which MSC 
mediate their immunosuppressive characteristics in vivo is important for the 
progression of MSC as a valuable cell therapy.  Identifying these exact mechanisms 
will contribute to current knowledge in MSC biology and help translate these 
remarkable stem cells into reliable therapies.  This thesis has progressed our 
understanding of MSC biology and delivered the models to make such translation 
possible. 
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